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Abstract
Cytochrome P450 enzymes (CYP, P450) play a crucial role in drug metabolism and
sterol biosynthesis. In humans, P450s catalyze more than 80% of drugs. P450s
such as CYP51 are also involved in steroid biosynthesis. CYP51 catalyzes the 14α-
demethylation of sterol-like molecules. CYP51 has been found to exist in all king-
doms. It has been used for antifungal drug design. It has also been shown to be a
good target for antiparasitic drug design. Understanding the mechanism of P450s
not only helps to invesigate drug metabolism but also to design parasite specific
inhibitors that do not inhibit human orthologs.
P450s are heme-containing enzymes. The active site is buried in the protein
and thus, substrates need to enter the active site and products need to exit from
the active site via ligand tunnels. P450s are membrane-bound proteins. They
anchor in the membrane with a single transmembrane helix. For the catalytic
reaction of P450s, two electrons need to be transferred from their redox partners.
In eukaryotes, the most often used redox partner of P450s is cytochrome P450
reductase (CPR). CPR is also a membrane-bound protein. The association between
P450 and CPR is driven by electrostatics. Two electrons are transferred from the
flavin mononucleotide (FMN) cofactor of CPR to the heme center of P450s.
Current experimental evidence does not provide a full understanding of dy-
namics of P450s, differences between P450s, of how P450s embed in the mem-
brane, of how ligands can enter and exit from the active site and of how P450s
interaction with CPR. A multiscale computational approach, including all-atom
molecular dynamics simulations, coarse-grain molecular dynamics simulations and
Brownian dynamics simulations was performed to tackle these problems.
A model of membrane-bound T. brucei CYP51 was built and the model was
shown to be consistent with existing experimental data. The dynamics of the
model of soluble T. brucei CYP51 were compared with those of models of soluble
human CYP51, human CYP2C9 and human CYP2E1. The dynamics of the model
of membrane-bound T. brucei CYP51 was also compared with those of models of
membrane-bound CYP2C9. The binding site residues of both T. brucei CYP51 and
human CYP51 are more rigid than those of CYP2C9 and CYP2E1. The results
suggest that differences between the active site residues of T. brucei and human
CYP51s may be key for designing T. brucei specific inhibitors. The ligand tunnels
in both T. brucei and human CYP51 were also studied. Tunnel 2f serves as the
predominant ligand tunnel in both proteins, but T. brucei CYP51 often uses the
solvent (S) tunnel, tunnel 1 and the water (W) tunnel as the second predominant
tunnel whereas human CYP51 uses tunnel 1. The difference in the use of ligand
tunnels may be important for ligand specificity of the two proteins. Analysis of
tunnel entrance residues shows differences between these residues in the two pro-
teins and this information can be helpful for designing T. brucei CYP51-specific
inhibitors which do not inhibit human CYP51.
Interactions of P450 and cytochrome P450 reductase were studied using Brow-
nian dynamics simulations and molecular dynamics simulations. Complexes of
soluble forms of different P450s, including CYP51, CYP2B4, CYP1A2, CYP2A6,
CYP2C9, CYP2D6 and CYP2E1 were investigated. The P450s bind to the reduc-
tase using a similar interface, the positively charged proximal side. The interface
residues on the proximal side of P450s are normally arginine and lysine residues
and those on CPR are aspartic acid and glutamic acid residues. P450s bind to CPR
with different affinities and these affinities can be inferred from the computed
binding energy of the complexes. A model of the membrane-bound complex of T.
brucei CYP51 and human CPR was built based on the membrane-bound model of
T. brucei CYP51 and the encounter complexes of P450s and CPR generated by the
Simulation of Diffusional Association (SDA 7) software, which was used for the
Brownian dynamics simulation. A 210 ns molecular dynamics simulation was per-
formed for the system. In the simulation, T. brucei CYP51 changed its orientation
slightly. The interface residues were maintained in the simulation and the distance
between the heme center of the P450 and the FMN cofactor of CPR shortened to
a distance suitable for electron transfer.
SDA 7 is a useful software package for performing Brownian dynamics simula-
tions of macromolecules. However, it has many inter-dependent input parameters
and the analysis of the results may be difficult for new users. A webserver for SDA
7 (webSDA) was built to improve the user-friendliness of SDA 7 and automate the
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procedure for preparing and running SDA jobs. The webserver will not only help
new users to to become familiar with the SDA software but also experienced users
to set up their simulations easily.
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Zusammenfassung
Cytochrom P450 Enzyme (CYP, P450) spielen eine wichtige Rolle im Stoffwech-
sel von Medikamenten und der Sterolbiosynthese. Humane P450s katalysieren
mehr als 80% aller Medikamente. P450s, z.B. CYP51, nehmen in dem Prozess
der Steroidbiosynthese teil. CYP51 katalysiert die 14-Demethylierung von Sterin-
molekülen. CYP51 existiert in allen Organismen. Es wurde als Drug Target für
antimykotische Medikamente verwendet. CYP51 könnte auch als Drug Target für
antiparasitische Medikamente verwendet werden. Das Verständnis über den Wirk-
mechanismus von P450 Enzymen erlaubt nicht nur den Metabolismus von Medika-
menten zu verstehen, sondern auch die Entwicklung von Parasiten-spezifischen
Wirkstoffen, welche nicht bei menschlichen orthologen Enzymen wirken.
P450 ist ein Hämprotein. Das aktive Zentrum ist im inneren des Protein,
deshalb müssen Substrate und Produkte über Tunnel zum aktive Zentrum ein
bzw. aus geschleust werden. P450 ist ein Membranprotein mit einer Transmem-
branhelix. Für die katalytische Reaktion der P450, sollen zwei Elektronen von
ihren Redoxpartner übertragen werden. In Eukaryoten ist meist Cytochrom P450-
Reduktase (CPR) als Redoxpartner eingesetzt. CPR ist ebenfalls ein Membranpro-
tein. Die Verbindung zwischen P450 und CPR wird durch elektrostatische Wech-
selwirkung vermittelt. Zwei Elektronen werden vom Flavinmononucleotid (FMN),
Cofaktor von CPR, zur Hämgruppe des P450 übertragen.
Aktuelle experimentelle Ergebnisse liefern kein vollständiges Verständnis für
die Dynamik der P450 Enzyme, der Unterschiede zwischen den P450, wie das
Enzym in der Membran integriert ist, wie Liganden zum aktiven Zentrum hin
und wieder weg transportiert werden und wie P450 mit CPR interagiert. Um
diese Aspekte weiter zu untersuchen wurde ein Mehrskalenansatz durchgeführt,
welcher „all-atom“-Moleküldynamiksimulationen, „coarse-grained“-Moleküldyna-
miksimulationen sowie Brownsche Dynamiksimulationen verwendet.
5
Ein Modell des membrangebundenen CYP51 von T. brucei wurde erstellt. Dieses
ist in Übereinstimmung mit bestehenden experimentellen Daten. Die Dynamik
des Modells von löslichem CYP51 von T. Brucei wurden mit den Modellen von lös-
lichem humanem CYP51, humanem CYP2C9 sowie humanem CYP2E1 verglichen.
Die Dynamik des Modells der membrangebundenen CYP51 von T. brucei wurde
auch mit Modellen der membrangebundenen CYP2C9 verglichen. Die Aminosäuren-
reste an der Bindungsstelle von beiden CYP51 von T. brucei und humaner CYP51
sind fester als die von CYP2C9 und CYP2E1. Die Ergebnisse zeigen, dass Unter-
schiede zwischen den Resten des aktiven Zentrums von T. brucei und humanem
CYP51s der Schlüssel für die Suche nach T. brucei spezifischen Inhibitoren sein
kann. Die Ligandtunnel in beiden T. brucei und menschlichem CYP51 wurden un-
tersucht. Tunnel 2f dient als vorherrschender Ligandtunnel in beiden Proteinen,
aber T. brucei CYP51 verwendet oft den Solvens(S) Tunnel, Tunnel 1 und den
Wasser (W) Tunnel als den zweit vorherrschenden Tunnel, wohin gegen men-
schliches CYP51 Tunnel 1 verwendet. Der Unterschied bei der Verwendung der
Ligandentunnel kann wichtig für die Ligandenspezifität von beiden Proteinen sein.
Die Analyse der Aminosäurereste am Tunneleingang zeigt Unterschiede zwischen
den Aminosäureresten der beiden Proteine. Diese Information kann für das Design
von T. brucei CYP51-spezifischen Inhibitoren wichtig sein.
Interaktionen von P450 und Cytochrom P450-Reduktase wurden mit Hilfe Brown-
scher Dynamiksimulationen und Moleküldynamiksimülationen untersucht. Kom-
plexe der löslichen Formen der verschiedenen P450, inkl. CYP51, CYP2B4, CYP1A2,
CYP2A6, CYP2C9, CYP2D6 und CYP2E1 wurden untersucht. Die P450 binden an
die Reduktase unter Verwendung einer ähnlichen Grenzfläche, die positiv prox-
imale Seite. Die Aminosäurereste der Grenzfläche auf der proximalen Seite des
P450 sind normalerweise Arginin- und Lysinreste. Die von CPR sind Asparaginsäure-
und Glutaminsäureresten. P450s bindet an CPR mit unterschiedlichen Affinitäten.
Diese Affinitäten können von der berechneten Bindungsenergien der Komplexe
abgeleitet werden. Ein Modell des membrangebundenen Komplexes von T. bru-
cei CYP51 und humanem CPR wurde aufgrund des membrangebundenen Mod-
ells von CYP51 (T. Brucei) und dem „encounter“-Komplex von P450 und CPR
erzeugt. Diese wurde durch Brownschen Dynamik-Simulation (Diffusional Associ-
ation Software, SDA 7) erzeugt. Eine 210 ns Moleküldynamiksimulation wurde für
das System durchgeführt. In der Simulation verändert CYP51 von T. brucei seine
Richtung in der Membran leicht. Die Aminosäurereste der Grenzfläche haben sich
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in der Simulation nicht verändert und hat die Distanz zwischen dem Häm des
P450 und dem FMN Cofaktor des CPR haben sich verkürzt. Der Elektrontransfer
ist mit der verkürzten Distanz möglich.
SDA 7 ist ein Software-Paket um Brownsche Dynamiksimulationen von Makro-
molekülen durchzuführen. Aber es hat viele verschiedene voneinander abhängige
Eingabeparameter und die Analyse der Ergebnisse kann für neue Nutzer schwierig
sein. Ein Webserver für SDA 7 (webSDA) wurde programmiert um die Benutzer-
freundlichkeit von SDA 7, durch Verbesserung und Automatisierung des Verfahrens
zur Vorbereitung und Durchführung SDA Jobs, zu erhöhen. Der Webserver ist hil-
freich für neue Benutzer, welche die SDA-Software benutzen, aber auch für er-
fahrene Benutzer um ihre Simulationen zu erstellen.
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Introduction
1.1 Protein Structure
Proteins are fundamental building blocks of life. In humans, muscle cells mainly
use two proteins, actin and myosin, to produce contractions. In brain, another
type of proteins, signaling receptors on the membrane of nerve cells can be used to
transduce signals to response to stimuli. There are many other biological processes
modulated by proteins, such as DNA transcription, RNA translation and the cell
cycle.
Basic building blocks of proteins are amino acids. An amino acid has three
functional groups: the amine group (-NH2), the carboxylic group (-COOH) and
the side chain (-R). The amine group and the carboxylic group are connected
by a carbon atom (Cα) between them. The side chain of an amino acid is the
organic substituent group (-R). Figure 1.1A shows the generic structure of amino
acids. There are 20 common amino acids. At pH 7, they can be divided into three
groups: charged amino acids, polar but not charged amino acids and hydrophobic
amino acids. Charged amino acids are sub-divided into positively and negatively
charged amino acids. Positively charged amino acids are arginine (ARG, R) and
lysine (LYS, K). Histidine (HIS, H) can also be positively charged depending on its
protonation state. Negatively charged amino acids are aspartic acid (ASP, D) and
glutamic acid (GLU, E). Polar amino acids are serine (SER, S), threonine (THR, T),
asparagine (ASN, N) and glutamine (GLN, Q). Less polar amino acids are glycine
(GLY, G), alanine (ALA, A), proline (PRO, P) and tyrosine (TYR, Y). Hydrophobic
amino acids are valine (VAL, V), isoleucine (ILe, I), leucine (LEU, L), methionine
(MET, M), phenylalanine (PHE, F), tryptophan (TRP, W) and cysteine (CYS, C).
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1.1. PROTEIN STRUCTURE
Figure 1.1: General structure of amino acids (A) and dipeptides (B).
Amino acids are connected by peptide bonds as shown in Figure 1.1B. The
peptide bond is a covalent bond formed by condensation of two amino acids.
There are two conformations for peptide bonds. The one shown schematically
in Figure 1.1B is the trans peptide bond, which is the predominant conformation
of peptide bonds. However, the cis conformation for peptide bonds may form in
proteins as well. The cis peptide bonds have both -NH and -C=O groups on the
same side of the peptide bond.
The primary structure of a protein is the amino acid sequence. The primary
structure is held together by peptide bonds. The amino acid sequence is translated
from RNA by ribosomes and RNA is transcribed from DNA by RNA polymerases.
Mutations in the primary structure of proteins may result in disorders of protein
function and thus cause human diseases.
The secondary structure is the general three-dimensional form of a protein.
There are three major secondary structure elements, the alpha helix, beta sheet
and loop. The secondary structure is characterized by hydrogen bond patterns.
The tertiary structure is the arrangement of secondary structures of proteins,
or the fold of protein. The folding is driven by burying hydrophobic residues inside
the protein and exposing the hydrophilic residues on the surface of the protein.
The tertiary structure of a protein is crucial for its function. Misfolded proteins
may lead to disrupted function of proteins and thus result in disease.
The quaternary structure is how subunits of proteins arrange in complexes. The
subunits can be of the same amino acid sequence (homo-oligomer) or of different
amino acid sequences (hetero-oligomer).
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1.2 Cytochrome P450 Enzymes
Cytochrome P450 enzymes (CYP, P450) constitute a protein superfamily which is
found in all the kingdoms of life existing in archaea, bacteria and eukaryota [1, 2].
The name is derived from the fact that, when the protein is complexed with carbon
monoxide (CO) in the reduced state, the protein has its absorption maximum at
450 nm [3]. In humans, there are 57 genes encoding P450s [4, 5]. These genes
are divided into 18 families and 44 subfamilies. Important families are CYP family
1 (CYP1), CYP family 2 (CYP2), CYP family 3 (CYP3) and CYP family 51 (CYP51)
[4]. The CYP1, CYP2 and CYP3 families are involved in drug metabolism and
steroid metabolism, and the CYP51 family is important for steroid biosynthesis
[4, 6]. CYP51 is also used as a drug target for anti-fungal drugs and anti-parasitic
drugs [7]. Important human P450s include CYP1A2, CYP2A6, CYP2C9, CYP2D6,
CYP2E1 and CYP3A4 which metabolize 70-80% of all drugs [1, 5]. The following
sections “Structure”, “Ligand Tunnels” and “Membrane-bound Cytochrome P450s”
are based on the review by Yu et al. [2].
1.3 Structure
As of November 2014, there are 645 structures of P450s in the Protein Data Bank
(PDB, http://www.pdb.org/pdb/home/home.do). 135 out of 645 structures are
human P450s. The sequence similarity between different P450 families is lower
than 40% [8]. However, the protein fold and secondary structure are conserved.
There are 12 α-helices, named A-L, and four β-sheets, named 1-4 [9, 10]. The
short helices between helices A-L are named with prime or double prime, such
as B’, F’ and G’ helices [8].There are two important blocks in P450s, the region
between B and C helices, the B-C loop region, and the region between F and G
helices, the F-G loop region.
These crystal structures have been solved for 23 different families of P450s and
are listed in Table 1.1. Most of the structures have ligands in the active site and
are in a closed form. A few CYP structures are in an open form and some of them
are partially open with ligands near the protein surface rather than in the active
site. Table 1.1 gives the length of the secondary structure elements in the B-C and
F-G blocks which are the regions of the protein that generally undergo the greatest
conformational changes between open and closed structures. We define the B-C
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block to extend from the beginning of the B-helix to the end of the C-helix, and
the F-G block to extend from the beginning of the F-helix to the end of the G-helix.
Although the overall fold of the CYPs is well conserved, the length and secondary
structure of the B-C and F-G blocks vary considerably. While the flexibility and
degree of conformational change of the B-C and F-G blocks of CYPs cannot be
deduced just from the secondary structure content alone, the secondary structure
does provide an indicator of the flexibility of the B-C and F-G blocks. In general,
going from loop to helix to sheet, the flexibility decreases whereas the rigidity
increases. The longer the loop region the block has, the more flexible this block
should be. For some crystal structures, parts of the B-C and F-G blocks are missing
because they are disordered in the crystal. In addition, the length of the B-C and F-
G blocks and the amino acid composition of these regions can also influence their
flexibility. But how exactly the flexibility relates to the conformational changes or
the transformation between open and closed states, is still unknown [11].
CYP PDBID Ligand
state
Conf. B-C block F-G block
αB B-C loop αC αF F-G loop αG
CYP1A1 4I8V _9_2_4___7______5_14_17 8_1_7_4__3___2_5__3_25
CYP1A2 2HI4 +L C _9_2_4___7______5_14_17 8_1_7_4__3___2_5__3_25
CYP2A6 1Z10,
1Z11,
2FDU,
2FDV,
2FDW,
2FDY,
2PG5,
3EBS
+L C _9_2_4_3_3______7__9_18 ___17_2__7_____5__4_25
2PG6,
2PG7
-L C _9_2_4_3_3______7__9_18 ___17_2__7_____5__4_25
3T3Q,
4EJJ
+L C _9_8___2_3______7__9_17 ___16_3_13_______5__25
3T3R +L C _9_8___2_3______7__9_17 ___17_2_13_______5__26
CYP2A13 2P85 +L C _9_2_4_3_3______7__9_18 ___17_2__7_____5__4_25
3T3S +L, -L C _9______13______7__9_18 ___16_3_____13____5_25
4EJG,
4EJH
+L, -L C _9_5_3_2_3______7__9_17 ___16_3_____13____5_24
4EJI +L C _8__8__2_3______7__9_17 ___16_3_____13____5_25
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CYP3A4 1W0G,
2V0M,
3NXU
+L C _9_2_5___9______4__8_15 ____6__9_8__2__9__5_18
1TQN,
1W0E
-L C _9_6_5_3_7______3__8_15 ____6__9_8__2__9__5_18
1W0F -L,
+LS
C _9_6_5_3_7______3__8_15 ____6__9_8__2__9__5_18
2J0D +L, -L O2MR _9_2_5____9_____4__8_15 ____9__2_7__2__9__5_18
3TJS +L O2MR _8_______17_____5__6_15 8_2_7_6_2_3___2_4_7_19
3UA1 +L C _8_______17_____5__6_15 ____6__10__8_1__9_7_15
CYP7A1 3DAX -L C _8_4___4_______13_14_10 ___21____6___3__3_1_13
3SN5 +L C _8_5_2_2_11__6____3_6_9 ___16_2__6____3_3_1_13
CYP8A1 3B6H +L,
+LS
I1 _8_6_2_2________9__10_9 ___20_4___17__2_4_7_12
CYP11A1* 3N9Y,
3N9Z,
3NA1,
3NA0
+L C _9___11__9__6___3__2_15 ___20_4______7____1_32
3MZS +L C _9___11_______10__11_14 ___19_4______7____1_30
CYP17A1 3RUK +L C _8_3_4___6_____6__13_15 ___16____10_____4_4_21
3SWZ +L C _8______13_____6__13_13 ___16____10_____3_5_23
CYP19A1 3EQM +L C _9_1_3___6_____7__11_15 ___19_3___5__1_3__1_26
3S79 +L C 13_6_7____________12_14 ___18_4___5__1_3__1_26
3S7S +L C _9_1_3___6_____7__12_14 ___18_4___5__1_3__1_26
CYP21A1 3QZ1 +L,
+LS
I1 _4________34_________15 ___12_8___8__1_3__5_26
CYP24A1* 3K9V,
3K9Y
+L,
+LS
O2 10______10____10__10_16 ___13_1___3__5_7__2_28
CYP46A1 2Q9F +L C _9_4_2_1__7_3_1_3_11_13 ___17_____11________32
3MDM +L C _9_4_2_1__7_3_1_3_11_13 ___18_3___3_______2_34
3MDR,
3MDT
+L CMR _9_4_2_1__7_3_1_3_11_13 ___18_2______7______32
2Q9G -L CMR _9_4_2_1__7_3_1_3_11_13 ___17_4_____10______27
3MDV +L CMR _8_8_8_2_2_2______11_15 ___16_2______7____1_30
CYP1B1 3PM0 +L C _8_______13_____9__9_16 ____6_3___8__9_5__3_30
CYP2B4 1SUO,
2Q6N
+L C _9_2_4_3__3_____7__9_19 ___18_1___9____5__4_24
3KW4 +L,
+LS
C _9_2_4_3__3_____7__9_19 ___18_1___9____5__4_24
3ME6 -L C _9_2_4_3__3_____7__9_19 ___18_1___9____5__4_24
3MVR +LS C _9_2_4_3__3_____7__9_19 ___18_1___9____5__4_24
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2BDM +L,
+LS
O12 _9_2_4____6_3_5_3__5_18 ___11_8___9_______9_25
3G5N,
3G93
+L,
+LS
O12 11_1_3____4_4_2_4__3_21 ___11_8_10_10__5__1_18
1PO5 -L O1 _9_2_3____________21_16 ___13_6___9____6__3_25
3R1A +L C _8_8_2__6___4_____10_17 ___18_1_____13____5_24
3R1B +L,
+LS
O12 _9_8_2____7_____9__3_17 ___11__1__2__5_10_9_23
3TK3 +L C 11_6_2____6_____4__9_17 ___16__3_______16_6_25
CYP2B6 3IBD +L C _8_5_3_2__6_____4__9_17 ___17__2_______13_5_25
3QOA +L C _8_3_4_3__6_4_3_4__2_14 ___18__1_______13_5_26
3QU8 +L, -L C _8_8_2__6_______4__9_17 ___18__1_______13_5_25
CYP2C5 1DT6 -L I1MR _9_2_4_____7____4_14_13 ___16_4_____11____4_25
1N6B,
1NR6
+L C _9_2_4_3_3______7__9_15 ___17_4___5__2__6_1_27
CYP2C8 1PQ2 -L,
+LS
C _9_2_3____7_____7__9_15 ___17_3___6__4__4_1_27
2NNH,
2NNI,
2NNJ,
2VN0
+L,
+LS
C _9_2_4_3_3______7__9_15 ___18_1___7__1_6__1_27
CYP2C9 1OG2 -L C _9_2_4_3_3______7_10_15 ___18_1___8__1_6__1_28
1OG5 +L C _9_2_4_3_3______7_10_15 ___18_1___8__1__6_1_28
1R9O +L I1MR _9_2_4_3__________18_15 ___18_4______7____8_26
CYP2D6 2F9Q -L C _9_2_3____7_____6_15_19 ___25____13____4____20
3QM4 +L I1 _9_3_3____7_____6_15_16 ___15_4__6___9__6_2_19
CYP2E1 3E4E,
3E6I,
3GPH,
3KOH,
3LC4
+L C 10_2_4_3_3______6_11_17 ___17__2__9_____4_6_25
3T3Z +L C _9_7_2_3________3_15_16 ___16__3__8_1___4_6_24
CYP2R1 3C6G,
3CZH,
3DL9
+L C _9_2_4____7_____7_11_17 ___17__2__8__1_5__4_23
CYP51 3JUS,
3LD6
+L C _8_6__2__2__10__4_3_2_12 ___30__7__6__10______31
3JUV -L C _8_6__2__2__10__4_3_2_12 ___30__7__6__10______31
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Table 1.1: Summary of conformations observed in the crystal structures of mammalian CYPs.
The structures with ligand(s) bound in the active site are denoted as “+L”, the apo structures
by “-L”. When bound and apo forms of the enzyme are present in the same structure (different
chains) with identical conformations, both labels “+L” and “-L” were used for the same structure.
“+LS” represents ligand(s) bound at the protein surface. The conformation type is labeled as: (i)
“O”-open; (ii) “I”-partially open; (iii) “C”-closed. The open conformations were classified into 2
sub-types: (i) “O1,”, “I1,”-structures with the open cleft between the B-C and F-G blocks (with the
2a, 2ac and 2c channels open); (ii) “O2”-structures with open cleft between the F-G block and the
β4 region (with the solvent and the 2f channels open). Incomplete structures are labeled with
“MR” and the number of missing residues is shown as “x” in the conformations of the B-C and F-G
blocks (columns 4, 5). The conformational signatures of the two blocks are defined as a sequence
of secondary structure elements (α-helix in italic text, β-strand in bold text, coil in normal text,
missing crystal residues in italic and bold text), each of which is formed by the indicated number
of residues. The helices αB, αC, αF, and αG are flanking helices of the 2 variable structure blocks.
(*) Crystal structures have been determined for 2 mitochondrial CYPs. Mitochondrial CYPs do not
have an N-terminal transmembrane helix.
Examples of closed, open and partially open crystal structures are shown in
Figure 1.2. CYP2B4 has been found to adopt a range of closed conformations
(Figure 1A) as well as different open conformations (Figure 1.2, B and C). One
of the open structures of CYP2B4 (PDB id: 3R1B) displays a very large conforma-
tional difference in the F-G block compared to the closed structure (Figure 1.2A
vs. B). The F and G helices are twisted to adapt to the movement of the combined
F’/G’ helices which make contacts to another protein subunit in the crystal. This
movement of the F-G block opens up a tunnel to the active site making it accessible
to ligands. We previously developed a nomenclature for the different ligand path-
ways through tunnels in CYPs which are distinguished by the secondary structure
elements lining them and their spatial location [12, 13]. In this open structure
(Figure 1.2B), the channel encompasses and merges pathways 2a, 2ac and 2b,
which all run between the F-G block and the B-C loop. Pathway 2a leaves the
protein between the F-G loop, B’ helix/B-B’ loop/B-C loop and the β1 sheet, path-
way 2c between the G and I helices and the B’ helix/B-C loop, and pathway 2ac
between pathways 2a and 2c. Pathway 2b leaves between the B-B’ loop and the
β1 and β3 sheets, whereas pathway 2d leaves between the N-terminus and he-
lices a/A’ and A, pathway 2e through the B-C loop, and pathway 2f between the F’
helix/F-G loop and the β5 sheet [12]. In the open structures of other mammalian
CYPs (CYP3A4 and CYP24A1) that are currently available, the ligand tunnel is
located between the F-G block and the β4 region and corresponds to the solvent
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channel (S) and pathway 2f. The solvent channel, so named because it has been
proposed as a route for water molecules [14], passes between the E, F and I helices
and the β5 sheet [12]. The two open structures of CYP3A4 show some disordered
missing residues near the end of the F helix.
In the partially open structure of human CYP3A4 (Figure 1.2D), the F-G loop
moves towards the B-C loop in the direction parallel to the heme plane leav-
ing the tunnels S and 2f open. The structure of the bovine P450C1 (CYP21A1)
has also been solved in a partially open conformation with a ligand ((9beta)-17-
hydroxypregn-4-ene-3,20-dione) trapped in the 2b ligand tunnel (Figure 1.2, E
and F). Here, it is the B-C loop rather than the F-G block that shows conforma-
tional diversity, its B-C loop lacks a B’ helix. In some of the other partially open
crystal structures listed in Table 1.1 though, the F-G block shows conformational
change. In two of these cases (for CYP2C5 and CYP2C9), part of the F-G loop is
disordered and missing from the structure.
1.4 Ligand Tunnels
1.4.1 Molecular Dynamics Techniques
MD simulations have been applied to CYPs to study many aspects of their function
including ligand tunnel analysis, prediction of metabolic products and design of
inhibitors or drugs. Here, we focus on their application to understand how the
ligands egress from the buried active site of CYPs. Table 1.2 shows the simula-
tions that have been done to study the ligand tunnels in eukaryotic CYPs. These
employ classical MD simulation, in some cases, together with enhanced sampling
procedures such as RAMD (random acceleration molecular dynamics), umbrella
sampling and SMD (steered molecular dynamics).
In classical MD simulations, the typical simulation lengths are currently ca.
10-100 nanoseconds. This time is much shorter than the timescale for enzymatic
turnover of CYPs and ligand dissociation [15]. Thus, while standard MD sim-
ulations can reveal many motions relevant to properties such as ligand tunnel
opening, they cannot currently give a full picture of how the CYPs function.
To study phenomena that take place on longer timescales than the duration of
a typical MD simulation, an enhanced sampling technique needs to be used. These
methods increase the sampling of the event of interest during the MD simulations.
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Figure 1.2: Comparison of closed, open, and partially open crystal structures of mammalian CYPs
with key helices labeled. (A) Closed structure of human CYP2B4 (PDB id: 3R1A). (B) Open (PDB
id: 3R1B) structure of rabbit CYP2B4. In this open structure, the F-G loop extends out to make
crystal contacts with another protein subunit in the crystal. (C) Open structure with another
conformation of rabbit CYP2B4 (PDB id: 3G5N) showing the possibility to adopt different open
conformations. (D) Structure of human CYP3A4 (PDB id: 2J0D) with the 2f and S tunnels open.
The partially open structure of bovine CYP21A1 (P450c21, PDB id: 3QZ1) is shown in cartoon (E)
and surface (F) representations. Both the ligand in the active site and the ligand trapped in the
2b tunnel, holding it open, are shown in stick representation. The proteins are shown in cartoon
representation with the heme cofactors in stick representation. The F-G loop region is shown in
red and the B-C loop/B’ helix in purple.
Random acceleration molecular dynamics (RAMD) was designed to study lig-
and egress from the buried active sites of enzymes such as CYPs and was first
applied to study the bacterial cytochromes P450cam and P450-BM3 [16, 17]. In
RAMD, a user-defined force with a randomly chosen direction is applied to the
center of mass of the ligand in the active site of the protein. The motion of the sys-
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tem is then propagated by classical MD simulation. After a pre-defined number of
timesteps, the distance that the ligand has traveled is checked and, if it is shorter
than a pre-defined minimum distance, the direction of the force will be changed.
If it is longer, the same force with the same direction will continue to be applied to
the ligand. The simulation is continued with the random force direction continu-
ally adjusted using the same criterion until the ligand has exited from the protein.
RAMD thus allows ligand egress to be observed in short simulations (in published
studies ranging from several ps to a couple of ns). Many RAMD trajectories can be
run for one ligand-receptor complex to explore the range of possible ligand egress
routes from a protein. RAMD provides a way to probe weak spots in the active
site cavity by which a ligand can leave. It provides mechanistic insights into how
ligand egress occurs but it should be born in mind that the timescale of RAMD
simulations does not correspond to the real ligand egress timescale. Furthermore,
RAMD will sample fast and/or ligand-induced conformational changes upon lig-
and egress better than low-frequency motions of the protein such as inter-domain
breathing.
The ligand egress routes identified by RAMD can be studied in more detail to
compute force and free energy profiles by several methods. SMD [33] has been
used in a number of studies of ligand egress from CYPs. As in RAMD, a force
is again applied to the center of mass of the ligand. In SMD, though, the force
is usually applied in the same direction throughout the simulation and thus the
route to be taken by the ligand must be known before the simulation is performed.
Analogously to an atomic force microscopy (AFM) experiment, the ligand is pulled
slowly out of the protein and the corresponding force profile is computed. Another
procedure to compute the free energy profile or potential of mean force (PMF) for
ligand egress from a protein is Umbrella Sampling. This is a method that allows
free energy barriers between two states to be computed by adding an additional
‘umbrella term’ to the force field to enhance the sampling of energetically unfavor-
able configurations in the vicinity of the free energy barriers. SMD and umbrella
sampling, as well as other methods for computing free energy profiles, can require
long calculations in order to obtain converged and accurate free energy profiles.
The difficulty in obtaining accurate free energy profiles for CYPs comes from the
difficulty of fully sampling the lower frequency, large scale degrees of conforma-
tional freedom. Thus, free energy barriers are generally overestimated but these
10
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approaches can be useful to estimate the relative free energy barriers, and thus
relative probabilities, of ligand egress by different routes.
1.4.2 Application of Molecular Dynamics Techniques to Study
Ligand Egress Tunnels
The ligand egress tunnels were firstly studied using prokaryotic P450s, such as
P450cam [34], P450BM-3 [16, 17, 34] and P450eryF [34]. Ligand tunnel 2a is
often used by these P450s for ligand egress. The first study of ligand tunnels in a
mammalian CYP was done using RAMD by Schleinkofer et al. [27]. Tunnel 2c was
found to be the predominant egress tunnel in the simulations of CYP2C5 in water.
Two mechanisms of ligand entrance and exit were proposed from these studies
based on the first crystal structure of a mammalian CYP, that of rabbit CYP2C5: a
one-pathway mechanism with the same entrance and exit route for substrates and
products (pathway 2a towards the membrane), and a two-pathway mechanism
with a different entrance route for substrates (pathway 2a) from the exit route for
the more polar products (pathway 2c to the cytoplasm).
SMD simulations starting with a human CYP2B1 structure derived by homology
modeling with testosterone docked in the active site showed the2c and 2e tunnels
to be the preferred tunnels [26]. Pathway 2e threads through the B-C loop. A
similar procedure was applied to the crystal structure of CYP3A4 with metyrapone.
Tunnel 2ewas found to have a higher probability to serve as the ligand exit tunnel
[21]. The preferred ligand exit tunnels for ketoconazole from the active site of
human CYP3A4 were pathway 2b and 2e using MD simulation and geometric
analysis with MOLAxis [23].
The protocol of using a conventional MD simulation followed by a combina-
tion of RAMD and SMD has been employed in several studies [16, 17, 19]. First,
tunnels are identified and the frequency of ligand egress through the different tun-
nels is computed with RAMD. Then, the most frequent egress routes are chosen for
computation of the force profile for ligand exit using SMD. Lastly, statistical analy-
sis of the PMF with methods such as Jarzynski’s equality [35] gives a quantitative
energetic comparison of the ligand tunnels. This protocol has been applied to sev-
eral mammalian CYPs, including human CYP2A6 [19] and human CYP2E1 [31].
Tunnels 2c was proposed to be the preferred egress tunnel for CYP2A6, whereas
tunnels 2a and 2c were preferred for CYP2E1. A recent RAMD study of human
12
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Figure 1.3: Ligand tunnels and secondary structure elements of a model of membrane-bound
CYP2C9. Not every CYP has all these ligand tunnels. (A) The dashed line shows the approximate
position of the membrane in the simulation of the membrane-bound CYP2C9 [30]. The F-G loop is
shown in red and the B-C loop in purple. The ligand tunnels are labeled following the nomencla-
ture in Ref. [12]. The identifier numbers of the simulations (see Table 1.2) in which the tunnel is
found to be a preferred ligand egress tunnel it shown next to the name of the tunnel. (B) A view
from the other side of the protein showing the other ligand tunnels. The same coloring scheme is
used as in (A).
CYP2C9 suggests multiple ligand exit tunnels depending on the ligand properties
(Figure 1.3). The main routes identified were tunnels 2a, 2ac, 2c and 2e. The
substrate flurbiprofen tended to exit via tunnel 2c or 2e whereas the flurbiprofen
product tended to exit via tunnel 2c. The charged form of the S-warfarin product
tended to exit by tunnels 2ac and 2e whereas the neutral form of the S-warfarin
product was found to exit preferentially through tunnel 2a from the soluble form
of CYP2C9. This latter route was shown to point into the lipid bilayer in the models
of membrane-bound CYP2C9 [29, 28].
Hendrychova et al. have systematically simulated the six major drug-metabolizing
CYPs (2A6, 2B4, 2C9, 2D6, 2E1, 3A4). Each CYP was simulated for 100 ns or
longer in aqueous solution [20]. A transformation from an open towards a closed
conformation of CYP2B4 was observed in these simulations. The systematic anal-
ysis of six major mammalian CYPs demonstrates that the variability in flexibil-
ity of the active site and the F-G loop contributes the largest movements in the
6CYPs.During the simulation, the ligand tunnels remained open in CYP2C9 and
CYP2B4, temporarily closed in CYP3A4 and CYP2D6, and were always closed in
CYP2A6 and CYP2E1.
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1.4.3 Aromatic Gating of Ligand Tunnels
The ligand tunnels are often gated by aromatic residues. Despite the conservation
of the CYP fold, there is a high diversity in the number and arrangements of the
aromatic gates in CYPs. From analysis of crystal structures, it has been suggested
that aromatic residues can form a network of gates that regulate the opening and
closing of different ligand tunnels cooperatively [36].
The gating of a ligand tunnel was first observed in a CYP in simulations of
bacterial P450cam in which ligand egress by tunnel 2a was gated by rotation
of phenylalanine and/or tyrosine residues [16, 17].In human CYP2C9 (PDB id:
1R9O, 1OG5), there are three phenylalanine residues (F100, F114, F476) which
act as aromatic gates of tunnel 2a (Figure 1.4, A and B). In Figure 1.4A, the three
aromatic residues are in a closed state where they cap the ligand in the bound
state, whereas in Figure 1.4B, the aromatic residues are in an open state which al-
lows for ligands to enter or exit. In a simulation of the membrane-bound CYP2C9,
opening motions of the aromatic gates were observed and the lipid bilayer also
stabilized the open aromatic gates [29]. In a study of the complex of CYP3A4 with
the ligand temazepam (PDB id: 1TQN), different gating residues were observed
for different ligand tunnels (Figure 1.4C) [22]. The pairs of aromatic residues
gating ligand tunnels 2a, 2b, 2c and 3 are, respectively, F57-F215, F108-F220,
F108-F241 and F213-F241.
Not all ligand tunnels in mammalian CYPs have gating aromatic residues. For
example, CYP2C5 (PDB id: 1N6B) is shown in Figure 1.4D. K241 and V106, which
are not aromatic residues, gate ligand tunnel 2c [27]. The residues at the same
position as the aromatic residues gating tunnel 2a in CYP2C9 are also shown in the
figure. There are two aromatic residues (F114 and F473) and one non-aromatic
residue (V100), suggesting that tunnel 2a to the membrane might be gated by
aromatic residues. Further potential aromatic gates have been identified in sim-
ulations of CYP2B1, CYP2E1 and CYP2A6. In the SMD simulation of CYP2B1,
the gating residues of tunnel 2e were F108 and F297 whereas F115 was the gat-
ing residue of tunnel 2b [26]. The ligand tunnel 2c of CYP2E1 has a ceiling of 5
phenylalanines over the active site [31]. F298 was suggested to be the gate keeper
due to its association with the opening and closing of the ligand tunnel. Mutagen-
esis of another of these phenylalanines, F478 to valine, has shown the importance
of this residue and its key position implicates it as the gate keeper for ligand tun-
nel 2a. In a similar study, rotation of the side chain of F111 was observed to occur
14
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Figure 1.4: Aromatic residues gating ligand tunnels in different CYPs. (A) Gating residues F100,
F114, and F476 (tunnel 2a) in a closed conformation of human CYP2C9 (PDB id: R9O). (B) Gating
residues F100, F114, and F476 in an open conformation in human CYP2C9 (PDB id: 1OG5). (C)
Gating residues F57-F215 (tunnel 2a), F108-F220 (tunnel 2b), F108-F241 (tunnel 2c), and F213-
F241 (tunnel 3) of human CYP3A4 (PDB id: 1TQN). (D) Gating residues of rabbit CYP2C5, K241-
V106 (tunnel 2c) and residues at the same position as the CYP2C9 aromatic gates (V100, F114,
and F473) indicate the diversity of the gating residues which are not limited to aromatic gates.
during ligand egress through tunnel 2c of CYP2A6 in RAMD and SMD simulations
[19].
1.5 Membrane-bound Cytochrome P450s
The simulations discussed so far were performed for each CYP in an aqueous en-
vironment. The eukaryotic CYPs are membrane bound but the inclusion of a lipid
bilayer in the simulation system is challenging because there is no experimentally
determined structure of a CYP in a lipid bilayer. It is important to model CYPs in
their membrane-bound form because the association with the membrane can influ-
ence the protein dynamics, the ligand binding kinetics and the binding selectivity
of CYPs.
While a number of models of how CYPs position and orient with respect to
a lipid bilayer have been constructed [30], these have been made by hand us-
ing molecular graphics and fitting to available experimental data and they give a
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range of possible orientations. Recently, Cojocaru et al. built a membrane-bound
model of a mammalian CYP in a1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
(POPC) bilayer from first principles using a combination of coarse-grain and atomic-
detail MD simulation techniques [29] (Figure 1.3). The model was made for hu-
man CYP2C9. The height of the protein above the membrane is consistent with the
experimental measurements, as are most of the buried and exposed residues. This
membrane-bound model gives indications of how the membrane can influence the
dynamics of CYPs and their ligand tunnels. In the membrane-bound form of hu-
man CYP2C9, the F-G loop is inserted into the membrane so that the 2a and 2f
ligand tunnels lead into the membrane. The other tunnels, including 2ac, 2b, 2c,
2d, 2e and S lead to the aqueous solution. This orientation of CYP2C9 above the
membrane, such that some of the potential ligand tunnels point into membrane
while others point towards the aqueous solvent, suggests that the preferred tunnel
for a given ligand depends on its hydrophilicity. Hydrophobic ligands would favor
the tunnels to/from the membrane (2a and 2f). Hydrophilic ligands would favor
the tunnels to/from the aqueous solution.
Since the flexible F-G block is inserted into the lipid bilayer and the B-C block
is partly interacting with the bilayer, the membrane can affect the flexibility of
the B-C and F-G blocks. In the simulations, the mobility of these regions of the
protein is reduced in the membrane-bound form compared to the soluble form
[30, 29, 24]. This suggests that the membrane could constrain the conformational
changes in these regions of the protein and hinder the conversion between open
and closed states. However, the simulations performed for the membrane-bound
CYP2C9 are relatively short (10 ns) and this time is not long enough to allow the
conformational changes between open and closed states to occur.
Other studies of membrane-bound CYPs give insights into the influence of the
membrane on the dynamics of mammalian CYPs. In simulations of soluble and
membrane-bound forms of CYP3A4 [24], tunnel 2b remained open in both the
soluble and the membrane-bound forms whereas tunnel 2e stayed open in the
soluble form and closed in the membrane-bound simulation. The movement of the
F and G helices resulted in the closing of tunnel 2e and was observed only in the
simulation of the membrane-bound form [24]. Berka et al. simulated CYP2C9 in
a phospholipid bilayer and found the solvent tunnel to be most open and suitable
for product egress [30].
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1.6 Focus of this thesis
Although there have been extensive computational studies of both prokaryotic
and eukaryotic P450s, the CYP51 family has not been studied a lot. Homology
models have been built and studied for Saccharomyces cerevisiae [37], human [38]
and Penicillium digitatum (plant) CYP51s [39]. Computational study for parasitic
CYP51s, which are important drug target for antiparastic drug design [7], such as
Trypanosoma brucei, have not been performed.
This thesis will focus on computational studies of T. brucei CYP51. It com-
pares dynamics of T. brucei CYP51 with that of human CYP51 and human drug-
metabolizing CYP51s in Chapter 3 and this chapter is based on the published
research paper by Yu et al. [40]. It investigates ligand tunnels in both T. brucei
and human CYP51s in Chapter 4. Chapter 5 is a study of interactions of different
P450s with their redox partner, cytochrome P450 reductase (CPR) and Chapter 6
is a study of the simulation of the complex of T. brucei CYP51 and human CPR in
the membrane. In the last chapter, Chapter 7, a webserver built for the Simulation
of Diffusional Association (SDA) software tool is described.
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Methods
2.1 Introduction
Computational methods offer a way to study biological systems and have been
developing very fast in recent years. Methods of computational biology use math-
ematical models to describe biological systems [41]. Computational methods give
a complementary way to experiments to study biological systems on the micro-
scopic scale.
The 2013 Nobel Prize in Chemistry was awarded to Martin Karplus, Michael
Levitt and Arieh Warshel “for the development of multiscale models for complex
chemical systems” (http://www.nobelprize.org/nobel_prizes/chemistry/laureates-
/2013/). This award not only shows that computational studies are important for
current molecular research, but also promotes the field of computational molecu-
lar studies.
Using computational methods can allow researchers to predict biomolecular
interactions, such as protein-ligand binding, protein-protein binding, and to study
the dynamics of biological systems, such as in this thesis, cytochrome P450 sys-
tems. There are many related theories and methods in molecular modeling and in
this chapter, it is impossible to cover all aspects. Here, only theories and methods
that were used in this PhD study are introduced and discussed.
2.2 Molecular Mechanics
Molecular mechanics (MM) is developed to model molecular systems using classi-
cal mechanics. In MM, interatomic energy terms are computed using force fields.
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Force fields define the mathematical equations to compute forces on each atom.
MM can be used to study interactions of macromolecules, investigate dynamics
of biological molecules and design inhibitors for macromolecules. Using MM can
reproduce experimentally determined properties, such as dynamics of proteins,
protein-protein association, as described in this thesis in Chapters 3, 4, 5 and 6.
2.3 Force Fields
Different force fields are used depending on the properties of the system of study.
All-atom (AA) force fields are used when every atom of a system is considered.
This section will introduce AA force fields. In united-atom (UA) force fields, only
non-hydrogen and polar hydrogen atoms are treated as particles. The effects of the
non-polar hydrogen atoms are subsumed into the parameters of the non-hydrogen
atoms that they are bonded to. UA force fields are beyond the scope of this thesis
and will not be introduced in detail. Various force fields can be applied and will
be introduced in the next section.
2.3.1 Components of a Force Field
A simple force field consists of bonded and non-bonded potential energies:
Etotal = Ebonded + Enonbonded (2.1)
The total energy of the system Etotal is the sum of the energies of the bonded
termsEbonded and the non-bonded termsEnonbonded. The bonded interactionsEbonded
include the bond stretching (bond) Ebond, the bond-angle bending (angle) Eangle
and the dihedral terms Edihedral:
Ebonded = Ebond + Eangle + Edihedral (2.2)
The non-bonded interactions Enonbonded include the electrostatic Eelectrostatics
and the van der Waals energies Evan der Waals:
Enonbonded = Eelectrostatics + Evan der Waals (2.3)
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2.3.2 Bonded Interactions
Bonded interactions describe the forces between atoms connected by chemical
bonds. These interactions are short-range interactions and stronger than non-
bonded interactions.
2.3.2.1 Bond stretching
The bond stretching term describes the energy to stretch a chemical bond between
two atoms. One common approach is to use the Hooke’s law formula, which is a
harmonic potential:
Ebond =
∑
bonds
ki
2
(li − li,0)2 (2.4)
Ebond is the total bond stretching energy. ki is the stiffness of the bond spring. li
is the bond length and li,0 is the equilibrium bond length. There are other forms for
the bond stretching energy, such as the Morse potential. Bond stretching energy is
normally the strongest of interactions and depends on the type of atoms.
2.3.2.2 Angle bending
The angle bending term describes the energy to change the angle between three
atoms connected by chemical bonds. Similarly to the bond stretching energy, it
can be described using Hooke’s law:
Eangle =
∑
angles
ki
2
(θi − θi,0)2 (2.5)
Eangle is the total angle bending energy. ki is the stiffness of the angle spring.
θi is the bond angle and θi,0 is the equilibrium bond angle.
2.3.2.3 Torsional terms
The bond rotation describes the energy to rotate an atom around a dihedral bond
angle between four atoms connected by chemical bonds.
Edihedral =
∑
torsions
Vn
2
(1 + cos(nω − γ)) (2.6)
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Edihedral is the total bond rotation energy. n is the periodicity of the curve of
the potential function. γ is a position on the ω axis of the potential curve. Vn is the
“barrier” height. There are other expressions for the torsional potential and this is
one term that often varies among force fields. For some bonds, there can be more
than one term from the cosine series expansion.
Improper torsions are introduced to force fields as an additional term which
uses a harmonic or periodic function to keep planar carbons and the three atoms
bonded to it in the same plane.
2.3.3 Non-bonded Interactions
The non-bonded interaction terms describe the interactions between atoms that
are not connected by chemical bonds. Interactions of atoms that are further away
than a certain distance are normally very weak and ignoring these interactions
will not change properties of a system. Thus, for the computation of non-bonded
interactions, a “cutoff” is introduced. The cutoff defines the range for the force
calculation and it can be defined and may vary between different systems. Non-
bonded interactions that are out of the range of the cutoff will not be computed.
The non-bonded interactions include electrostatic interactions and van der Waals
interactions. The electrostatic interactions are described by the Coulomb poten-
tial and the van der Waals interactions are often described by the Lennard-Jones
potential. The sum of both non-bonded interactions is:
Enonbonded =
N∑
i=1
N∑
j=i+1
(
4ij
[(
σij
rij
)12
−
(
σij
rij
)6]
+
qiqj
4pir0rij
)
(2.7)
The meaning of the symbols is explained in the next two sections.
2.3.3.1 Electrostatic Interactions
Electrostatic interactions are the attractive interactions between electropositive
elements and electronegative elements and the repulsive interactions between el-
ements with the same sign property. In classical force fields, partial charges of
atoms are used to compute electrostatic interactions. Coulomb’s law can be used
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to calculate electrostatic interactions between two molecules or between different
parts of the same molecule [41]:
Eelec =
NA∑
i=1
NB∑
j=i+1
qiqj
4pir0rij
(2.8)
NA is the number of partial charges on the first molecule and NB is that on the
second molecule. The formula sums pair-wise interactions between each pair of
atoms of the two molecules. qi and qj are the partial charges on the atom of the
first and second molecule, respectively. r0 is the permittivity of the environment
and rij is the distance between the two atoms.
2.3.3.2 Van der Waals Interactions
Van der Waals interactions are the forces not only between neutral atoms, but also
between charged atoms. These forces include the force between two permanent
dipoles (Keesom force), the force between a permanent dipole and a correspond-
ing induced dipole (Debye force) and the force between two induced dipoles (Lon-
don dispersion force). The Lennard-Jones potential is used to approximate van der
Waals interactions:
EV dW =
N∑
i=1
N∑
j=i+1
(
4ij
[(
σij
rij
)12
−
(
σij
rij
)6])
(2.9)
σij is the collision diameter and ij is the depth of the potential well. rij is the
distance between two atoms. The Lennard-Jones potential is widely used in force
fields to calculate van der Waals interactions of molecules.
2.3.4 Different Types of Force Field
Different force fields were developed to serve different purposes, but nowadays
most force fields can be used to solve similar problems. Some of the most pop-
ular force fields are: the Assisted Model Building with Energy Refinement (Amber)
force field [42], the Chemistry at HARvard Macromolecular Mechanics (CHARMM)
force field [43] and the GROningen MOlecular Simulation (GROMOS) force field
[44]. There are many papers comparing the differences between force fields to be
applied to different systems but it is difficult to determine which force field is bet-
ter than the others [45]. Choosing which force field to use depends on properties
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of the system of study and the questions to answer. Here, the Amber force field,
which is used in all-atom simulations of this thesis, will be introduced.
2.3.5 Amber Force Field
There have been many different versions of the Amber force field, such as ff94
[42], ff96 [46], ff99 [47], ff03 [48], ff10 [49], ff99SB [50], ff99SB-ILDN [51]
and ff99-PHI [52]. These force fields can be used for amino acids and nucleic
acids. The Generalized Amber Force Field (GAFF) is developed for small molecules
such as organic compounds and drug-like molecules [53]. Amber force fields are
implemented in simulation software packages such as AMBER [54] and NAMD
[55].
The functional form of the Amber force field [42] is the sum of the previously
mentioned energy terms:
Etotal =
∑
bonds
Kr(r − req)2 +
∑
angles
Kθ(θ − θeq)2+
∑
dihedrals
∑
n
Vn
2
[1 + cos(nφ− γ)]+
N−1∑
j=1
N∑
i=j+1
{
ij
[(
r0ij
rij
)12
− 2
(
r0ij
rij
)6]
+
qiqj
4pi0rrij
} (2.10)
In the Amber force field, experimental data and calculated quantum mechani-
cal data are used to refine the parameters to reproduce the experimental observa-
tions.
AMBER force field uses the restrained ESP-fit (RESP) charge model [42]. RESP
is from the electrostatic potential (ESP) fit atomic centered charges derived from
quantum mechanical calculations using a 6-31G∗ basis set [56]. The major prob-
lem of the ESP fit is that it was derived to reproduce intermolecular properties but
not intramolecular properties [57]. The RESP charge model was then developed
by Bayly et al. [57] to address problems of ESP fitting. This avoids large variations
of atomic charges for different conformations of molecules and improves derived
atomic charges for buried atoms [42]. RESP is a two-stage approach: weak con-
straints on methyl groups without forced symmetry are applied in the first stage
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and the second stage is to refit the methyl groups using forced symmetry and
strong constraints [57].
The ff96 [46] and ff99 [47] force fields are improved by fitting parameters
describing the ψ and φ potentials to tetrapeptide and dipeptide quantum confor-
mational energies [58]. The ff99SB force field improves the φ/ψ dihedral term
in the ff99 energy function [50]. This solves the problem of having unreasonable
conformations of glycine in ff99 [50].
2.4 Energy Minimization
2.4.1 Introduction
As previously described, the energy or potential energy of a system is the sum
of all particle/atom interaction terms of the system. Energy changes when the
coordinates of atoms of the system change. The dependence of energy on the
coordinates of atoms is referred to as the “potential energy surface”. It is important
in molecular modeling to find minimum points on the energy surface and how
coordinates change from one minimum point to another. The algorithm to find
minima on the energy surface is referred to as a “minimization algorithm”.
Minimization is the process of finding with which set of coordinates, the energy
of the system has its local minimum. This can be described as: given a system
with the energy of E, when E has its minimum, the first derivative of E is zero
and second derivatives are all positive:
∂E
∂xi
= 0;
∂2E
∂x2i
> 0 (2.11)
Solving the equation completely is normally impossible. Thus, minimization in
molecular modeling is finding a set of Cartesian coordinates which gives the local
minimum of E. Most minimization algorithms search for the nearest minimum,
rather than the global minimum. The minimum is indicated by the direction of the
first derivative. The steepness of the local minimum is indicated by the magnitude
of the gradient.
There are many minimization algorithms that are used in molecular modeling.
Here in this chapter, the steepest descents method and the conjugate gradient
method will be introduced. These two algorithms are first order minimization
methods. In first order minimization methods, the current configuration of the
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system (k) is the starting point for the next iteration (k + 1). The initial starting
configuration is the user input, which is often obtained from the PDB structure of
the protein.
2.4.2 The Steepest Descents Method
The steepest descents method walks down the energy “hill” in the direction of the
net force on the system. On a two-dimensional energy surface, a line can be drawn
from the starting point along the direction of the net force. On the line, the local
minimum will be passed through and then the local minimum can be chosen for
the starting point of the next step.
2.4.3 The Conjugate Gradient Method
One problem of the steepest descents method is the oscillatory behavior in narrow
valleys. Instead of having both the gradients and the direction of successive steps
orthogonal, in the conjugate gradient method, the directions are conjugate but
the gradients at each point are orthogonal [41]. For conjugate directions, if a
quadratic function has M variables, the minimum can be reached in M steps.
2.5 Molecular Dynamics Simulation
2.5.1 Introduction
Molecular dynamics simulation is a way to explore the dynamic properties of bi-
ological systems. Following energy minimization, MD simulation is used to in-
vestigate kinetic and thermodynamic properties of systems. MD simulations use
Newton’s equations of motion to compute the forces on atoms of the system in a
defined time interval, typically a timestep of 1-2 fs. The timestep should be de-
fined to be shorter than the fastest motion of atoms. A collection of microscopic
states of the system is called an ensemble. The average properties of an ensem-
ble can be compared with macroscopic experimental data to reproduce or predict
experimental data.
Certain state variables are kept constant in simulations and thus different sta-
tistical ensembles can be produced. Popular ensembles include: NPT which has
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constant number of particles (N), pressure (P) and temperature (T) in the simula-
tion of the system and NVT which keeps number of particles (N), volume (V) and
temperature (T) constant during the simulation.
2.5.2 Periodic Boundary Conditions
Avoiding boundary effects is important for simulations to reproduce macroscopic
data. A common boundary condition used in simulations of biological systems is
the periodic boundary condition. The periodic boundary condition mimics a “real”
environment by positioning molecules in a box with a defined size. The box can
be cubic, octahedral or have other shapes. The cubic box is most widely used. It
treats the periodic condition identically in all three dimensions. In a simulation,
when defining the minimum necessary size, the distance between the surface of
molecules and the edge of the box should be greater than the cutoff. In a periodic
box, when an atom diffuses out of a boundary of the box, it is considered to enter
the opposite side of the box. In this way, the system simulated, for example a
protein, keeps as whole in the simulation regardless of diffusion.
2.5.3 Non-bonded Cutoffs
In an MD simulation, the most computationally expensive part is to compute the
non-bonded forces. The bonded terms, which are bond-stretching, angle-bending
and torsional terms are proportional to the number of atoms/residues of a system.
However, the non-bonded terms should be calculated between each pair of atoms
and the algorithm to calculate of the non-bonded terms is N2 where N is the
number of atoms. To simplify the computation, cutoffs are used to truncate the
non-bonded interactions to only atom pairs within a certain distance. In this way,
the non-bonded interactions between atoms that are “far away” from each other
are set to zero. Using improper cutoffs might lead to wrong simulations.
However, even using cutoffs, it is still computationally expensive to compute
non-bonded interactions. This is because distances between each pair of atoms
need to be computed which is a similar magnitude effort to computing all the
energies. The “non-bonded neighbor” list can be used to further simplify the com-
putation. The non-bonded neighbor list records neighboring atoms of a given
atom. Because the neighbors of the atom are recorded, only interactions between
the atom and its neighbors need to be computed, rather than the pair-wise inter-
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actions of all atoms of the system. The cutoff for neighbor lists should be larger
than the cutoff of non-bonded interactions to make sure that all atoms within the
interaction range are in the list.
However, cutoffs make the potential energy and forces discontinuous. To elim-
inate this, a shifted potential is used by subtracting a constant term from the po-
tential. Another approach, which is used in most simulation software packages, is
to use a “switching function”. The switching function is the multiplication of the
potential energy by a polynomial function.
2.5.4 Electrostatics
Electrostatic forces are long range interactions. The charge-charge interactions
have to be properly modeled to reproduce the macroscopic properties of systems.
There are various methods to compute long range forces.
One such method is the Ewald summation method [59]. The Ewald summation
is computationally very expensive and many tradeoffs to accelerate the computa-
tion have been introduced. One solution is to use fast Fourier transforms (FFT) to
compute the reciprocal space summation and a grid-based approach such as the
particle-mesh Ewald (PME) method [60]. The PME method maps charges onto
grid points.
2.5.5 Constraint Dynamics
It is possible to constrain the motion of atoms, for example, the covalent bond
between two atoms. Constraints are requirements that the system has to satisfy. In
molecular dynamics, the most commonly used method to constrain systems is the
SHAKE algorithm [61]. The SHAKE algorithm is used to perform MD simulations
with fixed bond lengths. In constraint dynamics, the mathematical equations are
solved by taking the constraints into account.
2.5.6 Constant Temperature and Pressure
Molecular dynamics simulation naturally samples NVE ensemble in which the sys-
tem has constant volume and energy. But two other ensembles are often used to
compare simulation results with experiments. These are the NVT ensemble and
the NPT ensemble as introduced previously.
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2.5.6.1 Constant Temperature Dynamics
Constant temperature is often applied to molecular dynamics simulations. The
temperature is kept constant to investigate the dynamics of systems, such as pro-
teins. Other approaches may use different temperatures. For an unconstrained
system, the temperature and the time average of kinetic energy are related as:
〈Ek〉NV T = 3
2
NkBT (2.12)
Ek is the kinetic energy of the system. kB is the Boltzmann constant and T is
the temperature.
One way to control the temperature introduced by Berendsen [62], is to cou-
ple the system to an external heat bath. The temperature of the heat bath, Tbath
is then the desired temperature. The velocities are rescaled at each timestep of
simulations:
dT (t)
dt
=
1
τ
(Tbath − T (t)) (2.13)
τ is the coupling factor.
2.5.6.2 Constant Pressure Dynamics
Constant pressure condition is another often used condition in molecular dynamics
simulations. Most experiments are done under constant pressure and thus, to
compare with these experiments, it is necessary to keep the pressure constant.
When the pressure is constant, the volume of the simulation cell changes. The
volume fluctuation is determined by the isothermal compressibility, κ:
κ = − 1
V
(
∂V
∂P
)
T
(2.14)
In an isobaric simulation, the volume change can be facilitated by changing
the volume in all three directions or in one direction. Changing three directions is
often used for simulations of soluble systems, such as protein in water. Whereas
changing one direction is often used for simulations of membrane-bound systems,
which the volume change is facilitated by just changing the volume in the direction
perpendicular to the membrane plane, which is often z direction.
Many pressure control methods are similar to those of temperature control.
One commonly used method is the Berendsen pressure control. Instead of having
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a heat bath of constant temperature, a “pressure bath” of pressure, Pbath is coupled
to the system. The rate of change of pressure is:
dP (t)
dt
=
1
τp
(Pbath − P (t)) (2.15)
τp is the pressure coupling factor.
The “extended system” method of Anderson [63] can also be applied to pres-
sure control. In this method, an extra degree of freedom is introduced to the
system, which is similar to a piston acting on the system.
2.6 Solvent
Solvent is an important factor for simulating biological systems. There are two
major classes of solvent models: implicit solvent model and explicit solvent model.
Implicit solvent models the solvent environment without having “real” solvent
molecules. One of the most used models is the Generalized Born model. Im-
plicit solvent is computationally more efficient because of having no solvent par-
ticles but less “realistic”. Explicit solvent allows systems to have explicit solvent
molecules, such as water molecules. This approach is closer to the “real” environ-
ment than the implicit solvent. However, introducing solvent molecules causes the
computation to be more expensive.
Molecular dynamics simulations are more often performed with explicit sol-
vent molecules, mostly water molecules. Using aqueous solution is a condition
that is similar to biological environments. It is important to simulate proteins in
solvent to study the behavior of proteins. Different water models have been devel-
oped for molecular dynamics simulations. The simplest models are the three-site
transferable intermolecular potential (TIP3P) water, and the simple point charge
(SPC) water. Other water models include the four-site transferable intermolecu-
lar potential (TIP4P) water and the five-site transferable intermolecular potential
(TIP5P) water.
2.6.1 TIP3P Water Model
TIP3P water model is a three-site model [64]. Each water molecule has three
“atoms” representing the one oxygen and two hydrogen atoms of a water molecule.
All the three sites have partial charges and the oxygen site also has parameters for
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Lennard-Jones interactions. TIP3P water is widely used in modern molecular dy-
namics simulations because of its simplicity and computational efficiency.
2.6.2 SPC Water Model
The simple point charge (SPC) model is also a three-site water model [65]. Similar
to the TIP3P water model, it is a rigid model without having internal degrees of
freedom [65]. Experimental values are used to define many of the parameters of
this water model.
2.7 Coarse-grained Simulation
2.7.1 Introduction
All-atom (AA) molecular dynamics simulation offers a great tool to study biologi-
cal systems computationally, yields a great amount of information about biological
systems and allows researchers to predict the output of experiments. However,
one challenging problem of all-atom simulations is that for large systems, such as
those containing millions of atoms, the computation can be too expensive. This
limits the use of simulations for large systems, such as a system of proteins on
a membrane within a water box. Depending on the question to answer, another
limitation may be that the simulation time is too short to investigate biological pro-
cesses. The microscopic time scale is normally a few nano-seconds, whereas the
macroscopic time scale is often a few micro-seconds or even longer. Researchers
tend to simulate a system “long” enough to make their observations closer to the
reality. However, because of the limitation of computational power, currently a
simulation can rarely be performed for a time scale of more than a few micro-
seconds.
Coarse-grained (CG) methods are thus developed to counter these problems.
Coarse-grain methods simplify systems by introducing beads to represent groups
of atoms of a molecule. For example, for a protein, instead of representing all
atoms of amino acids as individual particles, a coarse-grained model might use
one bead to represent all backbone atoms and one to three beads to represent all
side chain atoms, depending on the size of the side chain. In this way, the num-
ber of particles in the system is reduced five to ten times in comparison with the
all-atom system. Coarse-grained simulations also allow much longer timesteps as
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high frequency motions are removed. As a result, with the same amount of com-
putational power, it is possible to run much longer simulations and simulations of
much bigger systems. For example, for a system of membrane-bound CYP51, it is
possible to simulate 3 µs in 48 hours using a coarse-grained model in comparison
to 8 ns using all-atom model with the same computational resources, as discussed
in Chapter 3.
2.7.2 Martini Coarse-grained Model
Various coarse-grained models have been developed. One of the most commonly
used methods is the Martini coarse-grained model for biomolecular systems. Mar-
tini was initially developed to simulate a large number of lipids [66] and later
extended to protein systems [67]. Martini has been proven to perform well for
lipid systems [66] and can also be used to study membrane-bound proteins. For
example, a membrane-bound model of cytochrome P450s can be simulated to de-
termine the preferred orientation of a P450 protein in a lipid bilayer [29, 40].
The Martini coarse-grained model maps multiple heavy atoms to one Martini
bead [66]. Four types of interaction sites are introduced, which are polar (P),
non-polar (N), apolar (C) and charged (Q). Subtypes are derived from these four
basic types [66].
In the Martini force field, the non-bonded and bonded interactions are treated
similarly to the all-atom force field introduced previously [66]: Solvent is treated
similarly to heavy atoms. One solvent bead represents four water molecules. An-
tifreeze particles have to be introduced to avoid freezing of water molecules [66].
The time scale in coarse-grained simulations is different from that in all-atom sim-
ulations. The time scale is normally 2- to 10-fold longer than all-atom simulations
[66].
Martini coarse-grained method was extended for amino acids after it was de-
veloped for lipids. Mapping for amino acids is shown in Figure 2.1. For interac-
tions of coarse-grained amino acids, the non-bonded terms and bonded terms are
implemented similarly to those of lipids.
2.7.3 Elastic Network Model
An elastic network model is a structure-based method for coarse-grained simula-
tions [68]. It can be used to describe the structural properties of a system, such
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Figure 2.1: Mapping of all-atom amino acids to coarse-grained amino acids. Figure taken from
[67].
as a protein. For proteins, when the elastic network model is not used, results of
coarse-grained simulations are not in good agreement with all-atom simulations
[68]. However, with elastic network, the results of global and local deformation of
proteins in coarse-grained simulations are in agreement with all-atom simulations
[68].
Interaction terms of the normal Martini force field for this elastic network
model are slightly modified, because the backbone bead, in this model, is posi-
tioned at Cα atoms [68]. The elastic network uses a simple spring model with
only two parameters, Rc and Kspring [68]. Rc and Kspring have to be tuned for
different systems to be comparable to all-atom simulations. In the initial study,
using Rc ranging from 0.8 to 1.0 nm and Kspring from 500 to 1000 kJ mol-1 nm-2
gives consistent results in comparison with all-atom simulations of proteins.
2.7.4 Reverse Conversion
Coarse-grained simulations allow longer simulations to be performed. However,
in many cases, particularly in the study of proteins, the lack of atom level informa-
tion might lead to unrealistic conclusions. It is necessary, in many cases, to start
with coarse-grained simulations to get information from long simulations that all-
atom simulations can not offer, for example, how a P450 protein orients on a
lipid bilayer. But all-atom simulations are required to study more detailed infor-
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mation of the system. Thus, it is important to allow the reverse conversion from
coarse-grained model to all-atom model. After that, all-atom simulations can be
performed using models obtained from a coarse-grained simulation as a starting
point.
Many tools have been developed to convert a Martini coarse-grained model
back to an all-atom model using the mapping information in topology files. There
are generally two steps of the reverse conversion. The first step is to backmap/-
superimpose atoms, that have been coarse-grained, onto coarse-grained beads.
The following step is to refine the superimposed all-atom structure. A common
approach is to use simulated annealing (SA). As previously discussed, simulated
annealing heats the system to a high temperature rapidly and then cools it down
slowly to allow the structure to explore its conformational space to find the most
stable conformation. Recently, a new tool named “Backward”, which is able to
transform both coarse-grained proteins and lipids back to atomistic structures, has
been developed [69].
2.8 Brownian Dynamics Simulation
2.8.1 Introduction
All-atom and coarse-grained simulations are two approaches to simulate micro-
scopic properties of biological systems and thus connect experiments with compu-
tational studies. Brownian dynamics (BD) is a mesoscopic (between macroscopic
and microscopic) approach to simulate biological systems. It allows simulations
of larger time scales in comparison with all-atom simulations. Thus, Brownian
dynamics can be used to study biological processes, such as protein-protein asso-
ciation.
2.8.2 Brownian Dynamics
Brownian motion is the motion of particles in random, small steps in fluids. Brow-
nian motion can be investigated by techniques such as light microscopy and was
observed by Robert Brown [70]. In Brownian dynamics simulations, particles
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move by systematic forces and stochastic collisions with solvent molecules [71].
In Brownian motion, the mean displacement ∆r of a particle in time ∆t is:
〈∆r2〉 = 6D∆t (2.16)
D is the translational coefficient. D can be calculated for spherical particles us-
ing Boltzmann constant kb, absolute temperature T, solvent viscosity η and radius
of the particle, a:
D = kbT/6piηa (2.17)
The method developed by Ermak and McCammon [72] is often used to sim-
ulate protein-protein association [71]. With this method, both translational and
rotational motions are considered.
The translational displacement is calculated as [71]:
∆r =
D∆t
kbT
F + R (2.18)
D is the translational diffusional coefficient. F is the net force on the particle
and vector R satisfies 〈R〉 = 0 and 〈R2〉 = 6D∆t. The rotational displacement is
calculated as [71]:
∆w =
DR∆t
kbT
T + W (2.19)
Similar to the equation of translational displacement, DR is the rotational dif-
fusional coefficient. T is the torque on the particle and W satisfies 〈W〉 = 0 and
〈W2〉 = 6DR∆t.
Brownian motion can be studied computationally using Brownian dynamics
simulations. Brownian dynamics simulations can be used to simulate systems in
which solutes are notably larger than solvent molecules. For a system of two so-
lutes, such as two proteins, Brownian dynamics simulation can be performed to in-
vestigate the encounter complexes of the two solutes and calculate the association
rates of the two solutes. Brownian dynamics can also be performed to simulate
systems of hundreds of solutes, which gives insights into the behavior of solutes in
an environment surrounded by many others of the same kind or different kinds of
solutes.
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2.8.3 The Simulation of Diffusional Association (SDA) Software
To simulate the diffusional association of proteins, the Simulation of Diffusional
Association (SDA) software package [73, 71] was developed to perform Brownian
dynamics simulation [73, 71]. SDA allows simulation of protein-protein associa-
tion which is crucial for many biological processes. The force field of SDA con-
siders interaction forces, such as electrostatic interactions, electrostatic desolva-
tion interactions, and hydrophobic desolvation (non-polar, soft-core) interactions.
Rigid body simulations can be performed with SDA. Rigid body simulations ne-
glect the internal flexibility of solutes. However, using different conformations of
solutes to perform rigid body docking, flexibility can be introduced into BD simu-
lations and this has been implemented in the newest version of SDA, SDA version
7 (SDA7, http://mcm.h-its.org/sda7/).
2.8.3.1 Interactions
As previously discussed, electrostatic, electrostatic desolvation and non-polar des-
olvation interactions can be used in SDA. The interaction energy of two solutes is
calculated as follows [74]:
∆G =
1
2
∑
i2
Φel1qi2 +
1
2
∑
j1
Φel2qj1 (2.20)
+
∑
i2
Φedesolv1q
2
i2 +
∑
j1
Φedesolv2q
2
j1
+
∑
m2
Φnpdesolv1SASAm2 +
∑
n1
Φnpdesolv2SASAn1
The first two terms are electrostatic interactions and the second two terms
are the electrostatic desolvation interactions. The last two terms are the non-
polar interactions. Φel1 and Φel2 are the electrostatic potential of the two solutes.
Φedesolv1 and Φedesolv2 are the electrostatic desolvation potential of the two solutes.
qi2 and qj1 are the charges on the two solutes. Φnpdesolv1 and Φnpdesolv2 are the
“burial potentials” and, SASAm2 and SASAn1 are the solvent accessible surfaces of
atoms m2 and n1.
36
2.8. BROWNIAN DYNAMICS SIMULATION
2.8.3.2 Effective Charges
The effective charge method (ECM) was developed to decrease computational
expenses of solving the Poisson-Boltzmann equation with partial atomic charges
on all atoms [75]. Effective charges for charged residues are assigned to certain
atoms. For example, for charged amino acids, charges are assigned to the “NZ”
atom of lysine, the “NH1” and “NH2” atoms of arginine, the “OD1” and “OD2”
atoms of aspartic acid and, the “OE1” and “OE2” atoms of glutamic acid. The
effective charges are computed to reproduce the electrostatic potential with an
inhomogeneous dielectric in a shell outside of the solute with a homogeneous
dielectric.
2.8.3.3 Electrostatics
The electrostatic energy of SDA is computed as [73, 71]:
∆Gel =
1
2
∑
i
qeffi1 (r)φ
el
2 (r) +
1
2
∑
j
qeffj2 (r)φ
el
1 (r) (2.21)
qeffi1 (r) and q
eff
j2 (r) are effective charges of the two solutes, that were fitted to
reproduce the electrostatic potentials φel1 (r) and φ
el
2 (r), respectively. The electro-
static potential of two solutes are pre-computed and assigned to grids centered on
the solutes. A Poisson-Boltzmann electrostatic potential value φel1/2 is assigned to
each grid point. Two common software packages/tools that can be used to gen-
erate electrostatic grids are the Adaptive Poisson-Boltzmann Solver (APBS) [76]
and the University of Houston Brownian Dynamics (UHBD) [77].
2.8.3.4 Electrostatic Desolvation
The electrostatic desolvation energy of SDA is computed as [78]:
∆Gedesolv =
∑
i
φedesolv(i)q
eff
i (r) (2.22)
= α
s − p
s(2s − p)
∑
i
∑
j
a3j
1 + krij
r4ij
exp(−2krij)
s is the relative dielectric permittivity of the solvent and p is that of the pro-
tein. k is the Debye-Hückel constant. The electrostatic desolvation is the penalty
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of interactions of charged atoms with cavities of the other protein. a3j is the radius
to define solute atoms for the penalty. rij is the distance between the ith charged
atom of the first protein and the jth cavity of the second protein.
2.8.3.5 Hydrophobic Desolvation
The non-polar energy of SDA is computed as [74]:
φnpdesolv(r) = βc

1 r < a
(b− r)/(b− a) a < r < b
0 r > b
(2.23)
β is a factor to convert the calculated buried area to non-polar desolvation
energy. c is a factor. The non-polar desolvation energy is assigned to each grid
point. The maximum distance that an interacting solute atom can lie from the
molecular surface is defined by a and b.
2.8.3.6 SDA Docking
The SDA software package has a number of functions. Three of the most popular
functions used are: SDA docking, SDA association and SDA multiple molecules.
SDA docking is used to generate structures of complexes that are driven by
diffusional motions for two input solutes. The two input solutes can be two pro-
teins, protein and DNA, protein and ligand, and so on. SDA employs Brownian
dynamics to perform the sampling of the positions of the solutes. Interactions
via electrostatic and non-polar intermolecular forces can be accounted for. SDA
docking is particularly helpful when there are biochemical data about structures
of encounter complexes. The biochemical data can then be used to introduce dis-
tance constraints to SDA docking to predict complexes of proteins as shown in
[79, 80, 81, 82]. The docked encounter complexes can then be refined by molec-
ular dynamics simulations considering the flexibility of the solutes [83]. Using
molecular dynamics simulation to refine encounter complexes can improve the
reproduction of experimentally determined structures of protein complexes [83].
2.8.3.7 SDA Association
The SDA association method can be used to compute the bimolecular diffusional
association rate constant for two input solutes. The relative diffusional motion of
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the two solutes is simulated by Brownian dynamics subject to interaction forces
[72].
2.8.3.8 SDA Multiple Molecules
SDA docking and SDA association use Brownian dynamics to simulate two so-
lutes. However, in the cellular environment, macromolecules are surrounded by
many other macromolecules, of the same kind or different kinds. The SDA mul-
tiple molecules (SDAMM) method simulates the diffusive motion of several hun-
dred macromolecules, subject to electrostatic, non-polar and steric intermolecular
forces. SDAMM allows simulations with several types of molecule, and differ-
ent conformations of each type of molecule. These simulations can be performed
to investigate the behavior of a molecule in a crowded environment, similar to
the cellular environment, to study physical and biological properties of molecule
[84, 85, 86, 87, 88].
2.9 Web Interfaces for Scientific Software
Scientific software is designed to serve certain scientific purposes. Running sci-
entific software normally needs many inter-dependent parameters and produces
multiple output files. Because of this nature, it is often not easy for beginners to
use a new scientific software tool. However, developing web interfaces for scien-
tific software provides a way to make scientific software more user-friendly, pro-
vide automatic generation of input parameters and easy visualization for results.
There are various frameworks to build web servers. In this section, the Play frame-
work and programming languages and tools used for webserver development will
be introduced.
2.9.1 Play Framework
The Play framework (https://www.playframework.com/) is a modern model-view-
controller (MVC) framework which has been used by many well-known web-
sites such as LinkedIn (https://www.linkedin.com/) and Klout (https://klout.
com/home). Two programming languages can be used in Play: Java (https:
//www.java.com/en/) and Scala (http://www.scala-lang.org/). Java is one of
the most popular programming languages and there are plenty of packages writ-
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ten in Java to support software development. Java is also a static typing language
which requires strict typing of variables.
Play can be used to build REpresentational State Transfer (REST) webservers.
A RESTful webserver is stateless, cacheable and has a layered system. By fol-
lowing the workflow of Play, the webserver built is a RESTful webserver. Play
uses the object relational mapping (ORM) technique to convert Java objects to
entries in relational databases and vice versa. Older versions of Play use the
Ebean ORM and newer version of Play use Java Persistence API (JPA) (https:
//www.playframework.com/). The ORM of Play is developed for persisting objects
to relational databases and retrieving data from relational databases to construct
objects. It is easy to use but the performance of persisting or retrieving big data
is not very good because of the difficulty of converting two intrinsically different
things.
Play also supports the design of asynchronous webservers, to allow webservers
to run jobs in parallel or asynchronously. Akka (http://akka.io/) can be used to
manage concurrent jobs on webservers and is integrated in Play. Actors of Akka,
which are messages to manage job execution, allow webservers to parallelize jobs
non-blockingly and the actor system is a very lightweight event-driven processes
which allows web servers to create and manage millions of actors.
2.9.2 Back-end Tools for webSDA
The Adaptive Poisson-Boltzmann Software (APBS, http://www.poissonboltzmann.
org/) is a tool to solve Poisson-Boltzmann equation for electrostatics of biological
macromolecules, such as proteins and nucleic acids, upon solvation. The Simula-
tion of Diffusional Association (SDA), as discussed previously, is a software pack-
age to perform Brownian dynamics simulations to study biological systems. Both
software packages are powerful scientific software and can be used by running
batch/shell commands.
The Apache Commons Exec (http://commons.apache.org/proper/commons-exec/)
is a powerful tool to execute external processes from Java. It provides a reliable
way to run commands, check the status of commands and reports error if neces-
sary. It can be used together with Akka to manage multiple concurrent jobs, which
make web servers robust.
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2.9.3 User Interface Tools
To design web interfaces, HTML5 and Cascading Style Sheets (CSS) are most com-
monly used. HTML5 is supported by all modern web browsers, such as Firefox,
Internet Explorer and Google Chrome. Bootstrap (http://getbootstrap.com/) is
a popular package for developing front-end web interfaces. It combines HTML,
CSS and JavaScript and allows fast and flexible development of web interfaces.
JavasSript is a programming language that allows the client-side scripts to in-
teract with users dynamically. JQuery (http://jquery.com/) and Ajax (http://
en.wikipedia.org/wiki/Ajax_(programming)) are different extensions of JavaScript.
jQuery is an open-source JavaScript library. Ajax supports asynchronous inter-
actions between the front-end and the back-end of webservers. By using the
above mentioned languages/techniques, dynamic, interactive and user-oriented
web servers can be built.
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Comparison of P450s
3.1 Introduction
Sterol 14-α demethylase (14DM or cytochrome P450 family 51 (CYP51)) enzymes
form a cytochrome P450 (CYP, P450) family which is essential in sterol biosynthe-
sis [7, 6]. The catalytic function of CYP51 is to remove the 14α-methyl group
from cyclized sterol precursors such as lanosterol [6]. CYP51 is the most ancient
CYP family and has been found in all the biological kingdoms [6, 89, 90, 91].
Drugs (azoles such as itraconazole) that inhibit CYP51 in fungi have been used to
treat human fungal infection for more than 20 years [92, 93]. CYP51 is also con-
sidered a good target for antiprotozoan drugs [94]. The inhibitor N-[(1R)-1-(2,4-
dichlorophenyl)-2-(1H-imidazol-1-yl)ethyl]-4-(5-phenyl-1,3,4-oxadiazol-2-yl)ben-
zamide (VNI) has been shown to inhibit CYP51 in protozoan pathogens, such as
Trypanosoma brucei and Trypanosoma cruzi, specifically but not to affect the hu-
man CYP51 [7]. VNI was tested in mouse models of the acute and chronic forms of
Chagas disease and the VNI-treated mice were all able to survive without severe
observable side effects [95]. Other inhibitors have also been found that target
parasitic CYP51s such as 14α-methylenecyclopropyl-∆7-24,25-dihydrolanosterol
(MCP, LNP) [96] and (R)-4’-chloro-N-(1-(2,4-dichlorophenyl)-2-(1H-imid-azol-1-
yl)ethyl)biphenyl-4-carboxamide (VNF) [97, 98, 99].
There are differences in many of the properties of CYP51 compared with other
P450s. The very low root-mean-square deviation (RMSD) (0.75 Å) between the
Cα atoms of the ligand-free and VNI-bound crystal structures of T. brucei CYP51
suggests high structural rigidity of the enzyme [7]. This notion has been supported
by the analysis of crystal structures of other eukaryotic CYP51 orthologs, including
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T. cruzi, Leishmania infantum and human, in ligand-free forms and co-crystallized
in complexes with different heme-binding inhibitors and with the substrate analog
MCP [96, 97, 100].
In crystal structures of eukaryotic CYP51 enzymes, there is only one wide open
ligand access tunnel [7]. This corresponds to tunnel 2f in Wade’s nomenclature
[12], and is lined by helices A’ and F” and the tip of the β4 hairpin [7, 96, 97,
100]. This tunnel is open (to a probe with a radius of 1.4 Å, corresponding to
the size of a water molecule) in all crystal structures and often accommodates the
longest portion of the ligand molecule that, in the case of VNI, approaches the
tunnel’s outer entrance (Protein Data Bank (PDB) ID: 3GW9), and in the case of
posaconazole, extends from the active site to the protein surface (PDB ID: 3K1O)
[97].
Little is known about the influence of the membrane on CYP51, the dynamics
of CYP51, and the opening and closing of ligand tunnels in CYP51. Here, we
address the questions: (i) In which orientation is the T. brucei CYP51 embedded in
the membrane and how is the flexibility of the protein influenced when it is in the
membrane? (ii) Is CYP51 more rigid compared with other membrane-bound CYPs
as suggested by the crystal structures? (iii) Why do inhibitors of parasitic CYP51s
not inhibit the human ortholog? Is this because of different flexibility or different
interactions of the binding cavity residues? (iv) How do the ligand tunnels open
and close? Which tunnels can be used for ligand (including substrate, product,
inhibitor and water) access and egress?
CYP51 is anchored in the membrane by a single N-terminal transmembrane
helix and has part of its globular domain embedded in the membrane. The po-
sitioning of CYPs in the membrane has been studied experimentally and by com-
puter simulation [101, 102, 103, 104, 105, 106, 107, 29, 30, 24, 108, 109]. A
few CYPs, including CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1, CYP3A4 and
CYP19, have been modeled and simulated in phospholipid bilayers using different
approaches [29, 30, 24, 110, 111, 112, 113]. The protocol described in ref. [29],
which involves a combination of coarse-grained and all-atom molecular dynamics
(MD) simulations, does not use prior knowledge about the protein-membrane in-
teractions and can be applied to predict the orientation of CYPs in the membrane
using solely the crystal structure of the globular domain.
To study the influence of the membrane on T. brucei CYP51, we built a model
of T. brucei CYP51 in a 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)
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bilayer using a procedure similar to that in ref. [29]. The positioning of CYP51
in the membrane in this model is in good agreement with available experimental
data [101, 102, 104, 107, 111]. We refer to this model as the “membrane-bound”
T. brucei CYP51. We also performed MD simulations of CYPs immersed in aque-
ous solvent without a bilayer. We refer to these models as “soluble” CYPs. Here,
we describe these models and the analysis of the protein dynamics during the
simulations. Simulations of several hundreds of nanoseconds duration have been
performed for some soluble CYPs, including P450cam [114, 115] and the major
human-drug metabolizing CYPs [24, 112, 20]. Here, we instead carried out a
number of shorter simulations of different CYPs in soluble and membrane-bound
forms in order to perform a comparative analysis of the dynamics of the active site
and ligand tunnel regions. We focused on comparing simulations of the soluble
models of T. brucei CYP51 and human CYP51 with human CYP2C9 and human
CYP2E1, and simulations of the membrane-bound model of T. brucei CYP51 with
membrane-bound models of human CYP2C9. The analysis reveals features spe-
cific to CYP51 relating to the flexibility of the active site and the heme propionate
groups, ligand access and egress tunnels, the opening of the water tunnel and
hydrogen-bonding networks. These have implications for the recognition of sub-
strates and inhibitors by CYP51.
3.2 Materials and Methods
3.2.1 Models of Soluble T. brucei and Human CYP51
The crystal structure of the ligand-free form of T. brucei CYP51 (PDB ID: 3G1Q
solved at 1.89-Å resolution) was used to build models for the simulations [116].
The first three residues of the N-terminus were mutated from GKL to the wild-
type PTD sequence with the mutation tool in PyMOL [117]. The PDB2PQR server
[117] was used to assign the protonation states of the ligand-free CYP51 at pH
7. HIS420 was doubly protonated. For the ligand-bound model, MCP (14α-
methylenecyclopropyl-∆7-24,25-dihydrolanosterol) was positioned in the active
site of the ligand-free model with Visual Molecular Dynamics (VMD) [118] by us-
ing the transformation matrix for superimposing the protonated ligand-free model
and the MCP-bound crystal structure (PDB ID: 3P99). This procedure could be ap-
plied because the cavity lining residues were in almost identical positions in the
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two crystal structures. This model was used rather than the crystal structure of the
complex to permit direct comparison of the ligand-free and ligand-bound systems.
For the simulation of human ligand-free CYP51, the crystal structure of human
CYP51 (PDB ID: 3LD6 solved at 2.80-Å resolution) with ketoconazole removed
was used. This structure was chosen because it has the best resolution. The same
procedure to that for T. brucei CYP51 was used to protonate the structure. HIS167
and HIS447 (close to the heme center) were doubly protonated.
3.2.2 MD Simulations of Soluble CYP51
The modeled protein structures were further processed with the tleap program of
AmberTools 1.5 [49]. The Amber ff99SB force field was used for the protein and
the generalized Amber force field (GAFF) for the POPC phospholipids [50, 53].
The parameters for the heme center were assigned as in references [29, 119].
The partial charges of MCP were derived using a two-stage Restrained Electro-
static Potential (RESP) fit method: RESP-A1A (HF/6-31G∗) of the R.E.D server
[120, 121, 57]. The parameter files of the two ligands were generated using the
Antechamber program of the AmberTools 1.5 with the GAFF [49, 53, 122]. The
systems were solvated in an octahedral box of three-site transferable intermolecu-
lar potential (TIP3P) water molecules that extended at least 12 Å from the protein
and were neutralized with counter ions [123]. The Amber (version 11) program
was used to minimize and equilibrate the systems. Periodic boundary conditions
with the Particle Mesh Ewald (PME) model for electrostatics were used. The en-
ergy minimization was performed in 14 stages, each with a harmonic restraint
(decreasing from 1000 to 0 kcal/mol·Å2) to the crystallographic positions on the
non-hydrogen atoms. For each restraint value, 1000 minimization cycles were
performed consisting of 100 cycles of steepest descent and 900 cycles of conju-
gate gradient. Heating to 300 K was then performed for 25 ps under constant
pressure, constant volume (NVT) conditions with a restraint of 50 kcal/mol·Å2 on
all non-hydrogen atoms. A timestep of 1 fs was used. Langevin dynamics with a
collision frequency γ = 1/ps was performed. After heating, the system was further
equilibrated in eight stages each with a decreasing restraint (50 to 0 kcal/mol·Å2)
on non-hydrogen atoms. For each restraint force constant, 25 ps of equilibration
was performed. The temperature was maintained at 300 K by Langevin dynam-
ics with a collision frequency γ = 1/ps, and the pressure was maintained at 1.0
bar by isotropic position scaling with a relaxation time of 1 ps. The same setup
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was applied to a final equilibration under constant pressure, constant temperature
(NPT) conditions with no positional restraints for 1 ns.
The production runs for the ligand-free T. brucei CYP51, MCP-bound T. bru-
cei CYP51 and ligand-free human CYP51 models were performed with NAMD2.9
[55]. For the MCP-bound T. brucei CYP51 simulation, the same force field as the
simulations of the ligand-free T. brucei CYP51 was used together with the same
minimization and equilibration protocol. The switching function was set to “on”,
and the non-bonded cutoff was set to 10 Å. All the bonds to hydrogen atoms were
constrained with the SHAKE algorithm. Temperature was controlled by Langevin
dynamics with a damping coefficient of 0.5/ps at 300 K. Pressure was controlled
by the Nosé-Hoover Langevin piston method with an oscillation period of 1 ps and
a damping time scale of 1 ps at 1.011325 bar. The production runs were 30 ns for
the two models of ligand-free and MCP-bound T. brucei CYP51 and 15 ns for the
model of ligand-free human CYP51 with a timestep of 1.5 fs.
3.2.3 MD Simulations of the Models of Soluble CYP2C9 and
CYP2E1
The MD simulation trajectories of the models of soluble CYP2C9 and CYP2E1 at
300 K from previous studies were analyzed (Table 3.1; and unpublished data by
Outi M. H. Salo-Ahen). The simulations of human CYP2C9 were performed us-
ing two models built from the crystal structure (PDB ID: 1R9O) with different
conformations of the F-G loop region (one model with F’ and G’ helices and the
other model with an F-G loop only) [29]. The simulations of human CYP2E1 were
performed using two CYP2E1 models based on two crystal structures (PDB ID:
3KOH, 3T3Z; and unpublished data by Outi M. H. Salo-Ahen). The trajectories
were compared with those of the soluble CYP51s.
3.2.4 Coarse-grained Model of Membrane-bound T. brucei CYP51
A model of the membrane-bound ligand-free T. brucei CYP51 was built using an
improved version of the protocol described in ref. [29]. MODELLER_9.10 [127]
was used to model the missing residues. The missing residues 1 to 21 were
predicted to form the transmembrane helix and modeled as a helix. Residues
22 to 34 were modeled as a loop (residues 22-28 were missing in the crystal
structure; more residues were modeled for the superimposed of the globular do-
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main). The modeled transmembrane helix and loop structure were then coarse-
grained using MARTINI2.1 with an elastic network between the non-bonded beads
[128, 67, 68, 66]. The elastic bond force constant was 1.19 kcal/mol·Å2 (500
kJ/mol·nm2), and the upper bond length cut off was 9 Å. The coarse-grained struc-
ture (modeled residues 1 to 34) was inserted into a pre-equilibrated bilayer of 602
coarse-grained POPC molecules [128]. The overlapping lipids within 3 Å of the
transmembrane helix were removed. A 5 µs simulation was performed to find the
preferred orientation of the transmembrane helix alone in the membrane. The
CYP PDB Environmentb Ligandc Ensembled Time (ns)
CYP51 (T. brucei) 3G1Q SOL —- NPT 30
3G1Q MEM —- NPγT 60
3P99e SOL MCP NPT 30
3P99e MEM MCP NPγT 15
CYP51 (human) 3LD6 SOL —- NPT 15
CYP2C9_M1 (human)a 1R9O SOL —- NPT 28.28
1R9O MEM — NPγT 18.75
1R9O SOL FLO NPT 27.84
1R9O MEM FLO NPγT 11.25
CYP2C9_M2 (human)a 1R9O SOL —- NPT 27.78
1R9O MEM —- NPγT 18.75
1R9O SOL FLO NPT 27.4
1R9O MEM FLO NPγT 11.25
CYP2E1 (human) 3KOH SOL —- NPT 10
3T3Z SOL —- NPT 10
Table 3.1: Main features of the all-atom molecular dynamics production simulations of the differ-
ent CYPs.
(a) The F-G loop region in the crystal structure of human CYP2C9 (PDB ID: 1R9O) is missing. Two
models of the F-G loop were generated for the simulations [29]. Model 1 has F’ and G’ helices and
model 2 has an unstructured F-G loop.
(b) SOL, the soluble CYPs (no membrane), MEM, the membrane-bound CYPs in a bilayer.
(c) The ligands used in the simulation. FLO, 4’-hydroxy flurbiprofen, MCP, 14α-
methylenecyclopropyl-∆7-24,25-dihydrolanosterol, —-, ligand-free structures.
(d) In the NPγT simulations of the membrane-bound CYPs, a surface tension, γ=60 dyn/cm was
applied to the plane of the membrane together with the pressure control to maintain the bilayer
dynamics [29]. A comparison of the area per lipid, the bilayer thickness and the order parameters
of the membrane in the 60 ns simulation of the membrane-bound CYP51 with experimental data
is plotted in Figures 3.1 & 3.2.
(e) Only the ligand MCP of 3P99 was transferred into the active site of the equilibrated ligand-free
CYP51 structure (originally derived from the crystal structure 3G1Q). The simulations were then
done starting with this structure (see Methods).
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Figure 3.1: Comparison of the experimental and simulated area per lipid and thickness of the
POPC membrane in the 60 ns simulation of membrane-bound T. brucei CYP51. The 60 ns trajectory
was sampled at 3 ns intervals which resulted in 20 snapshots for the calculation. The comparison
of (A) the computed the area per lipid and (B) the bilayer thickness with the experimental values
at 303 K and 323 K (dotted lines) is shown.
Figure 3.2: Comparison of the order parameters of the POPC membrane in the 60 ns simulation
of membrane-bound T. brucei CYP51 with the experimental values. The black symbols show the
experimental values and the red and green symbols the values from the simulations. “sn-1” is the
saturated chain of POPC and “sn-2” is the unsaturated chain of POPC. The SCD values of a few
carbon atoms of sn-2 were not observed in the experiments [124]. The SCD values of sn-1 are
higher than the experimental values and this is consistent with reference [125]. As in [125], the
C2 splitting was not reproduced in our simulations. The other SCD values of sn-1 are in agreement
with experimental values except that the minimum was at C11 instead of C10 which has previously
been seen for simulations with GAFF parameters [126].
protocol is the same as for the whole membrane-bound protein system (refer to
succeeding text).
A coarse-grained model of the T. brucei CYP51 globular domain (PDB ID:
3G1Q) was also generated with MARTINI and combined with the preferred ori-
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entation of the transmembrane helix in the 5 µs simulation. The elastic network
of the linker region (residues 22-36) connecting the transmembrane helix and the
globular domain was removed. Ten different initial orientations of the globular
domain with different angles and height above the membrane were generated by
changing the dihedral angles of this flexible loop region randomly as described in
ref. [29].
Each complex was then solvated in a box of coarse-grained water molecules
with the same x and y dimensions as the POPC bilayer taken from ref. [128] and
extending 26 nm along the z axis. The system was minimized with the steepest
descent method using GROMACS_4.5.5 [129, 130, 131, 132]. The system was
minimized until the maximum force was less than 10 kJ/mol·nm (23.8 cal/mol·Å)
for 10000 steps. Then the system was relaxed at 200 K for 50000 steps. After
that, a 3 µs simulation with a timestep of 20 fs was performed. Periodic boundary
conditions were applied. The electrostatic interactions and van der Waals interac-
tions were calculated with the“Shif” algorithm. The lower and upper cutoffs for
electrostatic interactions were 0 and 12 Å whereas those of the van der Waals in-
teractions were 9 Å and 12 Å. Temperature coupling using velocity rescaling with
a stochastic term was applied with a 1 ps time constant for coupling at 310 K.
Semi-isotropic Berendsen pressure coupling was used with a 2 ps coupling time
constant at 1 bar.
To check for possible artifacts from the definition of the elastic network, four
more simulations of the coarse-grained T. brucei CYP51 in the POPC bilayer were
performed after the removal of the elastic network for residues 22-23, 22-31, 22-
33, 22-35. Despite the differences in the definition of the elastic network, three of
these four simulations converged to the same orientation as the previous simula-
tions except the simulation with the elastic network removed for residues 22-31,
in which the protein did not embed in the membrane and the F-G loop region
was out of the membrane. Although the extent to which the elastic network was
different, the other three simulations converged to the same final orientation as
the nine out of 10 previous simulations. To check whether the flexibility of the
F-G loop influences the final orientation, one additional simulation was performed
with the elastic network of the F-G loop (residues 22-36 and 207-224) removed.
This simulation converged to the same final orientation as well.
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3.2.5 Reverse Conversion from the Coarse-grained to the All-
atom Model
The conversion from the coarse-grained model to the all-atom model was per-
formed separately for the membrane, the transmembrane helix (residues 1-21),
the linker region (residues 22-36) and the globular domain (residues 37-476).
The transmembrane helix and the globular domain were converted by superim-
posing the modeled structure of the trans-membrane helix and the equilibrated
all-atom models from the soluble ligand-free T. brucei CYP51 simulation, respec-
tively, onto the coarse-grained models. The same protocol as in reference [29] was
used to convert the lipids.
Because of the large conformational changes of the linker region, the MARTINI
reverse conversion tool was used to convert the linker region [133]. Firstly, the
MARTINI mapping information of the linker regions, which correlates the all-atom
amino acids with the coarse-grained beads of the amino acids, was used to position
the all-atom amino acids onto the coarse-grained beads after the coarse-grained
simulations. Then a subsequent simulated annealing was performed for 60000
steps with a timestep of 2 fs. The linker was coupled at 1300 K at the beginning
of the annealing; the temperature was decreased linearly to 300 K. The four parts
(transmembrane helix, the linker, the globular domain, and the POPC bilayer)
of the system were then combined, and the system was neutralized in a NaCl
concentration of 150 mM and solvated in a box of TIP3P water molecules (same
dimension as the membrane in the x and y directions and extending 16 nm in the z
direction). For the MCP-bound model, MCP was superimposed onto the active site
of the membrane-bound ligand-free T. brucei CYP51 by using the transformation
matrix calculated by superimposing it with the crystal structure (PDB ID: 3P99).
3.2.6 All-atom MD Simulations of Membrane-bound T. brucei
CYP51
The ff99SB force field was used for the protein and GAFF was used for the POPC bi-
layer [50, 53, 125]. Energy minimization of the all-atom system was performed in
Amber (version 12) [54] with decreasing force constants from 1000 to 0 kcal/mol·Å2.
One hundred cycles of steepest descent and 900 cycles of conjugate gradient were
used for each restraint value. The system was then equilibrated in NAMD2.9 as
described previously [29]. For the production runs, periodic boundary conditions
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Figure 3.3: Two views of CYP51 in the bilayer at the last snapshot of the 60 ns simulation of
ligand-free T. brucei CYP51. Important secondary structure elements are labeled. The B-C loop is
shown in purple and the F-G loop in red. The head groups of the POPC lipids are shown in yellow
and the membrane plane is the x-y plane. Two vectors (V1 and V2) that define the orientation of
the protein with respect to the membrane are represented by cylinders. V1 follows the I helix. V2
points from the first helical turn of the C helix to the last helical turn of the F helix. Vector V3
points along the transmembrane helix. The “Heme tilt” (orange) is the angle between the heme
plane (cyan arrow) and the normal to the membrane plane (black arrow). Detailed information of
the three angles is shown next to the cylinder representation of the three vectors. For more details,
refer to Materials and Methods: Data Analysis.
were used and the electrostatic interactions were calculated using the Particle
Mesh Ewald (PME) method. The NPT ensemble was applied with a target sur-
face tension of 60 dyn/cm. All bonds to hydrogen atoms were constrained with
the SHAKE algorithm. Temperature was controlled by Langevin dynamics with
a damping coefficient of 0.5/ps at 310 K on non-hydrogen atoms. Pressure was
controlled by the Nosé-Hoover Langevin piston method with an oscillation time of
1000 fs and a damping time of 1000 fs. A production run of 60 ns was performed
for the ligand-free model without restraints with a timestep of 1.5 fs. A production
run of 15 ns was performed for the MCP-bound model with the same setup.
3.2.7 Data Analysis
Three parameters [29] were used to define the position and orientation of the
globular domain on the membrane (Figure 3.3): (i) d: the distance of CYP51 from
the membrane was calculated by subtracting the z-coordinate of the center of mass
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of the protein from the z-coordinate of the center of mass of the membrane. (ii)
α: angle between the z-axis and vector V1; V1 is the vector defined by the center
of mass of the first (residues 278-282) and last (residues 304-308) helical turns of
the I helix. (iii) β: angle between the z-axis and vector V2; V2 is the vector defined
by the center of mass of one helical turn of the C helix (residues 122-126) and one
turn of the F helix (residues 202-206). For the coarse-grained simulations, the
system was analyzed only after the system was equilibrated and the parameters
fluctuated stably.
The angle γ between the z-axis and vector V3 was used to define the orienta-
tion of the transmembrane helix in the membrane. V3 is the vector defined by the
center of mass of the first (residues 1-5) and last (residues 17-21) helical turns of
the transmembrane helix. The heme tilt angle is the angle between the z-axis and
the average heme plane defined by the “NA”, “NB”, “NC” and “ND” atoms of the
heme. The “Height” of the proteins was calculated by taking the z-coordinate of
the highest non-hydrogen atom of the protein above the membrane and subtract-
ing the average z-coordinate of the phosphate groups (atoms: “P”, “O1P”, “O2P”,
“O3P” and “O4P”) of the upper leaflet of the lipid bilayer.
All the previously mentioned parameters were calculated in VMD [118]. The
RMSD and root-mean-square fluctuation (RMSF) calculations were performed us-
ing the cpptraj program of the AmberTools12 [54]. For the comparison of the com-
puted B-factors, the four CYPs (human CYP51, T. brucei CYP51, human CYP2C9
and human CYP2E1) were aligned with the sequence and structure alignment tool
PROMALS3D [134].
The area per lipid and the thickness of the membrane were analyzed with the
grid-based tool GridMAT-MD [135]. Two hundred grids were assigned to the x-y
plane and the x and y ratio was then modified according to the dimensions of
the membrane of the CYP system. Lipids that were within 10 Å of the protein
were removed for the calculation. The order parameters were calculated with the
g_order tool of the GROMACS_4.6 package [136].
The opening and closing of the ligand tunnels was analyzed using CAVER3.0
[32]. PDB format coordinate files (100-200) were generated along each trajectory
and were used as the input for the CAVER analysis. For example, in the membrane-
bound ligand-free model of T. brucei CYP51, 200 PDB files were generated from
the 60 ns simulation with a 0.3 ns sampling interval. The probe radius was as-
signed a value of 1.4 Å, corresponding to the size of a water molecule. A tunnel
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was considered to be open when the radius of the bottleneck was larger than 1.4
Å.
3.3 Results and Discussion
3.3.1 Model of T. brucei CYP51 in a POPC Bilayer
3.3.1.1 One predominant orientation of the membrane-bound T. brucei CYP51
An improved version of the protocol in ref. [29] as described in the Methods sec-
tion was used to build the membrane-bound ligand-free model of T. brucei CYP51.
In the 5 µs coarse-grained simulation of the transmembrane helix alone in the
POPC bilayer, the transmembrane helix adopted an orientation of 17 ± 8◦ to the
normal of the membrane (angle γ in Figure 3.3). In the coarse-grained simula-
tions of the whole protein in the POPC bilayer, nine out of the 10 simulations
converged to one final orientation after the system was equilibrated (Figure 3.4).
The three parameters defining the position of the protein after the equilibration of
the nine converged coarse-grained simulations were: d = 41.3 ± 1.8 Å, α = 82.2
± 6.3◦, and β = 126.5 ± 8.4◦ (Figure 3.5). One snapshot from the coarse-grained
simulations having values of all three parameters within 1% of the mean values
of the parameters was taken as the starting structure for the all-atom simulations.
In the all-atom simulations of the ligand-free and MCP-bound T. brucei CYP51, the
globular domain stayed in about the same orientation above the membrane. The
parameters were: d = 38.1 ± 0.9 Å, α = 82.8 ± 5.2◦, and β = 122.9 ± 6.0◦
(Figure 3.5).
3.3.1.2 Comparison with experimental data and with other CYP models sup-
ports the atomic detail models of the membrane-bound T. brucei
CYP51
In the simulation of the membrane-bound ligand-free T. brucei CYP51, the tilt an-
gle of the transmembrane helix to the normal of the bilayer was 20.1 ± 6.5◦ which
is similar to the transmembrane helix tilt angle of 17 ◦ measured for this helix from
CYP2B4 by solid state NMR spectroscopy [108]. In the model of membrane-bound
T. brucei CYP51, the F-G loop region (residues 206-224) is embedded in the mem-
brane which is consistent with experiments on other CYPs [103, 105, 106]. Table
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Figure 3.4: The fluctuations of the three measured parameters (d, α and β) during one of the ten
coarse-grained simulation of T. brucei CYP51 in POPC bilayer. The system was considered to be
equilibrated when all three parameters were fluctuating stably.
3.2 shows a comparison of the model of the membrane-bound T. brucei CYP51 with
experimental data and the models of CYP2C9 [29] and CYP3A4 [111]. The CYP51
model is mostly in good agreement with these experiments and shows about the
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Figure 3.5: The normalized distribution of the three measured parameters (d, α and β) in the
coarse-grained and all-atom simulations of CYP51. (A) The distance between the center of mass
of the membrane and the protein. The black line shows the distribution of the coarse-grained
simulation and the red line, the all-atom simulation. (B) The angle α between the vector V1 and
the z-axis and the angle β between the vector V2 and the z-axis. The black and red lines show
angles α and β in the coarse-grained simulation, respectively. The green and blue lines are angle α
and β in the all-atom simulation respectively. The distribution of these three parameters is similar
to those of the membrane-bound model of CYP2C9 with an unstructured F-G loop (CYP2C9_2)
[29].
same degree of agreement with experiments as the CYP2C9 and CYP3A4 models.
The measured heme tilt angle (between the heme plane and the normal to mem-
brane plane, as shown in Figure 3.3B) of CYP3A4 was 59.7 ± 4.1◦ in experiments
[111]. This angle was 63.1 ± 4.5◦ in our simulation of the ligand-free membrane-
bound T. brucei CYP51, this is close to the experimental value (Table 3.2) and that
in models of six human drug-metabolizing CYPs (CYP1A2, 67 ± 6◦; CYP2A6, 69
± 5◦; CYP2C9:,61 ± 4◦; CYP2D6, 72 ± 6◦; CYP2E1, 60 ± 5◦; and CYP3A4, 56
± 5◦) [112]. The membrane-bound model of T. brucei CYP51 also agrees quite
well with the predicted orientation (d, 41.6 Å; α, 83.7◦; β, 131.8◦) in the Ori-
entations of Proteins in Membranes (OPM) database for CYP51 although OPM
predicted a different orientation for CYP2C9 with the A helix region (residues:
45-66) not embedded in the membrane [29, 137]. After we built our models of T.
brucei CYP51, the structure of the full-length Saccharomyces cerevisiae CYP51 was
determined by crystallography [109]. The orientation of our model in lipid bi-
layer is consistent with this structure of a fungal CYP51. The computed B-factors
of the membrane-bound CYP51 in the simulation were compared with those of
the crystal structure and the simulated soluble form (Figure 3.6). The trends are
consistent for the three systems although, as expected, the computed B-factors
vary over a wider range in the simulations. The F-G loop region has lower mo-
bility in the membrane-bound simulation because this region is embedded in the
membrane.
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Figure 3.6: Comparison of B-factors of the ligand-free forms of T. brucei CYP51 in the crystal
structure, the soluble simulation and the membrane-bound simulation. The B-factors of the solu-
ble form (S) were computed for the last 9 ns and those of the membrane-bound form (M) were
computed for the last 15 ns of the simulations of the ligand-free models. The F-G loop is embedded
in the lipid bilayer thus this region is more rigid in the simulation of membrane-bound T. brucei
CYP51 than that of the soluble form. This is because the motions of the residues are restricted by
the lipid bilayer.
3.3.2 Dynamics of CYP51 and Implications
3.3.2.1 Lower mobility in the active site of CYP51 but not higher mobility at
the ligand access tunnel entrance
Comparison of the crystal structures suggested that CYP51 is less mobile than
other CYPs [7, 96]. Therefore, we compared the computed B-factors in the ligand-
free simulations of the four CYPs studied.
The simulations of soluble models of CYPs are converged shortly after equili-
bration, for example, in the simulation of the soluble model of ligand-free T. brucei
CYP51 (Figure 3.9). In the simulations of the soluble CYPs, the average computed
B-factor of T. brucei CYP51 (30.0 ± 32.4 Å2), averaged over all non-hydrogen
atoms and the last 9 ns of the simulations, and of human CYP51 (24.1 ± 22.7 Å2)
is similar to that of CYP2C9 (29.4 ± 39.8 Å2 and 31.5 ± 39.4 Å2) and of CYP2E1
(28.8 ± 33.2 Å2 and 27.9 ± 39.0 Å2) (Figure 3.7A). In the membrane-bound sim-
ulations, the average B-factor (over the last 12 ns) of the globular domain of T.
brucei CYP51 (35.7 ± 33.2 Å2) is also similar to that of CYP2C9 (32.1 ± 33.2 Å2
and 32.5 ± 33.2 Å2) (Figure 3.7B).
As the computed B-factors vary widely along the sequence, we next compared
the B-factors of two groups of residues, the substrate binding cavity residues and
the tunnel 2f entrance residues [100]. Residues of these two groups on T. brucei
CYP51 are shown in Figure 3.8 and the corresponding residues of human CYP2C9
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Figure 3.7: Comparison of the B-factors of the non-hydrogen atoms of different CYPs with the loop
regions (black), the ligand binding cavity residues (dark red) and ligand tunnel opening residues
(orange) labeled. The residue numbers of the CYPs correspond to the PROMALS3D alignment
(Figure 3.5). (A) Comparison of B-factors averaged over the last 9 ns of the two simulations with
soluble ligand-free forms of the two human CYP2C9 models, the two simulations with the two
human CYP2E1 models and the simulations of T. brucei CYP51 and human CYP51. (B) Comparison
of the B-factors averaged over the last 12 ns of the simulations with the membrane-bound ligand-
free forms of CYP2C9 and CYP51.
and human CYP2E1 were taken from the alignment (Figure 3.10). The substrate
binding cavity consists of the substrate recognition site 1 (SRS1, αB’-B’/C loop,
residues 102-116), the C helix (residues 124-130), SRS4 (residues 284-295) and
SRS5 (residues 355-361) [100, 138]. The ligand access tunnel 2f has entrance
residues including αA’ (residues 45-52), SRS2 (αF’, residues 208-214) and SRS6
(β4 hairpin, residues 457-462). The average B-factors of the Cα atoms of these
regions were computed and are given in Table 3.3. If the average of the computed
B-factors of the Cα atoms was relatively low, the region was considered to have
low mobility.
In the simulations of the soluble proteins, the average computed B-factor of
the Cα atoms of the binding cavity residues of T. brucei CYP51 (9.1 ± 2.8 Å2)
and human CYP51 (8.1 ± 3.0 Å2) is similar to that in the simulations of the two
human CYP2E1 models (8.0 ± 3.2 Å2 and 9.3 ± 5.0 Å2) but lower than that in
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Figure 3.9: Plots of the RMSD and radius of gyration during the 30 ns simulation of the soluble
ligand-free T. brucei CYP51. (A) RMSD plot of backbone atoms (red) and non-hydrogen atoms
(blue). (B) Radius of gyration plot of non-hydrogen atoms. The radius of gyration of the crystal
structure is shown by a dotted line.
the simulations of the two human CYP2C9 models (12.7 ± 9.6 Å2 and 14.2 ± 8.9
Å2) as shown in Figure 3.7A. In the membrane-bound simulations, the substrate
binding cavity also has lower mobility in the simulation of the membrane-bound
model of T. brucei CYP51 (9.8 ± 3.7 Å2) than in those of human CYP2C9 (11.8 ±
6.1 Å2 and 14.0 ± 8.6 Å2). In both the soluble and membrane-bound simulations
of CYP51, the binding cavity residues have low mobility (average B-factor less
than 10 Å2). The mobility of SRS1 of CYP51 is lower than that of CYP2C9 in both
soluble and membrane-bound simulations and one CYP2E1 simulation but similar
to that in the other CYP2E1 simulation. The C helix region of the binding cavity
has lower mobility in CYP51 than CYP2C9 and CYP2E1 in the soluble simulations.
In the membrane-bound simulations, the C helix of T. brucei CYP51 is less mobile
than the model 2 of CYP2C9. The C helix of model 1 of CYP2C9 has lower mobility
in this region because this region is partly embedded in the membrane. The SRS4
and SRS5 regions of all the CYPs studied have low mobility (average B-factor
mostly less than 10 Å2) in all the simulations.
The average computed B-factor of the 2f tunnel entrance residues of T. brucei
CYP51 (25.4 ± 15.6 Å2) and of human CYP51 (23.1 ± 15.1 Å2) is higher than that
of human CYP2E1 (12.8 ± 7.3 Å2 and 9.9 ± 5.3 Å2) and of human CYP2C9 (16.9
± 9.3 Å2 and 13.7 ± 11.2 Å2) (Figure 3.7A). That of CYP51s is also higher than
that of the 2a tunnel entrance residues of human CYP2E1 (18.9 ± 14.2 Å2 and
20.1 ± 16.1 Å2) and of human CYP2C9 (18.7 ± 8.1 Å2 and 19.8 ± 12.2 Å2). In
the membrane-bound simulations, the 2f tunnel entrance residues (αA’, SRS2 and
SRS6) also have higher mobility in T. brucei CYP51 (29.3 ± 14.6 Å2) than the 2a
tunnel entrance residues (β1, B-B’ loop and G’ helix) in human CYP2C9 (17.8 ±
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Figure 3.10: The PROMALS3D crystal structure-based alignment of the sequences of CYP51,
CYP2C9 and CYP2E1 [134]. The binding cavity residues and tunnel 2f entrance residues are
shown in green colored blocks. The aligned helices are in red and the aligned beta sheets in blue.
The score of the conserved amino acids is shown in the “conservation” row. The well-conserved
residues are labeled in the “consensus_aa” row. Conserved residues are uppercase letters. Consen-
sus amino acid symbols are: “l”: aliphatic (I, V, L); “@”: aromatic (Y, H, W, F); “h”: hydrophobic
(W, F, Y, M, L, I, V, A, C, T, H); “o”: alcohol (S, T); “p”: polar residues (D, E, H, K, N, Q, R, S, T);
“t”: tiny (A, G, C, S); “s”: small (A, G, C, S, V, N, D, T, P); “b”: bulky residues (E, F, I, K, L, M, Q,
R, W, Y); “+”: positively charged (K, R, H); “-”: negatively charged (D, E); “c”: charged (D, E, K,
R, H). The conserved secondary structures (consensus_ss) are represented by red “h” for α-helices
and blue “s” for β-strands.
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8.0 Å2 and 17.3 ± 14.1 Å2). The A’ helix and SRS6 of T. brucei CYP51 are more
mobile than those of CYP2C9 and of CYP2E1 (Table 3.3).
Figure 3.8: The substrate binding cavity residues
(dark red) and the ligand tunnel entrance
residues (orange) shown in the last snapshot of
the simulation of the membrane-bound ligand-
free T. brucei CYP51. The substrate binding cav-
ity residues are residues 102-116 (SRS1, αB’-B’/C
loop), 124-130 (αC), 284-295 (SRS4, αI) and
355-361 (SRS5). The residues at the entrance
of ligand tunnel 2f include αA’ (residues 45-52),
SRS2 (αF’, residues 208-214) and SRS6 (β4 hair-
pin, residues 457-462). The ligand MCP is shown
in cyan. The bilayer is shown in violet.
The differences between the com-
puted B-factors of the CYPs studied are
small and the overall mobility of these
CYPs does not differ a lot. However,
the binding cavity residues of CYP51s
are in general less mobile than those of
CYP2C9 and CYP2E1, and the tunnel
entrance residues of CYP51s more mo-
bile than those of CYP2C9 and CYP2E1.
3.3.3 Ligand Tunnels in CYP51
Figure 3.11 shows the tunnels between
the active site and the protein surface
[29]. Tunnel 2f (between helices A’, F”
and the tip of the β4 hairpin), leading
to the membrane, and tunnels 2b (be-
tween the B-B’ loop and the β1-2 and
β1-4 sheets), S (the solvent tunnel, between F, I helices and the β4 hairpin) and W
(the water tunnel, helix C and the β-bulge segment), leading to the solvent, were
observed to open in simulations of membrane-bound and soluble forms of the T.
brucei CYP51. Tunnel 2a (between the F-G loop, B-B’ loop and β1-1 sheet), point-
ing to the bilayer, and tunnels 2c (between the G and I helices, B’-C loop), 2ac
(between the B’ helix and G helix) and 2e (through the B-C loop) were closed
throughout the simulations of the membrane-bound form of T. brucei CYP51.
Some opening of tunnels 2e and 2ac was seen in the simulations of the soluble
form of T. brucei CYP51 (Figure 3.12).
3.3.3.1 Protein flexibility influences the opening and closing of ligand tun-
nels
In the simulations of T. brucei CYP51, dynamic opening and closing of the ligand
tunnels were observed. The 2f tunnel is open in the crystal structures and was
mostly open in the simulations (for 10-97% of the snapshots analyzed). The S
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tunnel is closed in the crystal structure (PDB id: 3G1Q) but was found to be open
in the simulations (for 2-73% of the snapshots analyzed). These two tunnels were
very often open in the simulations of the ligand-free soluble form and the ligand-
free membrane-bound forms. However, although these two tunnels were open in
the simulation of the MCP-bound membrane-bound form of T. brucei CYP51, they
were mostly closed in that of the MCP-bound soluble form. This indicates that the
membrane stabilized the opening of tunnels 2f and S when the ligand was bound
in the active site. The common entrance residues of tunnels 2f and S (SRS2 and
SRS6) are mobile in the MD simulations (discussed previously), and thus, these
two tunnels were able to open and close in the simulations. The B-C loop and C
helix modulate the opening and closing of most family 2 tunnels, including 2a, 2b,
2c, 2e and 2ac. These tunnels are closed in the crystal structures and because of
the low mobility of the B-C loop and C helix region (discussed previously), these
tunnels were mostly closed in the simulations (Figure 3.12). However, tunnel W,
Figure 3.11: Cartoon representation of T. brucei CYP51 showing the ligand tunnels of the
membrane-bound CYP51 analyzed in CAVER3.0 [32]. The important secondary structure elements
are labeled. The B-C loop is shown in purple and the F-G loop in red. The bilayer is shown in violet.
Tunnels that opened at least in one snapshot during the 60 ns simulation of the membrane-bound
ligand-free CYP51 are shown by sphere representations and labeled by circles with white letters.
Tunnel 2f (blue) leads to the membrane and tunnels 2b (orange), S (cyan), and W (yellow) lead
to the solvent. Tunnels 2a, 2c, 2e and 2ac that were not open in the 60 ns simulation are labeled
by white italic letters in gray circles.
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Figure 3.12: Percentage of the snapshots in which the ligand tunnels were open in the simulations
is shown for the ligand-free soluble T. brucei CYP51 (solid blue), MCP-bound soluble T. brucei
CYP51 (solid green), ligand-free membrane-bound T. brucei CYP51 (hatched blue), MCP-bound
membrane-bound T. brucei CYP51 (hatched green) and ligand-free soluble human CYP51 (solid
magenta). In CYP51s, the tunnels are located as follows: 2a: between the F-G loop, B-B’ loop
and β1-1 sheet, b: between the B-B’ loop and the β1-2 and β1-4 sheets, 2c: between the G and I
helices, B’-C loop, 2ac: between the B’ helix and G helix, 2e: through the B-C loop, 2f: between
helices A’, F” and the tip of the β4 hairpin, 3: between the F and G helices, S: between F, I helices
and the β4 hairpin and W: helix C and the β-bulge segment.
which is open in the crystal structures (Table 3.4), stayed open throughout most
of the simulations.
3.3.3.2 Tunnels 2f and S can serve as major ligand tunnels in CYP51
The open tunnels of CYP51 are different from those of the human drug-metabolizing
CYPs. In the simulations of CYP2C9, all the common tunnels (2a, 2b, 2c, 2ac, 2e,
and S) were mostly open in a least one of the eight simulations of the two mod-
els of the soluble and membrane-bound CYP2C9 models. The 2f tunnel was not
open in most of the CYP2C9 simulations [29]. The ligand tunnel analysis of the
simulations of the membrane-bound models of six human drug metabolizing CYPs
(CYP1A2, CYP2A6, CYP2C9, CYP2E1 and CYP3A4) shows that tunnel S was open
in all six simulated CYPs, tunnels 2b and 2c were open in five of the simulated
CYPs, tunnel W in four, and tunnels 2e and 2f in three [112]. However, tunnels 2f,
S and W were found to be wide open in all our simulations of T. brucei CYP51 and
the other tunnels were mostly closed. In the simulation of human CYP51, only
tunnels 2f and S were wide open.
The 2f tunnel has been proposed to serve as the substrate access channel for
CYP51 [7, 94]. Our simulations support the idea that tunnel 2f can serve as the
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ligand entrance tunnel for hydrophobic ligands, such as the CYP51 substrates,
to enter the buried active site from the membrane, where the sterol biosynthetic
pathway takes place. The ligands can exit by either tunnel 2f to the membrane or
tunnel S to the solvent, depending on the properties of the ligands.
3.3.4 Open Water Tunnel and Multiple Conformations of Heme
Propionate Groups
3.3.4.1 B-C loop rigidity keeps the W tunnel open
The W tunnel is directed toward the proximal surface of CYP51, and the residues
lining this tunnel are mostly in the proximal region of the B-C loop and the B
and C helices. This tunnel cannot serve as a substrate/product tunnel because
it is on the proximal (opposite from the substrate binding cavity) side of CYP51,
which is the expected binding face of CYP51 for the CYP reductase. The W tunnel
was found open only in the simulations of the membrane-bound models of six
human drug-metabolizing CYPs but was closed in the simulations of the soluble
models [112]. The open tunnel W in the membrane-bound form of CYP51 suggests
that it is possible that tunnel W has to be open to facilitate the interaction with
the reductase. This is different from the crystal structures of most human CYPs
that have this tunnel closed. In the human drug-metabolizing CYPs, the opening
and closing of this tunnel can be observed because the proximal side is flexible.
However, in CYP51, because of the rigidity of the C helix and β-bulge segment
(Figure 3.7), the residues lining the W tunnel are not able to facilitate the opening
and closing motions of this tunnel. As a result, this tunnel stays open in both the
crystal structures (Table 3.4) and simulations (Figure 3.12).
3.3.4.2 The two heme propionate groups adopt different conformations
Conformational changes of the A-propionate group have been observed in ex-
perimental and computational studies of mutants of the prokaryotic cytochrome
P450 BM3 [139, 140]. In these studies, the heme A-propionate group was shown
to adopt different conformations upon ligand binding. However, conformational
changes of the two propionate groups have not been reported in MD simulations
of wild-type CYPs. Here, we discuss the different conformations of the two propi-
onate groups of CYP51 in crystal structures and in our simulations of the wild-type
T. brucei CYP51.
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Figure 3.13: Different conformations and hydrogen bonding interactions of the two heme pro-
pionate groups in the crystal structures and simulations. The distance between the two heme
propionate groups and important hydrogen bonding partners is shown. (A) The most predomi-
nant conformation of the propionate groups observed in the crystal structures of CYP51 enzymes.
The coordinates are from T. brucei CYP51 (PDB id: 3G1Q). (B, C) Two alternative conforma-
tions of the propionate groups seen in the snapshots at 60 ns and 15 ns in the simulations of the
membrane-bound ligand-free and MCP-bound T. brucei CYP51, respectively. (D) The conformation
in the crystal structure and simulations of CYP2C9 (PDB id: 1R9O). (E, F) Two different confor-
mations in the crystal structures of T. cruzi (PDB id: 2WX2) and human CYP51 (PDB id: 3JUV),
respectively.
The B-propionate group of the heme connects the W tunnel and the active
site. The two heme propionate groups show different conformations in the CYP51
crystal structures from different organisms (Table 3.4 and Figure 3.13). Three
crystallographic conformations of the two heme propionate groups are shown in
Figures 3.13A, E and F and two conformations from the simulations in Figures
3.13B and C. Although small conformational changes of the A-propionate group
have been seen in the mutants of cytochrome P450 BM3 [139, 140], such high
flexibility of the A-propionate group, and the flexibility of the B-propionate group
has not been observed in simulations of other wild-type CYPs. In our simulations,
we found that the heme propionate groups of T. brucei CYP51 are able to oscillate
between different conformations (Figure 3.14) but they prefer the conformation
shown in Figure 3.13B which was shown to be occupied in all crystal structures of
the membrane-bound CYPs except those of CYP51 and CYP46A1 [24]. The confor-
mation in Figure 3.13C was not found in the crystal structures but was observed in
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Figure 3.14: The A-propionate angle to the heme plane and the distance of the beta-domain to
the heme plane. The angles and distances were plotted for all the four simulations of T. brucei
CYP51. The blue dotted line is the two values that were proposed by Denisov et al. [24]. In their
studies, all the membrane-bound CYPs except CYP51 and CYP46A1 have the A-propionate angle
less than 0 which is in the proximal side, and all the membrane-bound CYPs except CYP51 have
the beta-domain height smaller than 4.2 Å.
our simulations. The propionate groups might have different conformations when
binding to different ligands in the active site.
The conformational changes of the A-propionate group of cytochrome P450
BM3 have been shown to be an effect of mutations but not substrate binding and
suggested to influence heme reduction, catalytic efficiency and electron transfer
[140]. Our simulations suggest that the heme propionate groups of CYP51 have
higher flexibility than those of most of the other CYPs. The high flexibility of the
two propionate groups may compensate the rigidity of the binding cavity residues
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of CYP51. This flexibility may be important for ligand binding, electron transfer
and heme reduction in CYP51.
3.3.4.3 Opening of the W tunnel is affected by the conformation of the heme
B-propionate group and is facilitated by ligand binding in the active
site
Tunnel W stayed open to a 1.4 Å radius probe in the simulations of T. brucei CYP51.
We checked the width of tunnel W using CAVER with a bigger probe radius (2.0
Å) for the simulations of T. brucei CYP51. The influence of the conformation of the
heme propionate groups on the width of tunnel W was analyzed. In the ligand-
free simulations, tunnel W stayed closed to the 2.0 Å radius probe in the soluble
simulations and was open in 3.5% of snapshots from the membrane-bound simu-
lation. The heme propionate groups mostly adopted a conformation similar to that
in Figure 3.13B. However, in the ligand-bound simulations, they adopted a confor-
mation similar to Figure 3.13C and tunnel W was open to the 2.0 Å radius probe
in 28% of the soluble simulation and 65% of the membrane-bound simulation.
This analysis suggests that the conformation of the B-propionate group can
influence the opening width of tunnel W. In the presence of ligands in the active
site, tunnel W tends to be more open. Hence, the presence of a substrate in
the active site might facilitate the water transfer between the active site and the
solvent necessary for the catalytic cycle.
3.3.4.4 A hydrogen bond network determines the conformation of the heme
propionate groups
When the two heme propionate groups are in different conformations, they have
different hydrogen bonding partners (Figure 3.13 and Table 3.4). The two pro-
pionate groups in CYP51 have fewer hydrogen bonding partners than the propi-
onate groups in the other CYPs studied. In the crystal structures of CYP51, the
A-propionate has a maximum of three hydrogen bonds (two with R361) whereas
the B-propionate has a maximum of three hydrogen bonds (Table 3.4 and Figure
3.13A, E and F). However, in CYP2C9 (PDB id: 1R9O), the A-propionate forms
hydrogen bonds with R97, S365, H368 and S429 whereas the B-propionate forms
hydrogen bonds with R97, W120, R433 and one water molecule (represented by
a red sphere) (Figure 3.13D). Fewer hydrogen bonding partners might be one
reason for the flexibility of the two heme propionate groups in CYP51.
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Conformational changes of the two propionate groups, which are driven by
the changes of the interactions with neighboring residues, were seen in our sim-
ulations of T. brucei CYP51. The orientation of the A-propionate group is mainly
driven by the hydrogen bonding interaction with R361. The A-propionate group
changed its conformation from that in Figure 3.13A to that in Figure 3.13B when
the two hydrogen bonds with R361 were disrupted by water molecules in the ac-
tive site in the ligand-free simulation. However, when the hydrophobic ligand MCP
is bound in the active site, the water molecules were expelled from the active site.
To regain the two hydrogen bonds with R361, the A-propionate group changed its
conformation from that in Figure 3.13B to that in Figure 3.13C. Whereas the con-
formation of the A-propionate group is largely determined by the interaction with
one residue (R361), the conformation of the B-propionate group is determined by
its interaction with several neighboring residues, including R124 and H420. In the
simulation of the membrane-bound MCP-bound T. brucei CYP51, the transition of
the B-propionate group from the conformation in Figure 3.13B to that in Figure
3.13C was facilitated by reforming the hydrogen bond with H420.
The hydrogen bonding network between the two heme propionates and the
neighboring binding cavity residues plays a crucial role in maintaining the catalytic
activity of CYPs [141, 142]. Changes of the hydrogen bond network may affect
the binding of ligands, the electron transfer process and the release of water after
the catalytic reaction.
3.3.4.5 Functional implications for drug design
The rigidity of the binding cavity residues, from the comparison of CYP51 (T.
brucei and human), CYP2C9 (human) and CYP2E1 (human), is consistent with
the high substrate selectivity of CYP51. The rigidity restricts the reorientation
of the binding site residues upon ligand binding. Thus, only ligands that can fit
rather perfectly into the binding cavity can bind to the active site of CYP51. This
indicates that, for anti-parasitic drug design, the inhibitors have to fit the binding
pocket of CYP51 in a similar way to the substrates to have inhibitory effects.
The higher mobility of the tunnel entrance residues of CYP51 than that of other
CYPs can facilitate anti-parasitic drug design. The reason for the high mobility
could be that as the substrates of CYP51 are large compared with those of CYP2C9
and CYP2E1, the tunnel entrance residues have to open wider to allow the large
substrates to enter the active site of CYP51. This indicates that the design of large
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molecules that are able to enter the active site of CYP51 but not of human drug-
metabolizing CYPs such as CYP2C9 and CYP2E1, is possible. However, CYP3A4 is
able to bind to large inhibitors and this would have to be taken into consideration.
Comparison of the dynamics of T. brucei CYP51 and human CYP51 indicates
that there are limited differences in the SRS regions of the two proteins. Therefore,
inhibitors that can only inhibit parasitic CYP51s, and not the human orthologue,
may result from the differences in the substrate-contacting residues, such as F105
(L in human), M106 (T in human) and F290 (L in human), rather than differences
in the flexibility of the binding cavity residues.
3.4 Conclusion
A model of the membrane-bound T. brucei CYP51 was built and simulated with an
improved version of the protocol that has been applied to CYP2C9. The model is in
good agreement with available experimental data on CYPs. The F-G loop region is
more rigid in the simulation of the membrane-bound T. brucei CYP51 than in that
of the soluble T. brucei CYP51 because this region is embedded in the membrane.
We found that, unlike other membrane-bound CYPs (represented by CYP2C9
and CYP2E1) that have high flexibility in the active site and a large range of lig-
ands, the CYP51 active site is relatively rigid in simulations of both soluble and
membrane-bound forms. Longer and repeated simulations would be desirable to
gain a complete understanding of the dynamics of different CYPs. However, de-
spite their limited length, our simulations show distinct dynamics in the different
CYP forms.
Opening and closing of ligand tunnels were observed in CYP51. The simula-
tions suggest that the 2f tunnel is used as a ligand access tunnel and that both
2f and S can potentially be used as ligand egress tunnels. The simulations of the
membrane-bound form of T. brucei CYP51 indicate that ligands need to enter tun-
nel 2f from the membrane and can exit via 2f back to the membrane or via S to the
solvent. High flexibility is seen in the residues at the surface entrance to tunnel
2f in T. brucei CYP51. The rigid B-C loop keeps tunnel W open in both crystal
structures and simulations of T. brucei CYP51. The conformation of the two heme
propionate groups affects the opening width of tunnel W. Tunnel W opened wider
in the presence of ligands which indicates a role for this tunnel in water deliv-
ery between the active site and the bulk solvent. The hydrogen bonding network
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determines the conformation of the two heme propionate groups and can fur-
ther affect the binding and unbinding of ligands. The conformational changes of
the heme’s two propionate groups may be important for ligand binding, electron
transfer and heme reduction of CYP51.
Access of the ligands to the binding site of CYP51 is facilitated by the flexibility
of the 2f tunnel but the relative rigidity of the binding site means that high com-
plementarity in shape and chemical properties is required for binding in the active
site. The tunnels provide another potential target binding site for drugs apart from
the active site. Both tunnel 2f and tunnel W are more open in CYP51 than in the
other human CYPs studied, and might serve as sites for CYP51-specific ligands.
From the comparison of the dynamics of T. brucei CYP51 and human CYP51,
the reason for the specific inhibition of parasitic CYP51 does not appear to be the
difference in the flexibility of the active site but may arise from the differences in
the interaction properties of the binding site residues.
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Ligand Tunnels in P450s
4.1 Introduction
The sterol 14-α demethylase (14DM, CYP51) enzyme plays an important role in
sterol biosynthesis [7]. The inhibition of this enzyme has been used as a strategy
to develop anti-fungal drugs and, more recently, anti-parasitic drugs [7, 95, 97,
100, 96, 99]. As a member of the cytochrome P450 (CYP, P450) superfamily, eu-
karyotic CYP51 shares most of the common features of the CYPs, including: (i)
embedding in the membrane via immersion of part of its globular domain and a
single trans-membrane helix, (ii) a buried active site which requires the ligands to
enter and exit from the active site through certain pathways (ligand tunnels), and
(iii) two electrons need to be transferred from the redox partners for the catalytic
cycle. However, distinct features of CYP51 compared to other CYPs have been
observed in experiments and in molecular dynamics (MD) simulations. These fea-
tures include high substrate specificity, binding site rigidity, different open tunnels
between the active site and the protein surface, and plasticity of the two heme
propionate groups [7, 40]. Because of the key role of CYP51 for anti-parasitic
drug design, it is important to study the above mentioned features of CYP51. In
this paper, we focus on the study of how the ligands can enter and egress from
the active site of T. brucei CYP51, and consider both soluble and membrane-bound
forms of the protein. Investigations of the ligand access and egress pathways can
help to understand the ligand binding mechanism and ligand specificity of CYP51
and thus can help to design specific parasitic CYP51 drugs, that avoid deactivation
and side effects caused by other human drug metabolizing CYPs.
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The mappings of ligand tunnels that have been found in different P450s to T.
brucei CYP51 are, according to Wade’s nomenclature [12]: tunnel 2a (between the
F-G loop, B-B’ loop and β1-1 sheet) and tunnel 2f (between helices A’, F” and the
tip of the β4 hairpin) which lead to the membrane, and tunnels 1 (between the C,
D, H and L helices), 2b (between the B-B’ loop and the β1-2 and β1-4 sheets), 2c
(between the G and I helices, B’-C loop), 2ac (between the B’ helix and G helix),
2e (through the B-C loop), S (the solvent tunnel, between F, I helices and the β4
hairpin) and W (the water tunnel, helix C and the β-bulge segment) which lead to
the solvent (Figure 4.1).
Figure 4.1: Membrane-bound model of ligand-free T. brucei CYP51 [40]. The important tunnels
defined in Wade’s nomenclature are labeled (orange). The B-C loop is colored in purple and the
F-G loop in red. The heme is shown with sticks representation and helices structures elements are
also labeled.
Tunnels 2f, S and W have been shown to be open to a probe with a radius
of 1.4 Å, corresponding to the size of a water molecule, in standard MD simula-
tions [40]. However, it is computationally challenging to simulate ligand exit in
a feasible time in standard MD simulations. In order to make the simulation of
ligand exit computationally possible, the random acceleration molecular dynam-
ics (RAMD) simulation method was developed [16, 17]. In RAMD simulations, an
external, randomly oriented force is applied to the center of mass of the ligand to
accelerate the ligand exit. As a result, the ligand is able to exit the active site on
the time scale of a few hundreds of ps to 2 ns and multiple trajectories can be gen-
erated to explore alternative egress routes and mechanisms. RAMD has been suc-
cessfully used to study the ligand egress pathways of many soluble forms of CYPs
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such as P450cam, CYP2B1, CYP2C5, CYP3A4, CYP2E1, CYP2A6 and CYP2C9 and
membrane-bound forms of CYP19 [16, 17, 34, 27, 2, 28, 143, 26, 21, 31, 110].
The preferred ligand tunnels in these simulations are mostly the family 2 tunnels
including 2a, 2b, 2c, 2e and 2ac. These are all lined by the B-C loop. Because of
the differences of CYP51 from the other CYPs, it is interesting to study the ligand
tunnels of CYP51, especially in the membrane-bound form.
Here, we address the questions: Can the open tunnels of CYP51 in standard
MD simulations be used by inhibitors, substrates and products to enter and exit
the active site? Are different ligand tunnels used in the soluble and membrane-
bound forms? Which residues gate and modulate the opening and closing of the
ligand tunnels? Do the ligand tunnels differ between T. brucei CYP51 and human
CYP51?
To answer these questions, we built membrane-bound models of ligand-bound
CYP51 for four different ligands. These were based on our model of ligand-free
T. brucei CYP51 in a 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) bi-
layer [40]. The four ligands are two inhibitors, N-[(1R)-1-(2,4-dichlorophenyl)-2-
(1H-imidazol-1-yl)ethyl]-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide (VNI) [7] and
14α-methylenecyclopropyl-∆7-24,25-dihydrolanosterol (MCP, LNP) [96], the nat-
ural substrate of T. brucei CYP51 [144], obtusifoliol (OBT) (4α,14-dimethyl-5α-
ergosta-8,24(28)-dien-3β-ol), and the product with the 14α-methyl group removed,
δ4α-methyl-5α-ergosta-8,14,24(28)-trien-3β-ol (OBT_DM). The structures of these
four compounds are shown in Figure 4.2. We also built models of soluble forms of
T. brucei CYP51 and human CYP51 and simulated them with VNI, LNP, OBT and
OBT_DM, and with OBT and OBT_DM, respectively.
Figure 4.2: Chemical structures of the four ligands studied. The hydroxyl groups are colored in
red, nitrogens atoms in blue and chloride atoms in green.
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In our simulations, we found that tunnel 2f was the predominant tunnel for
all four ligands in both the soluble and the membrane-bound forms of T. brucei
CYP51. In T. brucei CYP51, the solvent (S) tunnel, tunnel 1 and the water (W)
tunnel were also used and the common tunnels found in the other CYPs [12, 2, 28]
were barely used. The conserved residues F105 and M460 play an important role
in modulating the opening of tunnel 2f and S. In human CYP51, tunnel 2f and
tunnel 1 were used.
4.2 Materials and Methods
4.2.1 Standard MD Simulations
The membrane-bound model of ligand-free CYP51 in a lipid bilayer of 602 POPC
molecules was built from the crystal structure of ligand-free T. brucei CYP51 (PDB
ID: 3G1Q) using a protocol combining coarse-grained and all-atom simulations as
described in [40, 29]. The coarse-grained simulations were performed to find the
predominant orientation of CYP51 above the membrane and the all-atom simula-
tions were then performed to refine the membrane-bound model and investigate
the dynamics of the system with this predominant orientation. For the soluble
models, because of the rigidity of the binding site residues of T. brucei CYP51, two
of the four ligands (VNI and MCP) were superimposed onto the binding site of
ligand-free CYP51 by using the ligand-bound crystal structures (PDB ID: 3GW9
and 3P99), respectively. Coordinates (sdf files, one conformation) of the other
two ligands (OBT and OBT_DM) were downloaded from PubChem (CID 65252
and 443237), respectively. They were positioned in the active site so as to adopt a
similar orientation to MCP, which is a sterol-like inhibitor. For membrane-bound
models of T. brucei CYP51, the ligands were superimposed onto the active site
of the last snapshot of equilibration from the corresponding equilibrated solu-
ble ligand-bound models. For the simulations of soluble human CYP51, the sub-
strate (OBT) and product (OBT_DM) were superimposed onto the binding site of
ligand-free human CYP51 (PDB ID: 3LD6 with crystal ligand removed) by using
the OBT-bound and OBT_DM-bound structures of T. brucei CYP51. The partial
atomic charges of the four ligands were derived from Hartree-Fock 6-31G* ab
initio calculations and restrained electrostatic potential fit (RESP) on the R.E.D
server [121, 120, 145]. Other parameters were derived with the Antechamber
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program of AmberTools12 [54]. The final AMBER parameters files are given in
the Appendix.
Systemi
Environ-
mentii
Methodiii
No. of
Trajectoriesiv
rMin (Å)v Length (ns)v
CYP51 + VNI (T. brucei)
SOL
MD 1 —– 2
RAMD
30 0.025 —–
30 0.050 —–
MEM
MD 1 —– 15
RAMD
30 0.025 —–
30 0.050 —–
CYP51 + MCP (T. brucei)
SOL
MD 1 —– 2
RAMD
30 0.025 —–
30 0.050 —–
MEM
MD 1 —– 15
RAMD
30 0.025 —–
30 0.050 —–
CYP51 + OBT (T. brucei)
SOL
MD 1 —– 2
RAMD
30 0.025 —–
30 0.050 —–
MEM
MD 1 —– 3.75
RAMD
30 0.025 —–
30 0.050 —–
CYP51 + OBT_DM (T. brucei)
SOL
MD 1 —– 2
RAMD
30 0.025 —–
30 0.050 —–
MEM
MD 1 —– 3
RAMD
30 0.025 —–
30 0.050 —–
CYP51 + OBT (human) SOL
MD 1 —– 2
RAMD
30 0.025 —–
30 0.050 —–
CYP51 + OBT_DM (human) SOL
MD 1 —– 2
RAMD
30 0.025 —–
30 0.050 —–
Table 4.1: (i) The CYP51-ligand complexes studied. The full names of the ligands are given
in the Introduction section and their structures are shown in Figure 4.2. (ii) The simulations
were of soluble models of CYP51 (SOL) and membrane-bound models of CYP51 (MEM). (iii)
Simulation method: “MD”, standard molecular dynamics; “RAMD”, random acceleration molecular
dynamics. (iv) “1” indicates that the standard MD simulation was performed once to produce the
input snapshots for RAMD. The last snapshot of the equilibration and the last snapshot of the
production run were used for RAMD. (v) The length of the standard MD production simulation is
listed. The exit time of different ligands via tunnel 2f in RAMD simulations varies, see Figure 4.6,
but the maximum time of one RAMD simulation was set to 2 ns.
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The ff99SB force field for the protein and the general amber force field (GAFF)
for the ligands and POPC lipids [125] were used in the simulations of CYP51s
[50]. The TIP3P water model was used for all simulations. The simulations of
soluble models were performed with the Amber11/12 software [49] and those of
membrane-bound models with NAMD2.9 [55]. The equilibration of the soluble
models was performed as described in Chapter 3.2.2. In the production run of the
soluble models, the non-bonded cutoff was set to 12 Å. Berendsen temperature
control and Langevin dynamics were used to maintain the temperature at 300
K and the pressure at 1 bar with a timestep of 1 fs. For the membrane-bound
models, the same simulation procedure with the same parameters as in ref. [40,
29] was applied. Production runs were performed with a timestep of 1.5 fs. In the
production run, the non-bonded cutoff was set to 10 Å. Langevin dynamics and
the Nosé-Hoover Langevin Piston method with a surface tension of 60 dyn/cm
applied to the lipid bilayer plane were used to maintain the temperature at 310 K
and the pressure at 1 bar. In all the simulations, all bonds to hydrogen atoms were
constrained with the SHAKE algorithm [61].
In the (12 ns) simulation of OBT_DM in the membrane after the RAMD simula-
tion, the last snapshot of the RAMD simulation was taken as the starting structure
with all the velocities and periodic box information from that RAMD simulation.
The production run was then performed directly with the same parameters as
standard MD simulations of membrane-bound models of T. brucei CYP51. The
simulation of only OBT_DM in the membrane was started from the snapshot after
the RAMD simulation. The snapshot at 7.5 ns of the 12 ns simulation with ligand
OBT_DM in the membrane was used as the starting structure of the RAMD sim-
ulation. A 7.15 ns production run was performed after removing CYP51 without
minimization and equilibration.
4.2.2 RAMD Simulations
Random acceleration molecular dynamics (RAMD) as implemented in NAMD2.9
was used to study the ligand egress pathways from the buried active site of CYP51
[16, 17, 34, 27, 28]. The same parameters as in the standard MD simulations
were used for the RAMD simulations except that the pressure in the simulations
of soluble CYP51 was controlled by a Berendsen barostat at 1 bar and a timestep
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of 2 fs was used. In RAMD simulations, the external acceleration, which, in all
our simulations is 0.035 kcal/Å·g, is applied with a random initial direction. The
distance traveled by the ligand was monitored at 100 fs (50 steps with a timestep
of 2 fs) time intervals. If the distance was greater than a pre-defined minimum
RAMD distance of 0.025 Å or 0.050 Å, the direction of the force was maintained. If
not, the direction of the force was changed to another randomly chosen direction.
When the accumulated distance traveled by the ligand was larger than the distance
between the exterior of the protein, defined as 30 Å for soluble models and 40
Å for membrane-bound models, and the active site, the RAMD simulation was
terminated and the ligand was considered “out”. But if the ligand did not exit
in 2 ns, the trajectory was recorded as “No exit”. For each model studied, the
last snapshot from the equilibration and one snapshot (500 ps for the soluble
models, 15 ns for the membrane-bound VNI- and LNP-bound models, 3.75 ns
for the membrane-bound OBT-bound model and 3 ns for the membrane-bound
OBT_DM-bound models) from the production run were used as initial structures
for performing RAMD simulations.
4.2.3 Analysis
The concatenation and analysis of the trajectories were performed with the cpptraj
tool of AmberTools12 [54]. The trajectory was visualized in VMD1.9 [118]. The
figures were made with VMD, PyMOL [116] and Maestro [146]. To plot the ligand
2D structures, the SMILES identifiers of VNI and MCP were taken from the PDB
structure (PDB ID: 3GW9 and 3P99) and those of OBT and OBT_DM from the
PubChem database.
4.3 Results and Discussion
4.3.1 Predominant Ligand Tunnels
For all four ligands (VNI, MCP, OBT and OBT_DM) in both soluble and membrane-
bound forms of T. brucei CYP51, the 2f tunnel was found to be the predominant
ligand exit tunnel in the RAMD simulations (Table 4.1, Figure 4.3). The 2f tunnel
is open in the crystal structures of parasitic CYP51s and was proposed to be the
major ligand tunnel of the CYP51 family [7, 109]. We found that the 2f tunnel
widened transiently to allow the ligands to exit from this tunnel and that this
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Figure 4.3: The percentage of ligand exit events along each of the ligand egress tunnels in the 60
RAMD simulations of each system. (A), soluble models and (B), membrane-bound models of T.
brucei CYP51.
widening was facilitated by the flexible movements of the residues at the 2f tunnel
entrance.
Figure 4.4: The percentage of ligand exit events along each of the ligand egress tunnels in the 60
RAMD simulations of the soluble models of OBT- and OBT_DM-bound human CYP51.
Tunnel S, tunnel 1 and tunnel W were also observed to be ligand egress routes
in the simulations of T. brucei CYP51 but were not used as often as tunnel 2f (Fig-
ure 4.3). The exit times of ligands via these tunnels are shown in Figure 4.7.
Tunnel W was used in the simulations of T. brucei CYP51 but the possibility of this
tunnel to serve as a ligand tunnel in vivo is very low because the entrance of this
tunnel is on the proximal side which is proposed to be the binding interface of the
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reductase [147]. However, in the simulations of soluble models of human CYP51,
tunnel 2f was mostly used and tunnel 1 was often used, tunnel 2a was rarely used
and tunnel S and tunnel W were not used at all. This shows different tunnel usage
in human CYP51 in comparison to T. brucei CYP51 (Figure 4.4). Tunnel S was
found to be open in standard MD simulations of other CYPs including CYP2C9,
CYP3A4 and CYP2D6 (20, 36, 37) and in RAMD simulations of human aromatase
(CYP19) [110]. Tunnel 1 has rarely been observed as a ligand exit tunnel in stan-
dard MD simulations [12]. However, the fact that tunnel 1 was often used in the
RAMD simulations of the soluble models of human CYP51, shows the potential of
tunnel 1 to serve as a ligand tunnel. Interestingly, in the crystal structure of My-
cobacterium tuberculosis H37Rv CYP51 (PDB ID: 2VKU), one bis(4-hydroxyphenyl)
methanone ligand (with two possible conformations) is trapped in the middle of
tunnel 1 (Figure 4.5) [148]. This suggests that tunnel 1 can serve as a ligand
exit tunnel although in this crystal structure, the opening of tunnel 1 results from
the I helix being kinked towards the distal side (away from heme). The I helix is
not fully conserved in M. tubercolosis, T. brucei and human CYP51, see Appendix.
However, the three residues of the kinked region are relatively well conserved with
“AGQ” in T. brucei and human CYP51 and “AGH” in M. tuberculosis CYP51 and the
following four residues are completely conserved. In our simulation, this large
conformational change of the I helix was not needed to allow the ligands to exit
from tunnel 1.
In the RAMD simulations of human CYP51 with OBT and OBT_DM, it took
much shorter times (below 0.5 ns) for the ligand to exit from the active site in
comparison to those of T. brucei CYP51 (Figure 4.6&4.8). This indicates that via
either tunnel 2f or tunnel 1, ligands can exit more easily and quicker from the
active site of human CYP51 than from that of T. brucei CYP51.
4.3.2 Ligand Tunnels in the Membrane-bound Model of T. bru-
cei CYP51
The association of T. brucei CYP51 with the membrane did not significantly in-
crease the average exit time through tunnel 2f of any of the ligands in our RAMD
simulations (Figure 4.6). In almost 95% of the egress trajectories via tunnel 2f,
the ligands entered the membrane after leaving the protein. For the other egress
events via tunnel 2f, the ligands entered the solvent.
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Figure 4.5: One ligand (bis(4-hydroxyphenyl)methanone, DBE) (shown in stick representation
in yellow and violet) with two conformations is trapped in tunnel 1 in the crystal structure of M.
tuberculosis CYP51 (PDB id: 2VKU). Tunnels 1, 2e, W and 2f are labeled and tunnels 1, 2e and W
are open to a water sized probe in this structure.
Figure 4.6: The time (ns) required for the ligands to egress through tunnel 2f in T. brucei CYP51 in
each RAMD trajectory. The RAMD simulations with the soluble models are shown in blue and those
with the membrane-bound models are shown in red. The average times of soluble simulations for
exit of VNI, MCP, OBT and OBT_DM are 54 ± 40 ps, 271 ± 244 ps, 865 ± 556 ps and 354 ± 340
ps, respectively. The average times of membrane-bound simulations for exit of VNI, MCP, OBT and
OBT_DM are 196 ± 121 ps, 527 ± 424, 945 ± 534 and 484 ± 295 ps, respectively.
The crystal structures show that the hydrophilic head of the ligands in the ac-
tive site faces towards the membrane. This means that when the ligands enter
the membrane from the protein, the ligands have the hydrophilic head pointing
towards the middle of the bilayer. This is in the opposite orientation to the lipids
with their polar head groups on the bilayer surface (Figure 4.9A). Ligand reorien-
tation would be necessary for the ligand to exist in the membrane. To investigate
whether such reorientation was possible, an additional standard MD simulation
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Figure 4.7: The time (ns) required for the ligands to egress through tunnels 1 (A), S (B) and W
(C) in T. brucei CYP51 in each RAMD trajectory. The RAMD simulations with the soluble models
are shown in dark blue and those with the membrane-bound models are shown in red.
Figure 4.8: The time (ns) required for the ligands to exit through tunnels 2f and 1 in the soluble
forms of human CYP51 in RAMD simulations with the substrate (OBT, blue) and the product
(OBT_DM, red). The average time for exit of OBT via tunnel 2f and tunnel 1 and, OBT_DM via
tunnel 2f and 1 are 95 ± 58 ps, 124 ± 150 ps, 132 ± 77 ps and 143 ± 106 ps, respectively.
with the natural product OBT_DM in the membrane in the presence of the protein
was performed starting from the end snapshot of a RAMD simulation. In this simu-
lation, after ca. 6.5 ns, OBT_DM rotated roughly 100◦ and changed its orientation
from hydrophilic head down in the middle of the bilayer to up towards the head-
group layer. This orientation is similar to that of the POPC lipids (Figure 4.9B).
A further simulation (7.15 ns length) without the protein allowed the OBT_DM
to orient in the same way as the lipids and to position its hydrophilic head in the
head group region of the bilayer (Figure 4.9C) after 150 ps and it kept this orien-
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Figure 4.9: The change in orientation of OBT_DM in the membrane upon exit from T. brucei
CYP51. (A) At the end of the RAMD simulation of T. brucei CYP51, the OBT_DM was orientated
with its hydrophilic head down in the middle of the bilayer. (B) After a subsequent standard MD
simulation of 6.5 ns, OBT_DM had changed its orientation in the membrane by about 100◦ so that
its hydrophilic head pointed up towards the lipid head groups. (C) A further subsequent simulation
without the protein starting with the snapshot of (B) allowed the hydrophilic part of OBT_DM to
orient in the head group regions of the phospholipid bilayer. Only the head groups of the POPC
bilayer are shown for clarity.
tation for the rest of the simulation. These results suggest that the substrates of
CYP51 can come from the membrane before the catalytic reaction and as products
re-enter the membrane afterwards, and reorient for the next step in catalysis.
4.3.3 Tunnel Entrance Residues and Ligand Specificity
Both T. brucei and human CYP51 uses tunnel 2f as the predominant ligand tun-
nel but they have different affinity to different inhibitors such as VNI [97]. The
difference between ligand specificity may result from the entrance residues of tun-
nel 2f which are not conversed in the two proteins as shown in Figure 4.10. The
secondary structure of the F-G loop region differs in the two proteins and the F-
G loop region of T. brucei CYP51 is closer to the A helix region than the human
CYP51. The tunnel entrance residues of tunnel 2f are F48, V77, P210, V213 and
F214 (F214 is only identified in T. brucei CYP51, not in human CYP51) in T. brucei
CYP51 and F77, F105, H236 and W239 in human CYP51.
The tunnel entrance residues of tunnel 1 (Figure 4.11) are better conserved
than those of tunnel 2f (Figure 7). These residues are Q126, F129 and M284 in
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Figure 4.10: Comparison of tunnel entrance residues of tunnel 2f of T. brucei CYP51 (PDB ID:
3P99) and human CYP51 (PDB ID: 3LD6). Ligands and heme cofactor are represented by stick
representation and in yellow and green, respectively. The B-C loop is in magenta and F-G loop
in red. Tunnel entrance residues are labeled in dark blue and important secondary structures are
labeled in black.
T. brucei CYP51 and Q155, M158 and M304 in human CYP51. When ligands exit
from tunnel 1, both F129 in T. brucei CYP51 and M158 in human CYP51 need
to undergo large side chain conformational changes to allow ligand passage via
tunnel 1. However, conformational change of the side chain of M is easier than
that of F which may result in ligand exit more often from tunnel 1 in human CYP51
than in T. brucei CYP51 (Figures 4.3&4.4).
The tunnel entrance residues of tunnel S are shown in Figure 4.12. These
residues are well conserved in T. brucei and human CYP51. However, tunnel S
is used in T. brucei CYP51 but not used in human CYP51. This is not due to the
tunnel entrance residues but the openness of the tunnel. Tunnel S was found to
be mostly closed in human CYP51 but to be open in T. brucei CYP51 in standard
MD simulations as shown in ref. [40]. The low openness of tunnel S in dynamics
of human CYP51 results in that this tunnel is not used in human CYP51.
Tunnel W was used in T. brucei CYP51 but is not considered as a ligand tunnel
because tunnel W leads to the interface between P450 and CPR. Tunnel W is not
conversed in T. brucei and human CYP51 (Figure 4.13). Tunnel W was not used in
human CYP51. Tunnel entrance residues of tunnel W in human CYP51 are more
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Figure 4.11: Comparison of tunnel entrance residues of tunnel 1 of T. brucei CYP51 (PDB ID:
3P99) and human CYP51 (PDB ID: 3LD6). Ligands and heme cofactor are represented by stick
representation and in yellow and green, respectively. The B-C loop is in magenta and F-G loop
in red. Tunnel entrance residues are labeled in dark blue and important secondary structures are
labeled in black.
polar than those in T. brucei CYP51 (Figure 10). This can make ligands of CYP51
which are normally hydrophobic ligands more difficult to exit in human CYP51
than in T. brucei CYP51. In standard MD simulations, tunnel W was found to be
open in T. brucei CYP51 and closed in human CYP51 [40].
4.3.4 Gating Residues of Ligand Tunnels
The tunnels through which ligand egress was most often observed in the RAMD
simulations of T. brucei CYP51 were tunnels 2f and S. Tunnel 2f was open at the
beginning of the RAMD simulations but not wide enough for the large ligands
studied to exit. Tunnel S was closed (Figure 4.15A&B). During the ligand exit,
tunnel 2f opened wider and tunnel S opened from the closed conformation (Figure
4.15C&D). The opening of the two tunnels allowed the exit of the ligands.
By analyzing the RAMD trajectories, we found two residues (F105 and M460)
that played an important role in the opening of these two tunnels and they are
considered to be the gating residues of these two tunnels. Long distances (more
than 5 Å) between these two residues correspond to open tunnels that can accom-
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Figure 4.12: Comparison of tunnel entrance residues of tunnel S of T. brucei CYP51 (PDB ID:
3P99) and human CYP51 (PDB ID: 3LD6). Ligands and heme cofactor are represented by stick
representation and in yellow and green, respectively. The B-C loop is in magenta and F-G loop
in red. Tunnel entrance residues are labeled in dark blue and important secondary structures are
labeled in black.
modate the entrance and exit of the ligands. When the ligands are in the active
site, they can help to keep the ligands in the active site during the catalytic reaction
(Figure 4.14A&C) by interacting with each other. Both residues are phyla-specific
in the CYP51 family. F105 is L in fungi and animals and I in T. cruzi and M460
is L in fungi [96]. In human CYP51, F105 is V and M460 is M. The mutations
F105Y and F105A lead to the loss of activity of Mycobacterium tuberculosis CYP51
(39). The F105Y or F105A mutant may influence the binding of substrates in the
active site. In our RAMD simulations, the concerted movement of the side chains
of F105 and M460 can result in either tunnel 2f or tunnel S opening for ligand
passage (Figure 4.14B&D), depending on the directions of the side chain confor-
mational changes. Because tunnel 2f leads to the membrane and tunnel S leads to
the solvent, these two gating residues can then determine whether the ligands are
released into the membrane or into the solvent.
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Figure 4.13: Comparison of tunnel entrance residues of tunnel W of T. brucei CYP51 (PDB ID:
3P99) and human CYP51 (PDB ID: 3LD6). Ligands and heme cofactor are represented by stick
representation and in yellow and green, respectively. The B-C loop is in magenta and F-G loop
in red. Tunnel entrance residues are labeled in dark blue and important secondary structures are
labeled in black.
4.4 Conclusion
The access and egress pathways of four ligands (VNI, LNP, OBT and OBT_DM)
from the buried active site of T. brucei CYP51 and OBT and OBT_DM from that of
human CYP51 were studied with RAMD simulations. Here, by simulating ligand
egress, we find that the preferred exit route of ligands is via tunnel 2f in both
soluble and membrane-bound forms of T. brucei CYP51 and soluble forms of hu-
man CYP51. In the RAMD simulations of T. brucei CYP51, tunnels S, 1 and W
can also serve as the egress pathway for the ligands to the solvent but is much
less frequently observed than tunnel 2f. For human CYP51, tunnels S and W were
not used for ligand egress in any of the simulated trajectories. However, tunnel 1
was used more often in human than in T. brucei CYP51, suggesting that tunnel 1
may serve as a ligand tunnel to the solvent in human CYP51. The use of tunnel
1 is supported by the crystal structure of Mycobacterium tuberculosis CYP51 which
shows one ligand in tunnel 1. The other tunnels are less likely to be used as ligand
tunnels. Tunnel entrance residues may be the key for ligand specificity of T. brucei
and human CYP51. The difference between tunnel entrance residues of tunnel 2f
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Figure 4.14: Reorientation of the gating residues of tunnel 2f and tunnel S, F105 and M460, in
T. brucei CYP51 during egress of MCP. The side chain orientations of F105 and M460 are shown
before (A) and during ligand exit (B) via tunnel 2f and before (C) and during ligand exit (D)
via tunnel S. The secondary structure is shown in yellow and the heme in cyan. Corresponding
snapshots of different views of the protein with a surface representation are shown in Figures
4.15A-D.
may result in different specificity of T. brucei and human CYP51 towards the same
ligand, such as VNI. The substitution of M to F in human CYP51 may result in the
more often use of tunnel 1 than T. brucei CYP51. In T. brucei CYP51, binding site
residues F105 and M460 are the gating residues of tunnel 2f and tunnel S. They
can not only modulate the opening of the two tunnels but also modulate whether
the ligands should go to the membrane or the solvent.
Despite reducing protein flexibility, the presence of the membrane bilayer did
not obviously increase the time needed for the ligand exit in our RAMD simula-
tions of membrane-bound models compared to the soluble models of CYP51. In
all our simulations of membrane-bound models of T. brucei CYP51, the ligands
preferred tunnel 2f as the exit tunnel and entered the membrane after leaving the
protein. Therefore, in CYP51, the results suggest that the substrates come from the
membrane and the products go back to the membrane after the catalytic reaction.
Our study helps to understand the ligand access and egress mechanism of
CYP51. Analysis of tunnel entrances residues show differences between T. bru-
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Figure 4.15: Tunnel opening during egress of MCP from T. brucei CYP51. The protein is shown
with a solvent accessible molecular surface representation. The heme is shown in stick representa-
tion (cyan carbons) and the ligand MCP in stick representation (violet carbons). The F-G loop is in
red and the B-C loop in purple. First snapshots of RAMD simulations are those taken after standard
MD simulation. (A) First snapshot of a RAMD trajectory with tunnel 2f open. (B) Snapshot from
the same trajectory at 132 ps showing that tunnel 2f has opened wider to allow the MCP to exit.
(C) First snapshot of another RAMD trajectory with the tunnel S closed to a 1.4 Å radius probe.
(D) Snapshot from the same trajectory at 902 ps showing that tunnel S has opened wide enough
to allow MCP to exit. The white space below the heme center shows the open tunnel W.
cei and human CYP51 which give insights into the design of parasite-specific in-
hibitors.
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Interactions of Cytochrome P450s
and Their Redox Partners
5.1 Introduction
Cytochrome P450s (CYPs, P450s) are heme-containing enzymes and exist in all
biological kingdoms. P450s play an important role in drug metabolism and sterol
biosynthesis. The most predominant catalytic function of P450s is to catalyze
monooxygenation of organic compounds. For the catalytic reaction, electrons
need to be transferred to the active site from the redox partners of P450s. There
are various redox partners of P450s. In prokaryotes, redox partners of P450s in-
clude putidaredoxin (Pdx), cindoxin (Cdx) and ferredoxin (Fdx). In eukaryotes,
these include adrenodoxin (Adx), cytochrome b5 and cytochrome P450 reductase
(CPR). Two electrons are transferred to the active site of P450s in two steps, one
electron per step. It is generally believed that two electrons are transferred from
the same kind of redox partner but the second electron may also come from a dif-
ferent kind of redox partner, for example, in mammals, the second electron may
come from CPR or cytochrome b5 [149]. CPR has different conformations includ-
ing a closed conformation (Figure 5.1A), a partially open conformation (Figure
5.1B) and an open conformation (Figure 5.1C). The closed conformation is used
for the internal electron transfer of CPR and the open conformation is used to
transfer electrons to other proteins such as P450s.
The electron transfer process of P450s has been studied a lot during the last
decades and a basic understanding of the system has been achieved. Complexes of
P450s and their redox partners have been crystallized by various groups [150, 151,
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152, 153]. The complex of the P450BM-3 domain and the flavodoxin-like flavin
domain (FMN domain) was the first crystallized complex of P450s and their redox
partners [150]. P450BM-3 is a bacterial P450 system that has the P450 domain
fused to a mammalian-like FMN domain in a single polypeptide chain [154]. This
structural information gives initial insights into how P450s can interact with their
redox partners. The flavin mononucleotide (FMN) cofactor locates at the inter-
face between the P450BM-3 domain and the FMN domain, and thus can transfer
electrons via salt bridges to the heme center, which is the active site of P450s.
However, the P450BM-3 domain and the FMN domain were separated and crys-
talized which may be the reason for the complex not being functional for electron
transfer and catalytic reactions. The complex of mitochondrial P450 11A1 and
adrenodoxin (Adx) was crystallized later [151]. A thorough study of interactions
of P450cam and putidaredoxin (Pdx) has been carried out by Tripathi et al. [152].
The complexes of both substrate-free and camphor-bound P450cam and putidare-
doxin were crystallized. The conformational changes of the binding interface with
Pdx upon camphor binding and a water-mediated H-bonded network for electron
transfer were observed. An NMR study was carried out by Hiruma et al. [153]
to study the complex of P450cam and Pdx. They were also able to crystallize the
complex and the crystallized complex is very similar to those obtained by Tripathi
et al. Two pathways with strong electrostatic coupling were proposed and the
electron transfer rate was calculated.
For complexes of eukaryotic P450s and CPR, there is no such complex crystal-
lized yet. However, mutation studies have been performed to study these interac-
tions. Im et al. summarized the experimental studies of interactions of CYP2B4
with both cytochrome P450 reductase and cytochrome b5 [149]. Mutations of
residues on the positively charged patch of the proximal side of CYP2B4, which
include R122A, R126A, R133A, R422A, K433A and R443A, significantly decreased
Kd of the complex as shown in Table 5.2 [149]. They also proposed important in-
terface residues on CPR, which are D113, E116, E142 and D144. A modeled
complex which was based on these mutation data was also built using PyMOL
[149]. Later on, the same group was able to crystallize the open conformation of
CPR [156]. This crystal structure gives a structural basis for studying the interac-
tions between P450s and CPR using computational methods. A mutation study by
Kenaan et al. showed two hydrophobic but surface exposed residues (V267 and
L270) on CYP2B4 that are important for the CYP-CPR interaction [157]. These
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Figure 5.1: Different conformations of CPR: closed conformation of human CPR (PDB ID: 3QE2)
[155] (A), partially open conformation of rat CPR (PDB ID: 3ES9) [156] (B) and open conforma-
tion of a model of human CPR (protocol described in Methods section) (C). The FMN domain is in
red and the FAD domain in green. The FMN (cyan), FAD (green) and NADPH (yellow) cofactors
are represented with sticks representation, so is the gating residue (W677, magenta) for internal
electron transfer.
two residues are not on the proposed proximal binding site of P450s but in the
region of the H and I helices. Mutations D113A, E115A and E116A on rat CPR
affect binding of CPR to its electron acceptors. Thus, these residues may reside on
the binding site of CPR to CYP2B1 [158].
Comparison of interactions between mammalian P450s and CPR has been ex-
tensively performed by Backes et al. [159, 160, 161, 162, 163]. They showed
that in a system of CYP2B4, CYP1A2 and CPR, CPR has higher affinity to CYP1A2,
and that CYP2B4 and CYP1A2 can form P450-P450 complexes [159]. Hazai et al.
built a model of the complex of CYP2C9 and CPR based on the crystal structure of
the complex of P450-BM3 and the FMN domain [164]. A model of CYP2D6 and
human CPR on a membrane was built and molecular dynamics simulations were
performed to study the dynamics of the system [165]. The complex of P450-BM3
and the FMN domain was used to build a model of CYP2B4 and the FMN domain of
reductase [166]. The positively charged clusters of 343R-345K and 433K-434R of
CYP2B4 were suggested to interact with the negatively charged clusters of 207D-
208D-209D and 113D-115E-116E of CPR, respectively.
However, due to the experimental difficulties and the complexity of the sys-
tems, there are still a lot of open questions about the interactions between P450s
and CPR. For example: How do different P450s interact with CPR? How do dif-
ferent P450s compete for CPR? Are there any differences in the affinity between
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different P450s for CPR? What is the possible route for the electron transfer be-
tween CPR and different P450s?
These questions are hard to answer by experiments and thus computational
methods provide a complementary way to tackle these problems. Here, we use a
combination of Brownian dynamics and molecular dynamics simulations to try to
answer these questions. With this approach, our simulations are able to reproduce
the experimental data and then we used this approach to investigate the interac-
tions between various P450s and CPR. Our simulations show that different P450s
bind to CPR using the same interface, which is on the proximal side of P450s,
but with different affinities (inferred from binding energies). P450s with ligands
bound in the active site are shown to have higher affinity to bind to CPR than the
ligand-free forms.
5.2 Methods
The procedure described in [83] was used to dock CPR to different P450s. The
procedure consists of two steps: the first step is to use Brownian dynamics simula-
tions to generate encounter complexes of the two proteins using biochemical data.
The following molecular dynamics (MD) simulation using implicit solvent is then
performed to refine complexes obtained from Brownian dynamics simulations.
5.2.1 Protein Structure Preparation
Crystal structures of complexes of P450s and their redox partners are used to
evaluate the use of Brownian dynamics simulations for systems of P450s and their
redox partners. The complexes used are: (1) the crystal structure of the complex
of the P450BM-3 domain and the flavin mononucleotide (FMN) domain (PDB ID:
1BVY), and (2) that of mitochondrial CYP11A1 and adrenodoxin (PDB ID: 3N9Y).
Crystal structures of P450s are used as starting structures for docking. The
PDB structures used for different P450s are shown in Table 5.1. When there are
ligands bound to the active site, ligands are removed when performing simula-
tions. The removal of ligands will have little influence on results of rigid-body
Brownian dynamics simulations. When there are missing residues that are not on
the possible binding interfaces for CPR of crystal structures, Brownian dynamics
simulations are performed without adding these missing residues. However, for
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CYP Organism PDB id Ligandi Resolution (Å) Missing Residuesii
1A1 Human 4I8V BHF 2.60 No
1A2 Human 2HI4 BHF 1.95 No
2A6 Human 2FDU D1G 1.85 No
2B4 Rabbit 1SUO CPZ 1.90 No
2C9 Human
1OG2 —– 2.60 No
1R9O FLU 2.00 Yes
2D6 Human
2F9Q —– 3.00 Yes
3TBG RTZ 2.10 No
2E1 Human 3T3Z 9PL 2.35 No
3A4 Human
1TQN —– 2.05 Yes
3NXU RIT 2.00 Yes
51 T. brucei 3G1Q —– 1.89 No
3P99 LNP 3.00 No
51 Human 3LD6 KKK 2.80 No
Table 5.1: CYP crystal structures used for docking to CPR. (i) Ligands in crystal structures
are: BHF: 2-phenyl-4H-benzo[H]chromen-4-one, D1G: N,N-dimethyl(5-(pyridin-3-yl)furan-
2-yl)methanamine, CPZ: 4-(4-chlorophenyl)imidazole, RTZ: 10-2-[(2R)-1-methylpiperidin-
2-yl]ethyl-2-(methylsulfanyl)-10H-phenothiazine, 9PL: (3S,4R)-3-ethyl-4-[(1-methyl-1H-
imidazol-5-yl)methyl]dihydrofuran-2(3H)-one, LNP: (3alpha,9beta,10alpha,13alpha)-30-
cyclopropylidenelanost-7-en-3-ol, KKK: ketoconazole. (ii) The missing residues do not include
missing residues on the N- and C-termini.
the refinement using molecular dynamics simulations, these residues are modeled
using the Modeller software as described in [29].
For CPR, chain B of PDB ID 3ES9, which is the open conformation of the rat
CPR, was used as the template to model the human CPR in the open conformation
(the alignment of human and rat CPR in Appendix). The FMN domain and FAD
domain of the crystal structure of human CPR (PDB ID: 3QE2) were superimposed
onto the chain B of rat CPR individually. The hinge region (residues 231-243) of
human CPR was also superimposed onto the hinge region of the crystal structure
and the missing residues (TGEE, 236-239) were then modeled in VMD.
PDB2PQR [117, 167] was used to add hydrogens to crystal structures as well
as the van der Waals radii and partial charges of amino acids. Proteins were
protonated at pH 7. The AMBER force field was used [42]. Generated files are in
PQR format. PQR files are PDB files with additional columns for the atomic charge
and radius of each atom. The parameters for the heme center were assigned as
in [119] and [29] and were added to the PQR file manually. The partial charges
of cofactors were derived using a two-stage RESP fit method: RESP-A1A (HF/6-
31G*) of the R.E.D server [121]. The parameter files of the two ligands were
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generated using the Antechamber program of AmberTools 1.5 with the generalized
Amber force field (GAFF) [54]. Hydrogens of cofactors were added using the tleap
program of AmberTools 1.5 and derived charges for cofactors were added to the
PQR files.
5.2.2 Brownian Dynamics Simulations
The electrostatic potential of the proteins was calculated with the adaptive Poisson-
Boltzmann software (APBS) by solving the non-linearized Poisson-Boltzmann equa-
tion [76]. In the APBS calculation, 193 grid points were used for all three dimen-
sions (x, y and z) with a 1 Å spacing. The ionic strength was set to 150 mM. A
dielectric constant of 2.0 was used for the protein and of 78.0 was used for the
solvent. Effective charge sites were defined using the effective charges for macro-
molecules in solvent (ECM) method [75]. Effective charge sites are on the charged
amino acids and cofactors (O1A, O2A, O1D and O2D atoms of heme and, O1P and
O2P atoms of FMN).
Rigid-body Brownian dynamics simulations were performed using the Simula-
tion of Diffusional Association (SDA 7) software package. In SDA simulations, the
larger protein is fixed, whereas the smaller protein is mobile with both rotational
and translational diffusional motions. 20000 SDA runs were performed. For the
exclusion grid, which was only applied to the first protein, to avoid clashing of
proteins, a spacing of 0.25 Å was used in simulations and the solvent probe radius
was set to 1.4 Å. At the beginning of simulations, the second protein was put at
a random orientation 150 Å away from the first protein. It diffuses under elec-
trostatic interactions. When the two proteins are close to each other and form an
encounter complex, this encounter complex is recorded only when the reaction
criterion is satisfied. In this case, the distance between the FE atom of the heme
and the N5 atom of the FMN cofactor is smaller than 25 Å. This constraint was
applied to ensure that the cofactors are close enough for electron transfer. 2000
encounter complexes were recorded.
The 2000 recorded complexes which have the lowest total interaction energy
were then clustered into ten clusters using the protocol described in [83]. A dis-
tance matrix was constructed by calculating the backbone root mean square devi-
ation (RMSD) of each docked protein configuration from each other. At the first
step, each docked structure was assigned to a separate cluster. The closest clusters
were then merged in the following steps until the number of clusters, in this case
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ten clusters, was obtained. A representative structure of each cluster was selected
which has the lowest RMSD to the centroid of the cluster.
5.2.3 Molecular Dynamics Refinement
Molecular dynamics simulation was used to refine cluster representatives after
rigid-body docking to introduce flexibility into the proteins. AMBER14 was used
to perform molecular dynamics simulations. The docked CPR was combined with
the P450 into one file after SDA docking. Parameters of cofactors were generated
using the procedure mentioned in Chapter 3.2.2. The tleap program of Amber-
Tools13 was used to generate the topology file of the complex. In minimization,
the maximum number of minimization cycles was set to 1000 and it was switched
from steepest descent to conjugate gradient after 500 steps. The modified gen-
eralized Born (GB) implicit solvent model was used for solvent and the GB salt
concentration was 100 mM [168]. The generalized Born/surface area (GB/SA)
method was used. In production runs, the GB implicit solvent model was also
used. Langevin dynamics with collision frequency γ=2 was used for temperature
coupling and no pressure scaling was used. No periodic boundary condition was
applied. Bonds involving hydrogen were constrained using the SHAKE method. A
timestep of 1 fs was used and the production run was performed for 100000 steps.
In the production run, the system was heated from 30 K to 300 K in the first 10000
steps and the temperature was kept constant thereafter.
5.2.4 Interface Residues
Interface residues were identified using the “InterfaceResidues” module of PyMOL
[116]. The cutoff value was set to 7.5 Å. The residues of one protein that were
within 7.5 Å of surface residues of the other protein were defined as interface
residues.
5.3 Results and Discussion
5.3.1 Validation of SDA for docking redox partners to P450s
A key advantage of SDA, in comparison to many other docking softwares and web
servers, is the possibility to use biochemical data as constraints in simulations.
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Figure 5.2: Comparison of SDA docked complexes of P450 (green) and electron transfer part-
ner (cyan) by Motiejunas et al. [83] (A) and in this study (B&C) with structures of the crystal
complexes (magenta) of (A) cytochrome P450cam and putidaredoxin (Pdx) (PDB ID: 4JWS), (B)
cytochrome P450-BM3 domain and FMN domain (PDB ID: 1bvy), and (C) cytochrome P450 11A1
and adrenodoxin (Adx) (PDB ID: 3N9Y).
SDA has been successfully applied to predict protein complexes in combination
with biochemical data [169, 82, 81]. SDA was used to predict the complex of
P450cam and putidaredoxin in 2007 [79]. The orientation of Pdx in the predicted
complex is similar (ca. 15◦ difference along x axis) to that in the crystal structure
of the complex published by Tripathi et al. in 2013 (Figure 5.2A) [152]. SDA and
subsequent molecular dynamics (MD) refinement were also used by Madrona et
al. [170] to predict the complex of P450cin and cindoxin. This shows that SDA
simulation followed by molecular dynamics refinement can be applied to predict
encounter complexes of P450s and their redox partners.
In this study, the two available complexes of P450s and their redox partners
are used to assess SDA: the complex of CYP11A1 and adrenodoxin (Adx) and that
of the P450BM-3 domain and the FMN domain. For the complex of CYP11A1
and Adx, the representative of the first lowest energy cluster is classified as an
acceptable CAPRI model [171] evaluated using the crystal complex (Figure 5.2C).
This representative has 19% native contacts and is considered to be acceptable
because it has more than 10% native contacts. SDA was able to predict a similar
orientation of the FMN domain to the crystal structure of the complex of P450BM-
3 domain and FMN domain (Figure 5.2B), although it is not classified as a CAPRI
acceptable model because the docked complexes have 0% native contacts. This
could due to the fact that the crystal complex is not active and the FMN domain
may have a slightly different binding interface in vivo because of restrictions due to
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CYP2B4 Kd (µM)i Cluster 1 Cluster 2 Cluster 3
Energyii Sizeiii Energyii Size iii Energy ii Size iii
WT 0.02 ± 0.02 -9.3 ± 1.0 5977 -10.3 ± 1.4 4996 -8.7 ± 0.6 3383
R122A 0.23 ± 0.08 -1.3 ± 0.5 550 -1.1 ± 0.3 263 -1.3 ± 0.3 238
R126A 0.27 ± 0.08 -2.5 ± 0.9 1419 -2.7 ± 0.7 1025 -2.7 ± 0.7 598
R133A 1.2 ± 0.57 -2.5 ± 0.9 2159 -2.0 ± 0.5 2219 -2.8 ± 0.6 1662
K433A 1.1 ± 0.81 -1.7 ± 0.5 1489 -1.8 ± 0.5 965 -1.5 ± 0.6 576
Table 5.2: Measurement of the binding affinities of CYP2B4 and rat CPR. (i) Experimental data
taken from [172]. (ii) Average total interaction energy (kBT) of all cluster members. (iii) Number
of structures of the cluster.
its fusion with the P450BM-3 domain. Another reason could be that SDA generates
diffusional encounter complexes, not fully bound complexes.
We then used SDA to compare experimental data on binding affinities when
residues on the proximal side of CYP2B4 were mutated. The interactions of
CYP2B4 with both cytochrome b5 and cytochrome P450 reductase have been ex-
tensively studied by Waskell et al. [149]. Their mutagenesis data show that when
one of R122, R126, R133, R422, K433 and R443 was mutated, the Kd of the
complex was increased dramatically [149]. Negatively charged interface residues
on CPR are E92, E142, D147 and D207 which are important for the interaction
with on CYP2B4. For comparison, the total energies of the top three clusters of
SDA were used. As shown in Table 5.2, with each of the single mutations, the
computed energy was much higher (less favorable) than the wild type. Although
having the same binding interface on CYP2B4, the orientation of CPR differs (Fig-
ures 5.4&5.3). There are far fewer encounter complexes recorded for the mutants
than the wild type, meaning that the mutations make the association less favor-
able. This result also shows the possibility of using the total interaction energy
from SDA to compare binding affinities of systems of P450s and CPR.
From our assessment and previous SDA usage, we believe that SDA together
with molecular dynamics refinement is a method to study interactions of P450s
and CPR. This will allow us to investigate interactions of different P450s and CPR,
compare the binding affinities of different P450s and compare the binding affini-
ties of P450s with and without ligands in the active site.
5.3.2 Interactions of CYP2B4 and CPR
By using SDA and MD refinement, we were able to generate complexes that are
similar to the models built by Waskell et al. using mutagenesis data [149]. As
101
5.3. RESULTS AND DISCUSSION
Figure 5.3: SDA recorded complexes of different mutants on the proximal side of CYP2B4: R122A:
(A), R126A: (B), R133A: (C) and K433A (D). CYP2B4 is in green, CPR in cyan, the heme center
in purple and FMN in yellow. The recorded complex of wild-type is shown in Figure 5.4. All
structures shown are representative structures of the first cluster and the mutated residues are
shown in orange.
Figure 5.4: Complexes of CYP2B4 (green) and the human CPR (cyan) generated by SDA without
(A) and with (B) MD refinement. The heme and FMN cofactors are show in purple and yellow,
respectively. The B-C loop of CYP2B4 is colored in magenta. Interface residues on the proximal
side of CYP2B4 are labeled and colored in dark blue and those of CPR in red. The interface
residues (D113, E115, E116, E142, D144) of CPR which were proposed to be interface residues
experimentally but are not identified in this study as interface residues are shown in orange and
labeled in black. The distance between the FE atom of heme and the N5 atom (labeled) of FMN is
23.2 Å in (A) and 20.0 Å in (B).
102
5.3. RESULTS AND DISCUSSION
shown in Figure 5.4, positively charged interface residues on CYP2B4 in our mod-
els are R122, R126, R133, R422 and K433, which is in very good agreement with
the previously mentioned mutagenesis data. Not all the interface residues that
were proposed (D113, E116, E142 and D144) are on the binding interface of CPR
[149].
It should also be noticed that the distance between the electron transfer atoms,
the iron (FE) atom of the heme cofactor and the nitrogen (N5) atom of the FMN
cofactor, shortened from 23 Å to 20 Å during MD refinement. This shows that
the SDA docked encounter complex is the favored encounter position for both
proteins. The distance of 20 Å is close enough for electron transfer. Electrons can
be transferred from FMN to intermediate residues and then to the heme center.
5.3.3 Interactions of CYP51s and CPR
Sterol 14α-demethylase (CYP51) plays an important role in sterol biosynthesis. It
can be used as a target for antiparasitic drugs and thus it is crucial to understand
differences between human and parasitic CYP51s to develop parasite specific in-
hibitors. Here, we docked the human CPR to both human and T. brucei CYP51s.
The average total interaction energy of the top three clusters of encounter
complexes of human CYP51 and human CPR is -18.1 kBT and that of T. brucei
CYP51 and human CPR is -8.5 kBT. The difference of the total interaction energy
indicates that human CYP51 has higher affinity for human CPR than T. brucei
CYP51. If the association of CYP51 and CPR is the rate limiting step of the catalytic
reaction, this result can help to explain the observation by Lepesheva et al. [6]
that the efficiency of reduction for human CYP51 is higher than that for T. brucei
CYP51 when using rat CPR for electron transfer as shown in Figure 4 of ref. [6].
Rat CPR has 92% sequence identity to human CPR and the residues surrounding
the FMN cofactor are well conserved. However, rat CPR has only 24% identity
to T. brucei CPR and the interface residues for the P450s are not conserved. The
reason for the higher efficiency of human CYP51 may be the faster association
of human CYP51 indicated by the more positively charged proximal side than T.
brucei CYP51 as shown in Figure 5.5.
Interface residues of T. brucei CYP51 and human CPR are shown in Figure 5.6.
Only three positively charged residues are identified on the interfaces of CYP51 of
both complexes in Figure 5.6.
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Figure 5.5: Comparison of electrostatic potentials of T. brucei and human CYP51. The approximate
proximal side is labeled by dashed circles. (A) The structure of T. brucei CYP51 with B-C loop in
magenta and F-G loop in red. (B) The comparison of electrostatics of the proximal side of T. brucei
and human CYP51. For T. brucei CYP51, positively and negatively charged patches are in cyan and
yellow, respectively. For human CYP51, those patches are in blue and red, respectively. (C) and (D)
are electrostatics (-0.1 and 0.1 kcal/mol e) of human and T. brucei CYP51 with blue for positive
and red for negative patches. The ionic strength was 150 mM at pH 7.
5.3.4 Interactions of Human Drug-metabolizing P450s and CPR
To study interactions of human drug-metabolizing CYPs with CPR, we used SDA
to dock crystal structures of CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1 and
CYP3A4 to CPR. The trend of the energy can help to analyze affinities of P450s
with CPR as shown previously. The electrostatic potential of P450s are shown in
Figure 5.7. As shown in Figure 5.8, CYP1A2 has much more favorable energy
in the SDA recorded encounter complexes with CPR and thus has much higher
affinity to bind to CPR than CYP2B4. This is in good agreement with the ex-
perimental data by Kelley et al. [159], in which they showed that in a mixture
of CYP2B4, CYP1A2 and CPR, CPR has higher affinity to bind to CYP1A2 than
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Figure 5.6: Complexes of T. brucei CYP51 (green) and the human CPR (cyan) generated by SDA
without (A) and with (B) MD refinement. The heme and FMN cofactors are show in purple and
yellow, respectively. The B-C loop of CYP51 is colored in magenta. Interface residues on the
proximal side of CYP51 are labeled and colored in dark blue and those of CPR in red. The distance
between the FE atom of heme and the N5 atom of FMN is 24.3 Å in (A) and 27.8 Å in (B).
CYP2B4. Amongst these P450s, CYP1A2, CYP2A6 and CYP3A4 have the most
favorable binding energy and thus highest affinity. The ligand-bound crystal struc-
tures of CYP2D6 and CYP3A4 should have higher affinity to bind to CPR which
indicates a higher affinity for P450s to bind CPR when substrates are bound to
the active site. The ligand-bound crystal structure of CYP2C9 has lower affinity to
CPR than the ligand-free structure, possibly because of the high inhibitory effect
of flurbiprofen.
CYP2A6, CYP2D6 and CYP2E1 are chosen as representatives to investigate
interactions between them and CPR. Figure 5.9 shows interactions of CPR with
these three human drug-metabolizing P450s. The same as previously mentioned
CYP2B4 and CYP51, they all bind to the FMN domain of CPR using the proximal
side. Although CPR binds using the same interface, the orientation and distance
to P450s differ when binding to different P450s. Figures 5.9A&B show the inter-
face of CYP2A6 and CPR. The highest number of interface residues of these three
P450s (Figure 5.9) was identified which is consistent with the lowest binding en-
ergy of CYP2A6 and CPR. The proximal side of CYP2A6 is highly positively charged
and this can be the reason for its strong interaction with CPR. The interaction of
CYP2D6 and CPR (Figures 5.9C&D) is similar to the model built by Sündermann
et al. [165]. For CYP2E1, it is similar to CYP2A6, although the distance between
heme and FMN increased after MD refinement.
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Figure 5.7: Electrostatic potential of the proximal side of P450s (-0.1 and 0.1 kcal/mol e) with
positive charges in blue and negative charges in red. All P450s have the same view as in Figure
5.5A.
5.4 Conclusion
Interactions of different P450s with cytochrome P450 reductase were studied us-
ing the SDA 7 software, which uses Brownian dynamics to generate encounter
complexes, and followed by molecular dynamics simulations in AMBER to refine
encounter complexes of SDA. SDA was able to reproduce encounter complexes of
P450s and their redox partners, which are in good agreement with crystal struc-
tures of corresponding complexes. In the generated encounter complexes of dif-
ferent P450s with CPR, binding interfaces are the positively charged proximal side
of P450s and the negatively charged patch next to the FMN cofactor of CPR.
MD refinement introduces flexibility to encounter complexes and refines inter-
actions of the two proteins. In approximate 50% of the P450s studied, after MD
refinement, the distance between the heme center and the FMN cofactor shortened
(Figure 5.9). The distance after MD refinement should be short enough for effec-
tive electron transfer from FMN to the heme center. However, in other cases, the
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Figure 5.8: Average total energy and number of structures of all ten clusters of SDA docking.
distance between the two cofactors increased, which makes it difficult to transfer
electrons. Therefore, the electron transfer may happen through a chain of residues
on both CPR and P450s to transfer electrons from CPR to P450s.
Mutagenesis study suggested binding site residues of CPR (D113, E115, E116,
E142 and D144) are mostly reproduced in different complexes. Our study also
suggests a few important interface residues that were observed in most of the
complexes, such as Q87, E92 and D147 on CPR. Further mutagenesis studies of
human or rat CPR may help to define the importance of these residues.
The SDA interaction energy analysis of CYP1A2 and CYP2B4 agrees with exper-
imental data and this analysis may help to compare binding affinities of different
P450s to CPR. When a P450 has more negative SDA interaction energy for CPR,
it should have high affinity for CPR. CYP1A2, CYP2A6 and CYP3A4 may have the
highest affinity for CPR.
Our systematic investigation of P450s with CPR shows similarities and differ-
ences between complexes of P450s CPR. Our study may give new insights into
interactions of P450s and their redox partners, help to understand the electron
transfer process and thus to understand the mechanism of P450s.
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Figure 5.9: Complexes of human drug-metabolizing CYPs (green) and the human CPR (cyan)
generated by SDA of CYP2A6 without (A) and with (B) MD refinement, CYP2D6 without (C) and
with (D) MD refinement, and CYP2E1 without (E) and with (F) MD refinement. The heme and
FMN cofactors are show in purple and yellow, respectively. The B-C loop of CYP51 is colored in
magenta. Interface residues on the proximal side of CYPs are labeled and colored in dark blue and
those of CPR in red. The distance between the “FE” atom of CYPs and the “N5” atom of the FMN
cofactor is 23.8 Å in (A), 21.8 Å in (B), 23.1 Å in (C), 25.9 Å in (D), 22.9 Å in (E) and 23.2 Å in
(F).
SDA generates diffusional encounter complexes. If large conformational changes
are required for the electron transfer process, SDA and MD refinement will not al-
low to simulate such conformational changes. However, we believe that our study
provides basic understanding of interactions between P450 and CPR.
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Simulation of a membrane-bound
model of T. brucei CYP51 and human
CPR
6.1 Introduction
As discussed in Chapter 5, for many P450s in eukaryotes, the redox partner is
cytochrome P450 reductase (CPR). CPR consists of three domains: the FMN do-
main which contains the flavin mononucleotide (FMN), the FAD domain with the
flavin adenine dinucleotide (FAD), and the NADPH domain with the nicotinamide
adenine dinucleotide phosphate (NADP). In eukaryotes, both proteins locate in
the endoplasmic reticulum (ER) membrane anchored with a trans-membrane he-
lix. The association of the globular domains of the two proteins is mainly driven
by electrostatic interactions [147]. The positively charged proximal side of P450
interacts with the negatively charged FMN domain of the CPR. However, so far,
no crystal structure has been solved of their complex, and little is known about
their interactions with the membrane or possible conformational changes of the
proteins upon binding or during the catalytic cycle.
Understanding the P450-CPR interaction in the membrane is of great interest.
First of all, it can help to investigate the catalytic mechanism of P450s in the native
membrane-bound form. It can give insights into the association and dissociation of
the two proteins in the membrane environment. Furthermore, the bound complex
can be used to study ligand access and egress tunnels in P450s which can be
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influenced by the protein-protein interactions. Lastly, it can help to improve the
prediction of drug metabolism by P450s and the design of drugs to bind to P450
drug targets.
Many studies have been carried out for the soluble forms of P450s and their
redox partners as discussed in Chapter 5. However, very little is known about the
structures of complexes of P450s and CPR in their native membrane-bound form,
especially, due to the difficulties of doing experiments with membrane-bound pro-
teins. Computational methods have been used to build models of different P450s
in the membrane. These models are shown to be in good agreement with ex-
perimental data [29, 30, 24, 111]. With these computational methods, it is also
possible to build models of membrane-bound forms of complexes of P450s and
CPR.
A systematic multi-scale simulation protocol employing coarse-grain and atomic
detail models has been established to model and simulate P450 in a 1-palmitoyl-
2-oleoyl-sn-glycero-3-phosphocholine (POPC) bilayer and this has been used to
model human CYP2C9 in a POPC bilayer [29]. Other researchers have also re-
cently built and simulated models of P450s in bilayers including for CYP2C9
[30], CYP3A4 [24, 111], CYP19 [110] and other human drug-metabolizing P450s
[112]. Sündermann et al. [165] performed a simulation of a complex of CYP2D6
and the open form of CPR in a bilayer. This complex was however built manu-
ally and the time scale of the simulation (10 ns) was too short to investigate the
dynamics of the equilibrated complex in the membrane.
Here, we present a new multi-scale simulation approach to model the ligand-
bound T. brucei CYP51 and human CPR in a POPC bilayer. We chose T. brucei
CYP51 because it is an important drug target for antifungal and antiparasitic drug
design as discussed in Chapter 3 and 4. The human CPR was used because there
is no crystal structure of T. brucei CYP51 and the human CPR has been shown to
be able to transfer electrons to T. brucei CYP51 [144]. Studying the interaction of
these two proteins can also help to design T. brucei CYP51 specific inhibitors. This
approach combines Brownian dynamics with the Simulation of Diffusional Associ-
ation (SDA 7) software to generate encounter complexes of CYP51 and CPR, and
coarse-grain and all-atom simulations to equilibrate and simulate the complexes
on the membrane.
Using this protocol, we built a model of CYP51 and CPR in complex on a
POPC bilayer. After a simulation of more than 200 ns, a stable complex was
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obtained. The distance between the heme center of CYP51 and the FMN cofac-
tor (semiquinone form) of CPR shortened in the simulation from 21.3 Å to 19
Å, which is short enough for effective electron transfer. We proposed a possible
electron transfer pathway, from the FMN cofactor, to the LYS421 residue, then to
the heme-coordinating CYS422 residue, and finally to the heme center.
6.2 Methods
The newly developed protocol is shown in Figure 6.1. The procedure to use the
SDA software to generate encounter complexes has been discussed in Chapter 5.
The first cluster representative after MD refinement of the simulation discussed
in Chapter 5.3.3 was used as the starting structure of the CYP51-CPR encounter
complex. The membrane-bound model of CYP51 on a POPC bilayer was discussed
previously in Chapter 3. The last snapshot of the simulation of membrane-bound
form of T. brucei CYP51 as discussed in Chapter 3 was used as the other starting
structure.
With the two initial structures, the CYP51 of the encounter complex was super-
imposed onto the model of membrane-bound CYP51. Missing N-terminus residues
1-68 of CPR including the trans-membrane helix (residues 23-43) and the missing
loop between the trans-membrane helix and the FMN domain (residues 44-68)
were modeled using Modeller and inserted into the membrane as described in
[29].
The same protocol and parameters as described in Chapter 3.2.6 were used to
simulate the system.
6.3 Results and Discussion
The membrane-bound model of the complex of T. brucei CYP51 and human CPR
was simulated for 217.5 ns. The RMSD analysis of backbone atoms of CYP51, the
FMN domain of CPR and the FAD domain of CPR is shown in Figure 6.2. The
B-factor analysis of the last 112.5 ns (when the system fluctuated stably) of non-
hydrogen atoms of the whole system (both CYP51 and CPR), CYP51, the FMN
domain of CPR and the FAD domain of CPR is shown in Figure 6.3 and the radius
of gyration analysis of the last 112.5 ns of those is shown in Figure 6.4.
111
6.3. RESULTS AND DISCUSSION
Figure 6.1: Protocol to build and simulate membrane-bound models of CYP51 and CPR.
6.3.1 The Complex in the Membrane
The starting structure and the equilibrated structure are shown in Figure 6.5. In
Figure 6.5A, the membrane-bound T. brucei CYP51 was taken after MD simulation
and the CPR was built onto it. In this model, the globular domain of CPR was
relatively far away from the membrane, with the FMN domain interacting with
the proximal side of CYP51 and the FAD domain extending away from the mem-
brane. However, the FAD domain of CPR got much closer to the membrane in the
simulation, although the distance between the center of mass of CPR and that of
the membrane remained mostly similar during the simulation (Figure 6.6). The
globular domain of CPR has a much larger distance to the membrane than that of
CYP51 in the simulation. The reason can be that CPR is prohibited from getting
much closer to the membrane because of its interaction with CYP51.
Figure 6.6 shows distance measurements. The distance between the center of
mass of CYP51 and that of the membrane fluctuated stably during the simulation.
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Figure 6.2: RMSD analysis of protein backbone atoms during the MD simulation of the membrane-
bound model of T. brucei CYP51 and CPR. RMSDs Cα atoms of whole system (both proteins),
CYP51, the FMN domain of CPR and the FAD domain of CPR are in cyan, blue, red and green.
Figure 6.7 shows the plot of the orientation of T. brucei CYP51 in the membrane.
This orientation is similar to that of only T. brucei CYP51 in the membrane as dis-
cussed in Chapter 3 and Figure 3.5. This shows that in the simulation, CYP51
keeps its orientation in the membrane and embedded slightly deeper in the mem-
brane in the complex form than only itself in the membrane (Figure 6.7). The
heme tilt angle of T. brucei CYP51 in the simulation of the complex in membrane
is 57.8 ± 5.0◦ which is in better agreement with experimental value for CYP3A4
than the membrane-bound model of only CYP51 as shown in Table 3.2.
The distance between CPR and membrane is much further than that between
CYP51 and membrane. Davydov et al. have shown that P450s tend to form com-
plexes and forming complexes can increase the affinity of P450s to bind to CPR
[159, 173, 174]. The result of forming complexes with other P450s may change
the orientation of P450s on the membrane, which make it easier to form com-
plexes with CPR than monometic P450s.
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Figure 6.3: B-factor analysis of protein non-hydrogen atoms during the last 112.5 ns of the MD
simulation of the membrane-bound model of T. brucei CYP51 and human CPR. B-factor of CYP51
when using the whole system as reference structure for superimposition (A, black) and CYP51 as
reference structure for superimposition (A, blue) and that of CPR when using the whole system
for superimposition (B, black) and, the FMN domain for superimposition and FAD domian for
superimposition (B, blue). When using CYP51 as reference structure for superimposition, the
modeled region (residues 1-29) was not computed. The FMN domain and the FAD domain of CPR
were used as reference structures for superimposition to compute B-factors for the FMN domain
and the FAD domain, respectively. The modeled region of CPR (residues 1-50 and 231-243) was
not computed.
6.3.2 Comparison of Interface Residues with Experimental Data
There are more interface residues after 217.5 ns simulation than before the simu-
lation as shown in Figures 5.5 and 6.8. In the simulation of the membrane-bound
model of the complex, CYP51 and CPR got much closer mainly driven by electro-
static interactions. As shown in Figure 6.8, six positively charged residues (lysines
and arginines) of CYP51 form strong electrostatic interactions with negatively
charged residues (aspartic acids and glutamic acids) of CPR. All five negatively
charged residues of CPR (D113, E115, E116, E142 and D144), which are proposed
to be important for interactions of P450 and CPR, are interacting with residues of
CYP51. The six positively charged residues of CYP51 used to interact with CPR lo-
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Figure 6.4: Radius of gyration analysis of protein non-hydrogen atoms during the last 112.5 ns
of the MD simulation of the membrane-bound model of T. brucei CYP51 and CPR. The radius of
gyration was computed for the whole system (cyan), CYP51 (blue) and, the FMN domain (red),
the FAD domain (green) of CPR and the crystal structure of CYP51 (PDB ID: 3G1Q) (black).
cate on different secondary structures of CYP51. They are not conserved in P450s,
although the positively charged proximal side of P450s is conserved.
6.3.3 Electron transfer from CPR to CYP51
The distance between the FE atom of the heme center and the N5 atom of the FMN
cofactor of CPR decreased during the simulation. The distance changed from the
start of the simulation with 2˜2 Å to the end of the simulation with 1˜9 Å. This
distance is not as close as the distance of 14.1 Å obtained from MD simulations of
the crystal structure of the complex of P450-BM3 and the FMN domain [175], but
it should be short enough for effective electron transfer.
The LYS421 residue (next to the heme-coordinating CYS422 residue) directly
interacts with the FMN cofactor as shown in Figure 6.8. It may form a short elec-
tron transfer pathway with CYS422 to transfer electrons from the FMN cofactor to
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Figure 6.5: Structure of the membrane-bound model of T. brucei CYP51 and human CPR before
(A) and after 142.5 ns MD simulation (B).
the heme. Thus this possible pathway is FMN-LYS421-CYS422-heme but further
computation and mutagenesis study are required to confirm this.
6.4 Conclusion and Outlook
A model of membrane-bound form of T. brucei CYP51 and human CPR was built
using a new multi-scale approach. Based on the model of membrane-bound T.
brucei CYP51, the membrane-bound CPR was built upon it. The 217.5 ns simu-
lation of the model shows that the interaction of CYP51 and CPR is stable in the
membrane-bound form. The stability of the complex was driven by the electro-
static interactions as inferred by the fact that the interface residues of CYP51 are
mostly positively charged lysine and arginine residues and the interface residues
of CPR are mostly aspartic acid and glutamic acid residues. The distance between
heme and FMN shortened in the simulation and a possible electron transfer path-
way of FMN-LYS421-CYS422-heme was proposed.
The proposed protocol gives the possibility to build models of membrane-
bound forms of different P450s and CPR. Having membrane-bound models of
P450s and CPR can help to compare P450s, to understand selectivity of CPR upon
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Figure 6.6: Analysis of distances between different domains of the membrane-bound model of
CYP51 and CPR during the simulation. These distances are distance between CPR and membrane
in red, that between the FMN domain of CPR and the FAD domain of CPR in green, that between
CYP51 and membrane in black, and that between the FE atom of the heme center of CYP51 and
the N5 atom of the FMN cofactor of CPR in blue.
Figure 6.7: The normalized distribution of the three measured parameters (d, α and β) of T.
brucei CYP51 in the simulation of the membrane-bound model of the complex of T. brucei CYP51
and human CPR in the membrane. The parameters are defined as in Chapter 3.2.7. Density plot of
the distance between the center of mass of CYP51 and that of the membrane in the complex form
with CPR in black and that of only CYP51 in the membrane in grey (A) and density plot of angle
α of CYP51 in complex form (red) and that of only CYP51 in the membrane (orange) and, angle
β of CYP51 in complex form (green) and that of only CYP51 in the membrane (cyan). The data
of distance, α angle and β angle of only CYP51 in the membrane are taken from the simulation of
the membrane-bound model of T. brucei CYP51 discussed in Chapter 3.
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Figure 6.8: Interface residues of T. brucei CYP51 and human CPR after MD simulation of the
membrane-bound form of the complex. CYP51 is in green and CPR in cyan. The B-C loop of
CYP51 is in magenta and F-G loop in red. The heme center is in purple and the FMN cofactor
in yellow. Residues that are within 7.5 Å of the other protein are selected as interface residues.
Only the positively (lysine and arginine) and negatively charged (aspartic acid and glutamic acid)
residues are shown and labeled. Interface residues of CYP51 are labeled in dark blue and those of
CPR in dark red. The distance between the FE atom of the heme and N5 atom of FMN is 18.4 Å.
different P450s and thus to aid drug design. The model of the membrane-bound
form of CYP51 and CPR is a fundamental model to understand behaviors of both
CYP51 and CPR in complex form on a lipid bilayer, which is the native environ-
ment. This model may help to design drugs against parasitic CYP51s, taken their
interaction with CPR into consideration.
118
7
webSDA, a Web Server for SDA 7
7.1 Introduction
Macromolecular interactions, such as protein-protein interactions and protein-
DNA interactions, are key to the function of biological systems. Studying macro-
molecular diffusional association computationally can give insights into biological
interactions. SDA (Simulation of Diffusional Association) is a Brownian dynamics
simulation software which can be used to perform macromolecular docking, to
compute bimolecular association rate constants, and to simulate molecular diffu-
sion for systems of many macromolecules [73, 71, 85]. Intermolecular forces are
computed from atomic-detail molecular structures. SDA has been used to generate
diffusional encounter complexes for a wide range of macromolecular complexes,
including those of barnase and barstar [71, 83], cytochrome P450 enzymes and
their redox protein partners [147, 79, 170], methionine aminopeptidase and the
ribosome [81], and the linker histone H5 and the nucleosome [80]. Moreover,
SDA has been used to calculate association rate constants [73, 71, 176, 177]
and simulate the diffusive motion of hundreds of macromolecules in solution
[85, 87, 178, 88, 86]. All these functions of SDA have been extensively vali-
dated against experimental data. Although SDA is made available for standalone
use, it cannot be used easily by non-experts because of its multitude of different
parameters and options, many of which are interdependent. Setting these param-
eters correctly and understanding their function demands a good understanding
of Brownian dynamics simulations and the structure of the SDA software.
webSDA is a web server which aims to eliminate these obstacles and make
SDA’s functionalities available to a broader audience. webSDA supports the gen-
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eration of diffusional encounter complexes (“SDA docking”), the calculation of
biomolecular diffusional association rate constants (“SDA association”) and the
simulation of the diffusive motion of several hundred macromolecules (“SDA mul-
tiple molecules”). The flexibility of the solutes can be accounted for by providing
several different conformations for one of the solutes (“SDA docking” and “SDA
association”) or each of the solutes (“SDA multiple molecules”). It allows users to
set up and run SDA simulations. webSDA automates the preparation of input files
by generating input parameters automatically. If one parameter is used in multiple
input files, it only needs to be defined once. Input files generated by webSDA can
also be downloaded for use with the standalone version of SDA.
7.2 webSDA Workflow
The workflow of webSDA is shown in Figure 7.1.
Step 0: To begin a simulation, users may enter the PDB identifiers of the macro-
molecules that they wish to simulate or upload coordinate files for the macro-
molecules in PDB or PQR format. PQR format files contain the atomic coordi-
nates, formatted as in PDB files from the Protein Data Bank (www.rcsb.org/pdb),
with partial atomic charges (Q) and atomic radii (R) instead of B-factors and oc-
cupancies. If PDB files are used, PQR files will be generated using the PDB2PQR
software, version 2.0.0 [117], with the AMBER force field and default parameters.
Users can also generate their own PQR files using the PDB2PQR web server [167].
After uploading coordinate files, users select one of the SDA methods: “SDA dock-
ing”, “SDA association” or “SDA multiple molecules”. Users then follow a sequence
of steps to set up and run an SDA job, guided by hints on the webSDA website. As
an example, the following steps show how to run an “SDA docking” simulation.
Step 1: Select target and mobile solutes: Users need to choose a target solute
and a mobile solute for the “SDA docking” job.
Step 2: Modify reaction criteria and effective charge sites: Reaction criteria
are distances between defined points in the solute molecules that are required
to be satisfied for an encounter complex to be recorded in an SDA simulation.
The default reaction criterion for “SDA docking” is predefined for the centers of
geometry of the solutes and requires that they approach within a distance equal
to the sum of the maximum extensions of the two solutes plus 12 Å. The reaction
criteria can be changed in the web interface and can be used to impose additional
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Figure 7.1: Workflow of webSDA
distance constraints which can be derived, e.g. from bioinformatics analysis or
experimental data, such as FRET and mutagenesis. Effective charges are used
in combination with electrostatic potential grids to approximate the electrostatic
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interactions between molecules [75]. Users can modify the effective charge sites
for non-standard atoms, such as found in low-molecular weight compounds, in
the web interface.
Step 3: Define input parameters for running SDA simulations: The automat-
ically generated SDA parameters are given to users. Users can modify the SDA
input parameters and run SDA simulations on the server. webSDA checks the in-
put parameters that users have changed and helps users to set correct parameters.
They may upload their own files (SDA input file, reaction criteria file and effective
charge sites file) to run their SDA simulations on the web server. The web server
can be used to run short jobs. The SDA input file can also be generated and down-
loaded together with the other files to run with the standalone version of the SDA
software, which is also freely available.
Step 4: Clustering: For “SDA docking”, the recorded diffusional encounter com-
plexes are clustered and the cluster representatives can be visualized with JSmol
on the web server or downloaded as described below.
7.3 Output
Besides the option to download output files, webSDA offers a convenient visu-
alization of the results. An example is given in Figure 7.2. For the results of
“SDA docking”, JSmol is used for visualization of the cluster representatives of the
diffusional encounter complexes. This provides users with an easy way to view
encounter complexes and decide which complexes to download for further anal-
ysis. For “SDA association”, the calculated association rate constants are plotted
using the R language, enabling users to visualize calculated association rate con-
stants immediately. For “SDA multiple molecules”, the JSmol plug-in is employed
to enable users to visualize the final snapshot of their simulations.
webSDA assigns each user a universally unique identifier (UUID). This enables
users to revisit all projects that they have run in the “My projects” page. There is
a link associated with this page and users can send this link to colleagues to share
projects.
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7.4 Examples of webSDA Usage
webSDA gives results consistent with the standalone version of SDA, which has
been extensively validated against experimental data [73, 81, 87]. webSDA pro-
vides example cases for each method. In Figure 7.2, we illustrate the perfor-
mance of webSDA for the simulation of the association of barnase and barstar
(PDB ID: 1BRS) and the simulation of many barnase molecules. With the “SDA
docking” method, cluster representatives of the docked barnase-barstar complexes
in good agreement with the crystal structure of the complex and results obtained
by Motiejunas et al. [83] are obtained.
It should be kept in mind that “SDA docking” uses Brownian dynamics simula-
tions to generate diffusional encounter complexes rather than fully docked com-
plexes. The encounter complexes can be refined by molecular dynamics simulation
to generate fully bound complexes, as shown in [83], but currently webSDA does
not support running molecular dynamics simulation.
The “SDA association” function is another important function of webSDA. For
the barnase and barstar complex at an ionic strength of 50 mM and pH 7, the asso-
ciation rate constant computed with “SDA association” is 4.1 x 108M -1s-1 (averaged
from three webSDA runs: 4.0 x 108M -1s-1, 4.0 x 108M -1s-1 and 4.3 x 108M -1s-1),
which is comparable with experimental data (3 x 108M -1s-1) (18) (Fig. 2) and the
simulation results reported by Gabdoulline and Wade [73].
The “SDA multiple molecules” function of webSDA can be used to perform
Brownian dynamics simulations of many molecules. This function of SDA has been
used to study the behavior of proteins in crowded environments and is shown to
be able to reproduce experimental data [85, 87, 178, 88, 86]. The long-time self-
diffusion coefficients, second virial coefficients and structure factors, calculated by
“DA multiple molecules”, agree with experimental values.
There are several webservers [179, 180, 181, 182, 183, 184] providing similar
functionality to “SDA docking” but they are often limited to proteins with standard
amino acid residues. “SDA docking” supports protein, DNA and RNA, and small
molecules, such as a cofactor, can be treated as part of a macromolecular structure.
For the calculation of association rate constants, the TransComp server (http:
//pipe.sc.fsu.edu/transcomp/) [185] computes association rate constants for
protein-protein and protein-RNA complexes. “SDA multiple molecules” is, to the
best of our knowledge, the first web server for performing simulations of hundreds
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Figure 7.2: Screenshots of webSDA showing key features of webSDA
to thousands of macromolecules, which can be used to study concentrated protein
solutions, and to investigate macromolecular crowding, or other phenomena in-
volving large numbers of macromolecules.
7.5 Technical Overview
The webSDA interface uses Javascript and HTML5 to control user interface (UI)
elements. The server uses the Play framework v. 2 and Apache commons.exec
to manage user sessions and server resources. PDB2PQR version 2.0.0 is used
to convert PDB files to PQR files [117, 167]. BioJava is used to process PDB ID
and download PDB files. Python scripts (Biopython) are used to check PQR files
and generate input parameters. SDA 7 (http://mcm.h-its.org/mcm) is used to
process PQR files, to generate grids (along with the Adaptive Poisson-Boltzmann
Software [76] to compute electrostatic potential grids), and to perform simula-
tions.
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7.6 Discussion and Outlook
webSDA is a web server to perform Brownian dynamics simulations of biomacro-
molecules. “SDA docking” allows users to generate diffusional encounter com-
plexes of two solutes (proteins, DNA or RNA). “SDA association” can be used to
compute the bimolecular association rate constant for a specified complex and
can be combined with “SDA docking” when the structure of the complex is un-
known. “SDA multiple molecules” is helpful for studying the diffusive behavior of
hundreds of molecules.
webSDA automates the widely used SDA software, generates input parame-
ters and files automatically, and offers user-friendly visualization of output results.
webSDA is useful for beginners learning how to perform Brownian dynamics sim-
ulations as well as for experts preparing input files for running simulations. Simu-
lation times and file sizes are limited on the webSDA server so webSDA allows the
generated input files to be downloaded for carrying out production runs with SDA
on local or high performance computing resources. We believe that webSDA will
be an easy-to-use tool for users who are interested in using Brownian dynamics
simulations to study biological systems. Currently webSDA does not support all
the functions of SDA. However, webSDA has a modular structure that will facilitate
the implementation of further methods and features in the future.
125

8
Conclusion
In this thesis, a multiscale computational study was performed for Trypanosoma
brucei CYP51, human CYP51, interactions of P450 and CPR and the membrane-
bound model of the complex of T. brucei CYP51 and human CPR. A webserver built
for the Simulation of Diffusional Association (SDA) software was also introduced.
Using all-atom molecular dynamics simulations, the dynamics of soluble forms
of T. brucei CYP51 was compared with those of human CYP51, human CYP2C9
and human CYP2E1. The binding site residues of both T. brucei CYP51 and human
CYP51 are less mobile than those of CYP2C9 and CYP2E1. Whereas the tunnel
entrance residues are more mobile in CYP51 than in CYP2C9 and CYP2E1. The
difference between the active site residues of T. brucei and human CYP51 may be
the key to design T. brucei specific inhibitors. A model of the membrane-bound
form of T. brucei CYP51 was built using a combination of coarse-grained and all-
atom simulations. Coarse-grained simulations were used to define the predom-
inant orientation of T. brucei CYP51 in the membrane and this orientation was
used as a starting point for the subsequent all-atom simulations. The model of
membrane-bound CYP51 showed similar dynamics to the soluble model, whereas
the F-G loop region which is buried in the membrane showed less mobility than
the soluble model because of its interactions with lipids.
The ligand tunnels in the model of soluble T. brucei CYP51, the model of
membrane-bound T. brucei CYP51 and that of soluble human CYP51 were also
studied using random acceleration molecular dynamics (RAMD). Tunnel 2f serves
as the predominant ligand tunnel in all three models. For T. brucei CYP51, when
CYP51 is in the membrane, it uses tunnel 1 and tunnel S more often than in the
soluble simulations. In the model of membrane-bound T. brucei CYP51, tunnel
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2f leads to the membrane but ligands were able to exit in the membrane-bound
model with a similar exit time to the soluble model. Human CYP51 uses only tun-
nel 1 as the second predominant ligand tunnel and exit times of ligands from the
active site of human CYP51 is shorter than those of T. brucei CYP51. The difference
between the use of ligand tunnels in T. brucei and human CYP51 may due to the
differences in the tunnel entrance residues and the ligand tunnel gating residues.
The interaction of P450 and cytochrome P450 reductase (CPR) was studied
using Brownian dynamics simulations and molecular dynamics simulations. Com-
plexes of soluble forms of different P450s, including CYP51, CYP2B4, CYP1A2,
CYP2A6, CYP2C9, CYP2D6 and CYP2E1 with CPR were investigated. P450s bind
to CPR using a similar interface, the positively charged proximal side, but the
orientation of CPR when binding to different P450s is different. The SDA total
interaction energy is found to be useful to compare the binding affinity of P450s
to CPR.
A model of the membrane-bound complex of T. brucei CYP51 and CPR was built
and simulated. In the simulation of over 200 ns, CYP51 kept its orientation in the
membrane but embedded slightly deeper into the membrane than in the simula-
tion of only CYP51 in the membrane. The distance between the “FE” atom of the
heme cofactor of CYP51 and the “N5” atom of the FMN cofactor of CPR short-
ened to ca. 19 Å. The protocol to build models of membrane-bound complexes of
P450s and CPR can be applied to model other complexes of P450s and CPR. Our
model of the membrane-bound complex of T. brucei CYP51 and CPR gives a basis
for understanding the interactions of the two proteins in the membrane, which
gives insights into the dynamics of the complex in their native membrane-bound
environment.
A webserver (webSDA) was built for the Simulation of Diffusional Association
(SDA 7) software package. SDA 7 was used to study the interaction between
P450 and CPR. webSDA was built to improve the user-friendliness of SDA 7. The
webserver automates the procedure to prepare and run SDA 7 and should be useful
for beginners who want to perform Brownian dynamics simulations.
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8.1 Limitations and Future Directions
8.1.1 Simulations of CYP51
The computational study of T. brucei CYP51 performed in this thesis gives a basis
for understanding the dynamics of T. brucei CYP51. This simulations also provide
structures of T. brucei CYP51 which can be used to design anti-parasitic drugs.
However, the simulation were performed for less than 100 ns and this was not
long enough to sample large conformational changes of T. brucei CYP51. The com-
parison of T. brucei CYP51 and human CYP51 shows some differences between the
two proteins, mainly the difference in binding cavity residues and tunnel entrance
residues. This information can be used in the design of parasite specific inhibitors.
Further docking studies are required to design these inhibitors and subsequent
experiments are required to test the computationally designed inhibitors.
The POPC bilayer was used in the simulations of models of membrane-bound
T. brucei CYP51. However, biological membranes are not composed of homoge-
nous lipids, but heterogenous lipids. Simulations with heterogeneous membranes
would provide insights into the dynamics of CYP51 in biological membranes.
8.1.2 Simulations of Ligand Tunnels
The study of ligand tunnels shows how ligands can exit from the active site of both
T. brucei and human CYP51. However, a force was applied to accelerate the exit of
ligands which may introduce artifacts to the system. Although ligand exit tunnels
can give insights into ligand entrance tunnel, simulations of ligand entrance are
required to understand how ligands can enter the active site of P450 and ligand
specificity of P450.
8.1.3 Simulations of Interaction of P450 and CPR
Simulations of P450 and CPR show the possible binding interfaces in the two
proteins. However, these simulations were performed with crystal structures of
individual (unbound) proteins and only relatively small conformational changes
can be sampled in simulations. Diffusional encounter complexes were generated
in these simulations and long MD simulations are required to equilibrate these
systems to generate bound complexes. Further simulations of the electron transfer
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process are required to simulate the electron transfer process and validate models
of the complexes of P450 and CPR generated in this thesis.
The simulation of a model of the membrane-bound complex of T. brucei CYP51
and human CPR provides a basis for the understanding interaction of the two
proteins on a lipid bilayer. However, there is not much experimental data about
the structure of the complex and it is difficult to validate the model. The proce-
dure can also be used to study P450-P450 interactions and generate structures of
P450-P450 complexes. Mutagenesis and crystallography experiments can be per-
formed to validate the model and these experimental data will give insights into
the interaction of the two proteins on the membrane.
8.1.4 webSDA
The web interface for SDA 7 was developed to improve the user-friendliness of
SDA. However, not all parameters of SDA 7 can be defined and not all functions of
SDA 7 are supported by webSDA. Further development of webSDA is required to
support parameters and functions of SDA 7 that are not yet supported by webSDA.
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3.2 Comparison of the order parameters of the POPC membrane in the
60 ns simulation of membrane-bound T. brucei CYP51 with the ex-
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heme plane (cyan arrow) and the normal to the membrane plane
(black arrow). Detailed information of the three angles is shown
next to the cylinder representation of the three vectors. For more
details, refer to Materials and Methods: Data Analysis. . . . . . . . 52
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3.5 The normalized distribution of the three measured parameters (d,
α and β) in the coarse-grained and all-atom simulations of CYP51.
(A) The distance between the center of mass of the membrane and
the protein. The black line shows the distribution of the coarse-
grained simulation and the red line, the all-atom simulation. (B)
The angle α between the vector V1 and the z-axis and the angle β
between the vector V2 and the z-axis. The black and red lines show
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those of the membrane-bound model of CYP2C9 with an unstruc-
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3.6 Comparison of B-factors of the ligand-free forms of T. brucei CYP51
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CYP51 than that of the soluble form. This is because the motions of
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3.7 Comparison of the B-factors of the non-hydrogen atoms of differ-
ent CYPs with the loop regions (black), the ligand binding cavity
residues (dark red) and ligand tunnel opening residues (orange)
labeled. The residue numbers of the CYPs correspond to the PRO-
MALS3D alignment (Figure 3.5). (A) Comparison of B-factors aver-
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3.9 Plots of the RMSD and radius of gyration during the 30 ns simula-
tion of the soluble ligand-free T. brucei CYP51. (A) RMSD plot of
backbone atoms (red) and non-hydrogen atoms (blue). (B) Radius
of gyration plot of non-hydrogen atoms. The radius of gyration of
the crystal structure is shown by a dotted line. . . . . . . . . . . . . 61
3.10 The PROMALS3D crystal structure-based alignment of the sequences
of CYP51, CYP2C9 and CYP2E1 [134]. The binding cavity residues
and tunnel 2f entrance residues are shown in green colored blocks.
The aligned helices are in red and the aligned beta sheets in blue.
The score of the conserved amino acids is shown in the “conserva-
tion” row. The well-conserved residues are labeled in the “consen-
sus_aa” row. Conserved residues are uppercase letters. Consensus
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H); “-”: negatively charged (D, E); “c”: charged (D, E, K, R, H). The
conserved secondary structures (consensus_ss) are represented by
red “h” for α-helices and blue “s” for β-strands. . . . . . . . . . . . 62
3.8 The substrate binding cavity residues (dark red) and the ligand tun-
nel entrance residues (orange) shown in the last snapshot of the
simulation of the membrane-bound ligand-free T. brucei CYP51.
The substrate binding cavity residues are residues 102-116 (SRS1,
αB’-B’/C loop), 124-130 (αC), 284-295 (SRS4, αI) and 355-361
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3.11 Cartoon representation of T. brucei CYP51 showing the ligand tun-
nels of the membrane-bound CYP51 analyzed in CAVER3.0 [32].
The important secondary structure elements are labeled. The B-
C loop is shown in purple and the F-G loop in red. The bilayer is
shown in violet. Tunnels that opened at least in one snapshot during
the 60 ns simulation of the membrane-bound ligand-free CYP51 are
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ange), S (cyan), and W (yellow) lead to the solvent. Tunnels 2a, 2c,
2e and 2ac that were not open in the 60 ns simulation are labeled
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3.13 Different conformations and hydrogen bonding interactions of the
two heme propionate groups in the crystal structures and simula-
tions. The distance between the two heme propionate groups and
important hydrogen bonding partners is shown. (A) The most pre-
dominant conformation of the propionate groups observed in the
crystal structures of CYP51 enzymes. The coordinates are from T.
brucei CYP51 (PDB id: 3G1Q). (B, C) Two alternative conforma-
tions of the propionate groups seen in the snapshots at 60 ns and
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4.1 Membrane-bound model of ligand-free T. brucei CYP51 [40]. The
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The heme is shown with sticks representation and helices structures
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1.1 Summary of conformations observed in the crystal structures of
mammalian CYPs. The structures with ligand(s) bound in the active
site are denoted as “+L”, the apo structures by “-L”. When bound
and apo forms of the enzyme are present in the same structure
(different chains) with identical conformations, both labels “+L”
and “-L” were used for the same structure. “+LS” represents lig-
and(s) bound at the protein surface. The conformation type is la-
beled as: (i) “O”-open; (ii) “I”-partially open; (iii) “C”-closed. The
open conformations were classified into 2 sub-types: (i) “O1,”, “I1,”-
structures with the open cleft between the B-C and F-G blocks (with
the 2a, 2ac and 2c channels open); (ii) “O2”-structures with open
cleft between the F-G block and the β4 region (with the solvent
and the 2f channels open). Incomplete structures are labeled with
“MR” and the number of missing residues is shown as “x” in the
conformations of the B-C and F-G blocks (columns 4, 5). The con-
formational signatures of the two blocks are defined as a sequence
of secondary structure elements (α-helix in italic text, β-strand in
bold text, coil in normal text, missing crystal residues in italic and
bold text), each of which is formed by the indicated number of
residues. The helices αB, αC, αF, and αG are flanking helices of the
2 variable structure blocks. (*) Crystal structures have been deter-
mined for 2 mitochondrial CYPs. Mitochondrial CYPs do not have
an N-terminal transmembrane helix. . . . . . . . . . . . . . . . . . 7
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1.2 Summary of the ligand tunnel simulations of mammalian cytochrome
P450s. i. PDB identifier of the crystal structure used for the simu-
lations. If the structure used is a modeled structure, this is denoted
by “Model”; ii. Solubility, “MEM” indicates simulation of the CYP
embedded in a lipid bilayer; “SOL” indicates simulation of a water
soluble form of the CYP without a lipid bilayer and without the N-
terminal transmembrane region of the protein; iii. Ligands present
in the simulations; iv. Tunnels are denoted by the nomenclature
described in ref. [12] (see Figure 1.3), the tunnels that are partially
open are shown in brackets; v. MD: molecular dynamics (these
studies give information on the dynamics of ligand tunnels, but
do not involve simulation of the process of ligand egress), RAMD:
random acceleration molecular dynamics, SMD: steered molecular
dynamics; vi. Plain MD simulation together with analysis of the
ligand tunnels without a ligand being present or considered explic-
itly using CAVER [32] or a similar approach; vii. DMZ:4-methyl-
N-methyl-N-(2-phenyl-2H-pyrazol-3-yl)benzenesulfonamide; “war-
farin” includes S-warfarin and 7-OH-S-warfarin in charged and neu-
tral forms; “flurbiprofen” includes flurbiprofen and 4-OH-flurbiprofen;
viii. These studies were mainly focused on the tunnel dynamics and
their gating residues, not on which tunnel is preferred as a ligand
exit tunnel. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
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3.1 Main features of the all-atom molecular dynamics production simu-
lations of the different CYPs. (a) The F-G loop region in the crystal
structure of human CYP2C9 (PDB ID: 1R9O) is missing. Two mod-
els of the F-G loop were generated for the simulations [29]. Model 1
has F’ and G’ helices and model 2 has an unstructured F-G loop. (b)
SOL, the soluble CYPs (no membrane), MEM, the membrane-bound
CYPs in a bilayer. (c) The ligands used in the simulation. FLO, 4’-
hydroxy flurbiprofen, MCP, 14α-methylenecyclopropyl-∆7-24,25-
dihydrolanosterol, —-, ligand-free structures. (d) In the NPγT sim-
ulations of the membrane-bound CYPs, a surface tension, γ=60
dyn/cm was applied to the plane of the membrane together with
the pressure control to maintain the bilayer dynamics [29]. A com-
parison of the area per lipid, the bilayer thickness and the order pa-
rameters of the membrane in the 60 ns simulation of the membrane-
bound CYP51 with experimental data is plotted in Figures 3.1 & 3.2.
(e) Only the ligand MCP of 3P99 was transferred into the active site
of the equilibrated ligand-free CYP51 structure (originally derived
from the crystal structure 3G1Q). The simulations were then done
starting with this structure (see Methods). . . . . . . . . . . . . . . 48
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3.2 Comparison of membrane-bound T. brucei CYP51 model with the
experiments, two human CYP2C9 models with different F-G loop
structures [29] and a CYP3A4 model [111]. (i) The residue num-
bers are adjusted from the CYP2C9 residue numbers according to
the alignment of CYP51 with CYP2C9 (Figure S2) and the align-
ment of CYP51 with CYP3A4 using the “align” function of PyMOL
[116]. (ii) The location of the residues with respect to the mem-
brane: “M” indicates that the residues are either in the membrane
or in the head group region of the membrane. “C” indicates that
the residues are in the cytosol. “M & C” indicates that the fragment
is partly in the membrane and partly in the cytosol. “M / C” indi-
cates that there are experiments showing a particular residue is in
the membrane while other experiments showed that this residue is
in the cytosol. (iii) These columns show whether the model is in
agreement with the experiments. “+”: the model is in good agree-
ment with the experiments. “+-”: the model is partly in agreement
with the experiments. “-”: the model is not in agreement with the
experiments. (iv) Residue 373 was shown to be deeper in the mem-
brane than the residues 39 and 72. (v) “Heme Tilt Angle” is the
angle between the heme plane and the normal of the membrane
plane. For CYP51 and the two models of CYP2C9, the heme tile
angle is computed as an average over snapshots from the produc-
tion runs of the simulations. For CYP3A4, the angle is computed
for the final model. (vi) “Height_1” is the height of the CYP above
the lipid bilayer measured by atomic force microscopy in the ex-
periments and the distance between the z-coordinate of the highest
non-hydrogen atom of the protein and the average z-coordinate of
the phosphate group of the upper leaflet of the lipid bilayer. (vii)
“Height_2” is the distance between the center of mass of the pro-
tein and the center of mass of the membrane. (*) References are
(a): [102], (b): [107], (c): [104], (d): [111] and (e): [101] and
experiments were carried out for the CYP listed in the third column. 57
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3.3 Average computed B-factors (Å2) of Cα atoms in specific regions of
the simulated CYPs. The B-factors for the soluble simulations were
computed from the last 9 ns of the two simulations with soluble
ligand-free forms of the two human CYP2C9 models, the two simu-
lations with the two human CYP2E1 models, and the simulations of
T. brucei CYP51 and human CYP51. The B-factors of the membrane-
bound simulations were computed from the last 12 ns of the simu-
lations with the membrane-bound ligand-free forms of CYP2C9 and
CYP51. (a) Simulations were performed without a lipid bilayer (S,
soluble model) or with a lipid bilayer (M, membrane-bound model). 60
3.4 Accessibility of the water tunnel to solvent and hydrogen bonding of
the two heme propionate groups in the crystal structures of CYP51.
If there is more than one chain, chain A is used. (i) with (+) or
without (-) ligand in the active site. (ii) The water tunnel (tun-
nel W) is accessible (+) or inaccessible (-) to the solvent (with a
probe radius of 1.4 Åin PyMOL). (iii) The propionate is on the distal
side (Distal) or the proximal side (Proximal) of the heme plane, or
roughly parallel (Parallel) to it. (iv) The hydrogen bonding partners
of the heme propionate groups. A hydrogen bond is considered to
be formed when the distance between the two non-hydrogen atoms
is less than 3.3 Å. The residue number is the residue number in the
corresponding PDB structures. “—-”: the propionate has no hydro-
gen bonding with surrounding residues. “Ligands”: the propionate
makes hydrogen bonds to the ligands. (v) There are residues miss-
ing in the B-C loop and C helix region of the crystal structures.
2W09, 2W0A, 2CI0 and 1X8V have the B’-C loop missing. 2CIB has
the B’-C loop and the beginning of the C helix missing and 1H5Z
has the C helix missing. (vi) The B-propionate has rotated 120 de-
grees towards the I helix because of the interaction with the two
ligands (one in the binding site and the other in the ligand tunnel
1). (vii) There are two conformations of the B-propionate group in
the crystal structure. One conformation is on the distal and one on
the proximal side of the heme plane. . . . . . . . . . . . . . . . . . 70
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4.1 (i) The CYP51-ligand complexes studied. The full names of the
ligands are given in the Introduction section and their structures are
shown in Figure 4.2. (ii) The simulations were of soluble models of
CYP51 (SOL) and membrane-bound models of CYP51 (MEM). (iii)
Simulation method: “MD”, standard molecular dynamics; “RAMD”,
random acceleration molecular dynamics. (iv) “1” indicates that the
standard MD simulation was performed once to produce the input
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last snapshot of the production run were used for RAMD. (v) The
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time of different ligands via tunnel 2f in RAMD simulations varies,
see Figure 4.6, but the maximum time of one RAMD simulation was
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30-cyclopropylidenelanost-7-en-3-ol, KKK: ketoconazole. (ii) The
missing residues do not include missing residues on the N- and C-
termini. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
5.2 Measurement of the binding affinities of CYP2B4 and rat CPR. (i)
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energy (kBT) of all cluster members. (iii) Number of structures of
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The lib file for parameters of ligand VNI: 
 
!!index array str 
 "VNI" 
!entry.VNI.unit.atoms table  str name  str type  int typex  int resx  int flags  int seq  int elmnt  dbl chg 
 "O1" "o" 0 1 131072 1 8 -0.539900 
 "C1" "c" 0 1 131072 2 6 0.580500 
 "N1" "n" 0 1 131072 3 7 -0.523100 
 "H1" "hn" 0 1 131072 4 1 0.247100 
 "C2" "c3" 0 1 131072 5 6 0.122200 
 "H2" "h1" 0 1 131072 6 1 0.119600 
 "C3" "c3" 0 1 131072 7 6 -0.047300 
 "H32" "h1" 0 1 131072 8 1 0.075300 
 "H33" "h1" 0 1 131072 9 1 0.075300 
 "N2" "na" 0 1 131072 10 7 0.018900 
 "C4" "cc" 0 1 131072 11 6 -0.374800 
 "H4" "h4" 0 1 131072 12 1 0.215900 
 "C5" "cd" 0 1 131072 13 6 0.100400 
 "H5" "h4" 0 1 131072 14 1 0.133400 
 "N3" "nd" 0 1 131072 15 7 -0.567300 
 "C6" "cc" 0 1 131072 16 6 0.250500 
 "H6" "h5" 0 1 131072 17 1 0.084900 
 "C7" "ca" 0 1 131072 18 6 0.085200 
 "C8" "ca" 0 1 131072 19 6 -0.167900 
 "H8" "ha" 0 1 131072 20 1 0.175200 
 "C9" "ca" 0 1 131072 21 6 -0.124500 
 "H9" "ha" 0 1 131072 22 1 0.152300 
 "C10" "ca" 0 1 131072 23 6 -0.008500 
 "CL1" "cl" 0 1 131072 24 6 -0.086800 
 "C11" "ca" 0 1 131072 25 6 -0.018400 
 "H11" "ha" 0 1 131072 26 1 0.133500 
 "C12" "ca" 0 1 131072 27 6 -0.036000 
 "CL2" "cl" 0 1 131072 28 6 -0.087200 
 "C13" "ca" 0 1 131072 29 6 -0.050400 
 "C14" "ca" 0 1 131072 30 6 -0.107600 
 "H14" "ha" 0 1 131072 31 1 0.145900 
 "C15" "ca" 0 1 131072 32 6 -0.096500 
 "H15" "ha" 0 1 131072 33 1 0.123200 
 "C16" "ca" 0 1 131072 34 6 -0.156900 
 "C17" "ca" 0 1 131072 35 6 -0.096500 
 "H17" "ha" 0 1 131072 36 1 0.123200 
 "C18" "ca" 0 1 131072 37 6 -0.107600 
 "H18" "ha" 0 1 131072 38 1 0.145900 
 "C19" "cc" 0 1 131072 39 6 0.638400 
 "N4" "nd" 0 1 131072 40 7 -0.404300 
 "N5" "nd" 0 1 131072 41 7 -0.359000 
 "C20" "cc" 0 1 131072 42 6 0.589900 
 "O2" "os" 0 1 131072 43 8 -0.335700 
 "C21" "ca" 0 1 131072 44 6 -0.148300 
 "C22" "ca" 0 1 131072 45 6 -0.073600 
 "H22" "ha" 0 1 131072 46 1 0.109500 
 "C23" "ca" 0 1 131072 47 6 -0.117700 
 "H23" "ha" 0 1 131072 48 1 0.140000 
 "C24" "ca" 0 1 131072 49 6 -0.160900 
 "H24" "ha" 0 1 131072 50 1 0.151900 
 "C25" "ca" 0 1 131072 51 6 -0.117700 
 "H25" "ha" 0 1 131072 52 1 0.140000 
 "C26" "ca" 0 1 131072 53 6 -0.073600 
 "H26" "ha" 0 1 131072 54 1 0.109500 
!entry.VNI.unit.atomspertinfo table  str pname  str ptype  int ptypex  int pelmnt  dbl pchg 
 "O1" "o" 0 -1 0.0 
 "C1" "c" 0 -1 0.0 
 "N1" "n" 0 -1 0.0 
 "H1" "hn" 0 -1 0.0 
 "C2" "c3" 0 -1 0.0 
 "H2" "h1" 0 -1 0.0 
 "C3" "c3" 0 -1 0.0 
 "H32" "h1" 0 -1 0.0 
 "H33" "h1" 0 -1 0.0 
 "N2" "na" 0 -1 0.0 
 "C4" "cc" 0 -1 0.0 
 "H4" "h4" 0 -1 0.0 
 "C5" "cd" 0 -1 0.0 
 "H5" "h4" 0 -1 0.0 
 "N3" "nd" 0 -1 0.0 
 "C6" "cc" 0 -1 0.0 
 "H6" "h5" 0 -1 0.0 
 "C7" "ca" 0 -1 0.0 
 "C8" "ca" 0 -1 0.0 
 "H8" "ha" 0 -1 0.0 
 "C9" "ca" 0 -1 0.0 
 "H9" "ha" 0 -1 0.0 
 "C10" "ca" 0 -1 0.0 
 "CL1" "cl" 0 -1 0.0 
 "C11" "ca" 0 -1 0.0 
 "H11" "ha" 0 -1 0.0 
 "C12" "ca" 0 -1 0.0 
 "CL2" "cl" 0 -1 0.0 
 "C13" "ca" 0 -1 0.0 
 "C14" "ca" 0 -1 0.0 
 "H14" "ha" 0 -1 0.0 
 "C15" "ca" 0 -1 0.0 
 "H15" "ha" 0 -1 0.0 
 "C16" "ca" 0 -1 0.0 
 "C17" "ca" 0 -1 0.0 
 "H17" "ha" 0 -1 0.0 
 "C18" "ca" 0 -1 0.0 
 "H18" "ha" 0 -1 0.0 
 "C19" "cc" 0 -1 0.0 
 "N4" "nd" 0 -1 0.0 
 "N5" "nd" 0 -1 0.0 
 "C20" "cc" 0 -1 0.0 
 "O2" "os" 0 -1 0.0 
 "C21" "ca" 0 -1 0.0 
 "C22" "ca" 0 -1 0.0 
 "H22" "ha" 0 -1 0.0 
 "C23" "ca" 0 -1 0.0 
 "H23" "ha" 0 -1 0.0 
 "C24" "ca" 0 -1 0.0 
 "H24" "ha" 0 -1 0.0 
 "C25" "ca" 0 -1 0.0 
 "H25" "ha" 0 -1 0.0 
 "C26" "ca" 0 -1 0.0 
 "H26" "ha" 0 -1 0.0 
!entry.VNI.unit.boundbox array dbl 
 -1.000000 
 0.0 
 0.0 
 0.0 
 0.0 
!entry.VNI.unit.childsequence single int 
 2 
!entry.VNI.unit.connect array int 
 0 
 0 
!entry.VNI.unit.connectivity table  int atom1x  int atom2x  int flags 
 1 2 2 
 2 3 1 
 2 29 1 
 3 4 1 
 3 5 1 
 5 6 1 
 5 7 1 
 5 18 1 
 7 8 1 
 7 9 1 
 7 10 1 
 10 11 4 
 10 16 4 
 11 12 1 
 11 13 4 
 13 14 1 
 13 15 4 
 15 16 4 
 16 17 1 
 18 19 4 
 18 27 4 
 19 20 1 
 19 21 4 
 21 22 1 
 21 23 4 
 23 24 1 
 23 25 4 
 25 26 1 
 25 27 4 
 27 28 1 
 29 30 4 
 29 37 4 
 30 31 1 
 30 32 4 
 32 33 1 
 32 34 4 
 34 35 4 
 34 39 1 
 35 36 1 
 35 37 4 
 37 38 1 
 39 40 4 
 39 43 4 
 40 41 4 
 41 42 4 
 42 43 4 
 42 44 1 
 44 45 4 
 44 53 4 
 45 46 1 
 45 47 4 
 47 48 1 
 47 49 4 
 49 50 1 
 49 51 4 
 51 52 1 
 51 53 4 
 53 54 1 
!entry.VNI.unit.hierarchy table  str abovetype  int abovex  str belowtype  int belowx 
 "U" 0 "R" 1 
 "R" 1 "A" 1 
 "R" 1 "A" 2 
 "R" 1 "A" 3 
 "R" 1 "A" 4 
 "R" 1 "A" 5 
 "R" 1 "A" 6 
 "R" 1 "A" 7 
 "R" 1 "A" 8 
 "R" 1 "A" 9 
 "R" 1 "A" 10 
 "R" 1 "A" 11 
 "R" 1 "A" 12 
 "R" 1 "A" 13 
 "R" 1 "A" 14 
 "R" 1 "A" 15 
 "R" 1 "A" 16 
 "R" 1 "A" 17 
 "R" 1 "A" 18 
 "R" 1 "A" 19 
 "R" 1 "A" 20 
 "R" 1 "A" 21 
 "R" 1 "A" 22 
 "R" 1 "A" 23 
 "R" 1 "A" 24 
 "R" 1 "A" 25 
 "R" 1 "A" 26 
 "R" 1 "A" 27 
 "R" 1 "A" 28 
 "R" 1 "A" 29 
 "R" 1 "A" 30 
 "R" 1 "A" 31 
 "R" 1 "A" 32 
 "R" 1 "A" 33 
 "R" 1 "A" 34 
 "R" 1 "A" 35 
 "R" 1 "A" 36 
 "R" 1 "A" 37 
 "R" 1 "A" 38 
 "R" 1 "A" 39 
 "R" 1 "A" 40 
 "R" 1 "A" 41 
 "R" 1 "A" 42 
 "R" 1 "A" 43 
 "R" 1 "A" 44 
 "R" 1 "A" 45 
 "R" 1 "A" 46 
 "R" 1 "A" 47 
 "R" 1 "A" 48 
 "R" 1 "A" 49 
 "R" 1 "A" 50 
 "R" 1 "A" 51 
 "R" 1 "A" 52 
 "R" 1 "A" 53 
 "R" 1 "A" 54 
!entry.VNI.unit.name single str 
 "VNI" 
!entry.VNI.unit.positions table  dbl x  dbl y  dbl z 
 -0.922000 2.279000 0.821000 
 -0.726000 1.185000 0.359000 
 -1.732000 0.424000 -0.131000 
 -1.525000 -0.444000 -0.565000 
 -3.126000 0.830000 -0.006000 
 -3.236000 1.285000 0.963000 
 -3.466000 1.908000 -1.053000 
 -2.722000 2.687000 -0.981000 
 -3.426000 1.504000 -2.055000 
 -4.772000 2.491000 -0.847000 
 -5.106000 3.436000 0.094000 
 -4.383000 3.843000 0.768000 
 -6.426000 3.668000 -0.073000 
 -7.052000 4.344000 0.471000 
 -6.921000 2.896000 -1.091000 
 -5.912000 2.217000 -1.518000 
 -5.938000 1.506000 -2.320000 
 -4.017000 -0.399000 -0.097000 
 -4.085000 -1.117000 -1.290000 
 -3.518000 -0.780000 -2.140000 
 -4.859000 -2.251000 -1.431000 
 -4.891000 -2.782000 -2.363000 
 -5.599000 -2.690000 -0.349000 
 -6.587000 -4.111000 -0.497000 
 -5.560000 -2.013000 0.852000 
 -6.134000 -2.356000 1.690000 
 -4.769000 -0.881000 0.969000 
 -4.756000 -0.100000 2.526000 
 0.659000 0.609000 0.276000 
 0.916000 -0.759000 0.267000 
 0.116000 -1.471000 0.348000 
 2.213000 -1.227000 0.199000 
 2.415000 -2.281000 0.202000 
 3.272000 -0.327000 0.134000 
 3.021000 1.039000 0.154000 
 3.836000 1.737000 0.112000 
 1.721000 1.502000 0.233000 
 1.518000 2.555000 0.265000 
 4.642000 -0.843000 0.051000 
 5.028000 -2.050000 0.003000 
 6.400000 -2.023000 -0.068000 
 6.742000 -0.799000 -0.057000 
 5.675000 0.013000 0.017000 
 8.089000 -0.224000 -0.113000 
 8.279000 1.152000 -0.085000 
 7.434000 1.811000 -0.021000 
 9.561000 1.672000 -0.139000 
 9.706000 2.737000 -0.117000 
 10.652000 0.823000 -0.221000 
 11.647000 1.229000 -0.263000 
 10.463000 -0.551000 -0.249000 
 11.309000 -1.211000 -0.313000 
 9.186000 -1.077000 -0.196000 
 9.028000 -2.139000 -0.217000 
!entry.VNI.unit.residueconnect table  int c1x  int c2x  int c3x  int c4x  int c5x  int c6x 
 0 0 0 0 0 0 
!entry.VNI.unit.residues table  str name  int seq  int childseq  int startatomx  str restype  int imagingx 
 "VNI" 1 55 1 "?" 0 
!entry.VNI.unit.residuesPdbSequenceNumber array int 
 0 
!entry.VNI.unit.solventcap array dbl 
 -1.000000 
 0.0 
 0.0 
 0.0 
 0.0 
!entry.VNI.unit.velocities table  dbl x  dbl y  dbl z 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 
The frcmod file for parameters of ligand VNI is: 
 
Force field parameter for VNI ligand 
MASS 
 
BOND 
 
ANGLE 
 
DIHE 
ca-ca-cc-nd   1    2.550       180.000           2.000      same as X -c2-ca-X  
ca-ca-cc-os   1    2.550       180.000           2.000      same as X -c2-ca-X  
ca-cc-os-cc   1    1.050       180.000           2.000      same as X -c2-os-X  
cc-os-cc-nd   1    1.050       180.000           2.000      same as X -c2-os-X  
 
IMPROPER 
ca-n -c -o         10.5          180.0         2.0          General improper torsional angle (2 general atom types) 
c3-cc-na-cc         1.1          180.0         2.0          Using default value 
cd-h4-cc-na         1.1          180.0         2.0          Using default value 
cc-h4-cd-nd         1.1          180.0         2.0          Using default value 
h5-na-cc-nd         1.1          180.0         2.0          Using default value 
ca-ca-ca-ha         1.1          180.0         2.0          General improper torsional angle (2 general atom types) 
c -ca-ca-ca         1.1          180.0         2.0          Using default value 
ca-ca-ca-cc         1.1          180.0         2.0          Using default value 
ca-nd-cc-os         1.1          180.0         2.0          Using default value 
 
NONBON 
 
The lib file for parameters of ligand MCP(LNP in PDB files) is: 
 
!!index array str 
 "LNP" 
 "lnp" 
!entry.LNP.unit.atoms table  str name  str type  int typex  int resx  int flags  int seq  int elmnt  dbl chg 
 "CAA" "c3" 0 1 131072 1 6 -0.079100 
 "HAA2" "hc" 0 1 131072 2 1 0.050600 
 "HAA3" "hc" 0 1 131072 3 1 0.050600 
 "CAB" "c3" 0 1 131072 4 6 -0.039700 
 "HAB" "hc" 0 1 131072 5 1 0.101300 
 "CAC" "c2" 0 1 131072 6 6 -0.114100 
 "CAD" "c3" 0 1 131072 7 6 0.004400 
 "CAE" "c3" 0 1 131072 8 6 0.088100 
 "CAF" "c3" 0 1 131072 9 6 -0.193100 
 "HAF2" "hc" 0 1 131072 10 1 0.068600 
 "HAF3" "hc" 0 1 131072 11 1 0.068600 
 "CAQ" "c3" 0 1 131072 12 6 0.019700 
 "HAQ" "hc" 0 1 131072 13 1 0.030900 
 "CAP" "c3" 0 1 131072 14 6 -0.201200 
 "HAP2" "hc" 0 1 131072 15 1 0.061100 
 "HAP3" "hc" 0 1 131072 16 1 0.061100 
 "CAO" "c3" 0 1 131072 17 6 -0.051400 
 "HAO2" "hc" 0 1 131072 18 1 0.062300 
 "HAO3" "hc" 0 1 131072 19 1 0.062300 
 "CAV" "c3" 0 1 131072 20 6 0.090200 
 "HAV" "hc" 0 1 131072 21 1 0.007700 
 "CAY" "c3" 0 1 131072 22 6 -0.155100 
 "HAY1" "hc" 0 1 131072 23 1 0.032000 
 "HAY2" "hc" 0 1 131072 24 1 0.032000 
 "HAY3" "hc" 0 1 131072 25 1 0.032000 
 "CAZ" "c3" 0 1 131072 26 6 -0.028300 
 "HAZ2" "hc" 0 1 131072 27 1 0.003800 
 "HAZ3" "hc" 0 1 131072 28 1 0.003800 
 "CBA" "c3" 0 1 131072 29 6 0.004200 
 "HBA2" "hc" 0 1 131072 30 1 0.005800 
 "HBA3" "hc" 0 1 131072 31 1 0.005800 
 "CBB" "c3" 0 1 131072 32 6 -0.103500 
 "HBB2" "hc" 0 1 131072 33 1 0.025000 
 "HBB3" "hc" 0 1 131072 34 1 0.025000 
 "CBC" "c3" 0 1 131072 35 6 0.214500 
 "HBC" "hc" 0 1 131072 36 1 -0.013800 
 "CBD" "c3" 0 1 131072 37 6 -0.241100 
 "HBD1" "hc" 0 1 131072 38 1 0.053300 
 "HBD2" "hc" 0 1 131072 39 1 0.053300 
 "HBD3" "hc" 0 1 131072 40 1 0.053300 
 "CBE" "c3" 0 1 131072 41 6 -0.241100 
 "HBE1" "hc" 0 1 131072 42 1 0.053300 
 "HBE2" "hc" 0 1 131072 43 1 0.053300 
 "HBE3" "hc" 0 1 131072 44 1 0.053300 
 "CAS" "c3" 0 1 131072 45 6 -0.087300 
 "HAS1" "hc" 0 1 131072 46 1 0.019800 
 "HAS2" "hc" 0 1 131072 47 1 0.019800 
 "HAS3" "hc" 0 1 131072 48 1 0.019800 
 "CAR" "c2" 0 1 131072 49 6 -0.310200 
 "HAR" "ha" 0 1 131072 50 1 0.147900 
 "CBF" "cu" 0 1 131072 51 6 0.180600 
 "CBG" "cx" 0 1 131072 52 6 -0.301700 
 "HBG2" "hc" 0 1 131072 53 1 0.132400 
 "HBG3" "hc" 0 1 131072 54 1 0.132400 
 "CBH" "cx" 0 1 131072 55 6 -0.301700 
 "HBH2" "hc" 0 1 131072 56 1 0.132400 
 "HBH3" "hc" 0 1 131072 57 1 0.132400 
 "CAJ" "c2" 0 1 131072 58 6 -0.141500 
 "HAJ" "ha" 0 1 131072 59 1 0.079600 
 "CAI" "c3" 0 1 131072 60 6 -0.061100 
 "HAI2" "hc" 0 1 131072 61 1 0.032000 
 "HAI3" "hc" 0 1 131072 62 1 0.032000 
 "CAH" "c3" 0 1 131072 63 6 0.012300 
 "HAH" "hc" 0 1 131072 64 1 0.049400 
 "CAG" "c3" 0 1 131072 65 6 0.038500 
 "CAK" "c3" 0 1 131072 66 6 -0.044500 
 "HAK2" "hc" 0 1 131072 67 1 0.028400 
 "HAK3" "hc" 0 1 131072 68 1 0.028400 
 "CAL" "c3" 0 1 131072 69 6 -0.006400 
 "HAL2" "hc" 0 1 131072 70 1 0.018700 
 "HAL3" "hc" 0 1 131072 71 1 0.018700 
 "CAM" "c3" 0 1 131072 72 6 0.084100 
 "HAM" "h1" 0 1 131072 73 1 0.064600 
 "CAN" "c3" 0 1 131072 74 6 0.178500 
 "CAW" "c3" 0 1 131072 75 6 -0.235700 
 "HAW1" "hc" 0 1 131072 76 1 0.062800 
 "HAW2" "hc" 0 1 131072 77 1 0.062800 
 "HAW3" "hc" 0 1 131072 78 1 0.062800 
 "CAX" "c3" 0 1 131072 79 6 -0.235700 
 "HAX1" "hc" 0 1 131072 80 1 0.062800 
 "HAX2" "hc" 0 1 131072 81 1 0.062800 
 "HAX3" "hc" 0 1 131072 82 1 0.062800 
 "OBH" "oh" 0 1 131072 83 8 -0.667800 
 "HOBH" "ho" 0 1 131072 84 1 0.432300 
 "CAT" "c3" 0 1 131072 85 6 -0.285700 
 "HAT1" "hc" 0 1 131072 86 1 0.072500 
 "HAT2" "hc" 0 1 131072 87 1 0.072500 
 "HAT3" "hc" 0 1 131072 88 1 0.072500 
!entry.LNP.unit.atomspertinfo table  str pname  str ptype  int ptypex  int pelmnt  dbl pchg 
 "CAA" "c3" 0 -1 0.0 
 "HAA2" "hc" 0 -1 0.0 
 "HAA3" "hc" 0 -1 0.0 
 "CAB" "c3" 0 -1 0.0 
 "HAB" "hc" 0 -1 0.0 
 "CAC" "c2" 0 -1 0.0 
 "CAD" "c3" 0 -1 0.0 
 "CAE" "c3" 0 -1 0.0 
 "CAF" "c3" 0 -1 0.0 
 "HAF2" "hc" 0 -1 0.0 
 "HAF3" "hc" 0 -1 0.0 
 "CAQ" "c3" 0 -1 0.0 
 "HAQ" "hc" 0 -1 0.0 
 "CAP" "c3" 0 -1 0.0 
 "HAP2" "hc" 0 -1 0.0 
 "HAP3" "hc" 0 -1 0.0 
 "CAO" "c3" 0 -1 0.0 
 "HAO2" "hc" 0 -1 0.0 
 "HAO3" "hc" 0 -1 0.0 
 "CAV" "c3" 0 -1 0.0 
 "HAV" "hc" 0 -1 0.0 
 "CAY" "c3" 0 -1 0.0 
 "HAY1" "hc" 0 -1 0.0 
 "HAY2" "hc" 0 -1 0.0 
 "HAY3" "hc" 0 -1 0.0 
 "CAZ" "c3" 0 -1 0.0 
 "HAZ2" "hc" 0 -1 0.0 
 "HAZ3" "hc" 0 -1 0.0 
 "CBA" "c3" 0 -1 0.0 
 "HBA2" "hc" 0 -1 0.0 
 "HBA3" "hc" 0 -1 0.0 
 "CBB" "c3" 0 -1 0.0 
 "HBB2" "hc" 0 -1 0.0 
 "HBB3" "hc" 0 -1 0.0 
 "CBC" "c3" 0 -1 0.0 
 "HBC" "hc" 0 -1 0.0 
 "CBD" "c3" 0 -1 0.0 
 "HBD1" "hc" 0 -1 0.0 
 "HBD2" "hc" 0 -1 0.0 
 "HBD3" "hc" 0 -1 0.0 
 "CBE" "c3" 0 -1 0.0 
 "HBE1" "hc" 0 -1 0.0 
 "HBE2" "hc" 0 -1 0.0 
 "HBE3" "hc" 0 -1 0.0 
 "CAS" "c3" 0 -1 0.0 
 "HAS1" "hc" 0 -1 0.0 
 "HAS2" "hc" 0 -1 0.0 
 "HAS3" "hc" 0 -1 0.0 
 "CAR" "c2" 0 -1 0.0 
 "HAR" "ha" 0 -1 0.0 
 "CBF" "cu" 0 -1 0.0 
 "CBG" "cx" 0 -1 0.0 
 "HBG2" "hc" 0 -1 0.0 
 "HBG3" "hc" 0 -1 0.0 
 "CBH" "cx" 0 -1 0.0 
 "HBH2" "hc" 0 -1 0.0 
 "HBH3" "hc" 0 -1 0.0 
 "CAJ" "c2" 0 -1 0.0 
 "HAJ" "ha" 0 -1 0.0 
 "CAI" "c3" 0 -1 0.0 
 "HAI2" "hc" 0 -1 0.0 
 "HAI3" "hc" 0 -1 0.0 
 "CAH" "c3" 0 -1 0.0 
 "HAH" "hc" 0 -1 0.0 
 "CAG" "c3" 0 -1 0.0 
 "CAK" "c3" 0 -1 0.0 
 "HAK2" "hc" 0 -1 0.0 
 "HAK3" "hc" 0 -1 0.0 
 "CAL" "c3" 0 -1 0.0 
 "HAL2" "hc" 0 -1 0.0 
 "HAL3" "hc" 0 -1 0.0 
 "CAM" "c3" 0 -1 0.0 
 "HAM" "h1" 0 -1 0.0 
 "CAN" "c3" 0 -1 0.0 
 "CAW" "c3" 0 -1 0.0 
 "HAW1" "hc" 0 -1 0.0 
 "HAW2" "hc" 0 -1 0.0 
 "HAW3" "hc" 0 -1 0.0 
 "CAX" "c3" 0 -1 0.0 
 "HAX1" "hc" 0 -1 0.0 
 "HAX2" "hc" 0 -1 0.0 
 "HAX3" "hc" 0 -1 0.0 
 "OBH" "oh" 0 -1 0.0 
 "HOBH" "ho" 0 -1 0.0 
 "CAT" "c3" 0 -1 0.0 
 "HAT1" "hc" 0 -1 0.0 
 "HAT2" "hc" 0 -1 0.0 
 "HAT3" "hc" 0 -1 0.0 
!entry.LNP.unit.boundbox array dbl 
 -1.000000 
 0.0 
 0.0 
 0.0 
 0.0 
!entry.LNP.unit.childsequence single int 
 2 
!entry.LNP.unit.connect array int 
 0 
 0 
!entry.LNP.unit.connectivity table  int atom1x  int atom2x  int flags 
 1 2 1 
 1 3 1 
 1 4 1 
 1 9 1 
 4 5 1 
 4 6 1 
 4 65 1 
 6 7 1 
 6 58 2 
 7 8 1 
 7 17 1 
 7 49 1 
 8 9 1 
 8 12 1 
 8 45 1 
 9 10 1 
 9 11 1 
 12 13 1 
 12 14 1 
 12 20 1 
 14 15 1 
 14 16 1 
 14 17 1 
 17 18 1 
 17 19 1 
 20 21 1 
 20 22 1 
 20 26 1 
 22 23 1 
 22 24 1 
 22 25 1 
 26 27 1 
 26 28 1 
 26 29 1 
 29 30 1 
 29 31 1 
 29 32 1 
 32 33 1 
 32 34 1 
 32 35 1 
 35 36 1 
 35 37 1 
 35 41 1 
 37 38 1 
 37 39 1 
 37 40 1 
 41 42 1 
 41 43 1 
 41 44 1 
 45 46 1 
 45 47 1 
 45 48 1 
 49 50 1 
 49 51 2 
 51 52 1 
 51 55 1 
 52 53 1 
 52 54 1 
 52 55 1 
 55 56 1 
 55 57 1 
 58 59 1 
 58 60 1 
 60 61 1 
 60 62 1 
 60 63 1 
 63 64 1 
 63 65 1 
 63 74 1 
 65 66 1 
 65 85 1 
 66 67 1 
 66 68 1 
 66 69 1 
 69 70 1 
 69 71 1 
 69 72 1 
 72 73 1 
 72 74 1 
 72 83 1 
 74 75 1 
 74 79 1 
 75 76 1 
 75 77 1 
 75 78 1 
 79 80 1 
 79 81 1 
 79 82 1 
 83 84 1 
 85 86 1 
 85 87 1 
 85 88 1 
!entry.LNP.unit.hierarchy table  str abovetype  int abovex  str belowtype  int belowx 
 "U" 0 "R" 1 
 "R" 1 "A" 1 
 "R" 1 "A" 2 
 "R" 1 "A" 3 
 "R" 1 "A" 4 
 "R" 1 "A" 5 
 "R" 1 "A" 6 
 "R" 1 "A" 7 
 "R" 1 "A" 8 
 "R" 1 "A" 9 
 "R" 1 "A" 10 
 "R" 1 "A" 11 
 "R" 1 "A" 12 
 "R" 1 "A" 13 
 "R" 1 "A" 14 
 "R" 1 "A" 15 
 "R" 1 "A" 16 
 "R" 1 "A" 17 
 "R" 1 "A" 18 
 "R" 1 "A" 19 
 "R" 1 "A" 20 
 "R" 1 "A" 21 
 "R" 1 "A" 22 
 "R" 1 "A" 23 
 "R" 1 "A" 24 
 "R" 1 "A" 25 
 "R" 1 "A" 26 
 "R" 1 "A" 27 
 "R" 1 "A" 28 
 "R" 1 "A" 29 
 "R" 1 "A" 30 
 "R" 1 "A" 31 
 "R" 1 "A" 32 
 "R" 1 "A" 33 
 "R" 1 "A" 34 
 "R" 1 "A" 35 
 "R" 1 "A" 36 
 "R" 1 "A" 37 
 "R" 1 "A" 38 
 "R" 1 "A" 39 
 "R" 1 "A" 40 
 "R" 1 "A" 41 
 "R" 1 "A" 42 
 "R" 1 "A" 43 
 "R" 1 "A" 44 
 "R" 1 "A" 45 
 "R" 1 "A" 46 
 "R" 1 "A" 47 
 "R" 1 "A" 48 
 "R" 1 "A" 49 
 "R" 1 "A" 50 
 "R" 1 "A" 51 
 "R" 1 "A" 52 
 "R" 1 "A" 53 
 "R" 1 "A" 54 
 "R" 1 "A" 55 
 "R" 1 "A" 56 
 "R" 1 "A" 57 
 "R" 1 "A" 58 
 "R" 1 "A" 59 
 "R" 1 "A" 60 
 "R" 1 "A" 61 
 "R" 1 "A" 62 
 "R" 1 "A" 63 
 "R" 1 "A" 64 
 "R" 1 "A" 65 
 "R" 1 "A" 66 
 "R" 1 "A" 67 
 "R" 1 "A" 68 
 "R" 1 "A" 69 
 "R" 1 "A" 70 
 "R" 1 "A" 71 
 "R" 1 "A" 72 
 "R" 1 "A" 73 
 "R" 1 "A" 74 
 "R" 1 "A" 75 
 "R" 1 "A" 76 
 "R" 1 "A" 77 
 "R" 1 "A" 78 
 "R" 1 "A" 79 
 "R" 1 "A" 80 
 "R" 1 "A" 81 
 "R" 1 "A" 82 
 "R" 1 "A" 83 
 "R" 1 "A" 84 
 "R" 1 "A" 85 
 "R" 1 "A" 86 
 "R" 1 "A" 87 
 "R" 1 "A" 88 
!entry.LNP.unit.name single str 
 "LNP" 
!entry.LNP.unit.positions table  dbl x  dbl y  dbl z 
 1.037000 -1.069000 -1.605000 
 1.377000 -1.879000 -2.235000 
 1.179000 -0.163000 -2.180000 
 1.872000 -0.987000 -0.309000 
 1.679000 -1.913000 0.229000 
 1.336000 0.147000 0.562000 
 -0.094000 0.604000 0.292000 
 -1.005000 -0.618000 -0.050000 
 -0.472000 -1.296000 -1.342000 
 -1.024000 -0.955000 -2.212000 
 -0.647000 -2.365000 -1.283000 
 -2.411000 0.059000 -0.109000 
 -2.466000 0.614000 -1.041000 
 -2.347000 1.093000 1.058000 
 -2.769000 2.042000 0.751000 
 -2.932000 0.756000 1.909000 
 -0.861000 1.253000 1.457000 
 -0.590000 2.289000 1.608000 
 -0.651000 0.732000 2.382000 
 -3.680000 -0.825000 -0.065000 
 -3.700000 -1.352000 0.887000 
 -3.713000 -1.870000 -1.187000 
 -2.874000 -2.551000 -1.137000 
 -3.694000 -1.393000 -2.164000 
 -4.612000 -2.474000 -1.136000 
 -4.941000 0.065000 -0.124000 
 -4.850000 0.864000 0.604000 
 -4.984000 0.550000 -1.099000 
 -6.267000 -0.657000 0.140000 
 -6.448000 -1.400000 -0.629000 
 -6.199000 -1.198000 1.083000 
 -7.450000 0.314000 0.202000 
 -7.225000 1.087000 0.935000 
 -7.547000 0.826000 -0.755000 
 -8.802000 -0.319000 0.569000 
 -8.675000 -0.852000 1.510000 
 -9.857000 0.770000 0.788000 
 -9.550000 1.468000 1.562000 
 -10.809000 0.341000 1.088000 
 -10.024000 1.339000 -0.123000 
 -9.289000 -1.325000 -0.480000 
 -10.259000 -1.728000 -0.205000 
 -8.610000 -2.163000 -0.590000 
 -9.393000 -0.850000 -1.453000 
 -1.004000 -1.648000 1.105000 
 -1.488000 -1.268000 1.996000 
 -0.008000 -1.954000 1.391000 
 -1.543000 -2.541000 0.809000 
 -0.083000 1.605000 -0.884000 
 -0.530000 1.294000 -1.811000 
 0.424000 2.813000 -0.856000 
 0.694000 4.047000 -1.596000 
 1.461000 4.042000 -2.354000 
 -0.122000 4.721000 -1.800000 
 1.128000 3.878000 -0.144000 
 0.600000 4.445000 0.606000 
 2.179000 3.756000 0.059000 
 2.095000 0.694000 1.488000 
 1.702000 1.478000 2.114000 
 3.539000 0.368000 1.711000 
 3.689000 0.162000 2.766000 
 4.095000 1.282000 1.523000 
 4.126000 -0.811000 0.892000 
 3.902000 -1.715000 1.454000 
 3.428000 -0.973000 -0.505000 
 3.894000 0.171000 -1.428000 
 3.493000 0.034000 -2.427000 
 3.493000 1.113000 -1.065000 
 5.421000 0.270000 -1.520000 
 5.836000 -0.592000 -2.031000 
 5.686000 1.134000 -2.129000 
 6.094000 0.415000 -0.156000 
 5.793000 1.374000 0.262000 
 5.701000 -0.687000 0.852000 
 6.244000 -0.298000 2.247000 
 7.325000 -0.262000 2.217000 
 5.954000 -1.037000 2.989000 
 5.901000 0.670000 2.588000 
 6.416000 -2.018000 0.512000 
 7.430000 -1.995000 0.889000 
 5.908000 -2.857000 0.976000 
 6.497000 -2.216000 -0.545000 
 7.498000 0.404000 -0.285000 
 7.767000 1.124000 -0.840000 
 3.779000 -2.337000 -1.140000 
 3.224000 -2.493000 -2.055000 
 4.817000 -2.434000 -1.401000 
 3.535000 -3.151000 -0.464000 
!entry.LNP.unit.residueconnect table  int c1x  int c2x  int c3x  int c4x  int c5x  int c6x 
 0 0 0 0 0 0 
!entry.LNP.unit.residues table  str name  int seq  int childseq  int startatomx  str restype  int imagingx 
 "LNP" 1 89 1 "?" 0 
!entry.LNP.unit.residuesPdbSequenceNumber array int 
 0 
!entry.LNP.unit.solventcap array dbl 
 -1.000000 
 0.0 
 0.0 
 0.0 
 0.0 
!entry.LNP.unit.velocities table  dbl x  dbl y  dbl z 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 
The frcmod file for parameters of ligand MCP (LNP in PDB files) is: 
 
remark goes here 
MASS 
 
BOND 
 
ANGLE 
c3-c2-cu   64.330     123.420   same as c2-c2-c3 
ha-c2-cu   50.040     120.940   same as c2-c2-ha 
cx-cu-cx   62.700     116.520   same as c3-c2-c3 
 
DIHE 
c3-c2-cu-cx   1    6.650       180.000           2.000      same as X -c2-c2-X  
c2-cu-cx-hc   1    0.380       180.000          -3.000      same as hc-c3-c2-c2 
c2-cu-cx-hc   1    1.150         0.000           1.000      same as hc-c3-c2-c2 
c2-cu-cx-cx   1    0.000         0.000           2.000      same as X -c2-c3-X  
ha-c2-cu-cx   1    6.650       180.000           2.000      same as X -c2-c2-X  
cx-cu-cx-cx   1    0.000         0.000           2.000      same as X -c2-c3-X  
cx-cu-cx-hc   1    0.000         0.000           2.000      same as X -c2-c3-X  
 
IMPROPER 
c2-c3-c2-c3         1.1          180.0         2.0          Using default value 
c3-cu-c2-ha         1.1          180.0         2.0          Using default value 
c2-c3-c2-ha         1.1          180.0         2.0          Using default value 
 
NONBON 
 
The lib file for parameters of ligand OBT (substrate of T. brucei CYP51) is: 
 
!!index array str 
 "OBT" 
!entry.OBT.unit.atoms table  str name  str type  int typex  int resx  int flags  int seq  int elmnt  dbl chg 
 "O1" "oh" 0 1 131072 1 8 -0.684400 
 "H41" "ho" 0 1 131072 2 1 0.425200 
 "C20" "c3" 0 1 131072 3 6 0.177900 
 "H28" "h1" 0 1 131072 4 1 0.030300 
 "C17" "c3" 0 1 131072 5 6 0.067600 
 "H22" "hc" 0 1 131072 6 1 0.070700 
 "C10" "c3" 0 1 131072 7 6 -0.012700 
 "H8" "hc" 0 1 131072 8 1 0.012400 
 "C5" "c3" 0 1 131072 9 6 0.018800 
 "C8" "c2" 0 1 131072 10 6 -0.024000 
 "C4" "c2" 0 1 131072 11 6 -0.010400 
 "C2" "c3" 0 1 131072 12 6 0.083700 
 "C1" "c3" 0 1 131072 13 6 0.132700 
 "C3" "c3" 0 1 131072 14 6 0.089200 
 "H1" "hc" 0 1 131072 15 1 -0.011000 
 "C9" "c3" 0 1 131072 16 6 -0.037000 
 "H6" "hc" 0 1 131072 17 1 0.016100 
 "H7" "hc" 0 1 131072 18 1 0.016100 
 "C6" "c3" 0 1 131072 19 6 -0.086200 
 "H2" "hc" 0 1 131072 20 1 0.018100 
 "H3" "hc" 0 1 131072 21 1 0.018100 
 "C13" "c3" 0 1 131072 22 6 0.044500 
 "H13" "hc" 0 1 131072 23 1 -0.004500 
 "C22" "c3" 0 1 131072 24 6 -0.025600 
 "H31" "hc" 0 1 131072 25 1 -1.000000E-04 
 "H32" "hc" 0 1 131072 26 1 -1.000000E-04 
 "C25" "c3" 0 1 131072 27 6 -0.020800 
 "H39" "hc" 0 1 131072 28 1 0.027600 
 "H40" "hc" 0 1 131072 29 1 0.027600 
 "C26" "c2" 0 1 131072 30 6 -0.018800 
 "C27" "c3" 0 1 131072 31 6 0.190600 
 "H42" "hc" 0 1 131072 32 1 0.025900 
 "C29" "c3" 0 1 131072 33 6 -0.207000 
 "H45" "hc" 0 1 131072 34 1 0.049100 
 "H46" "hc" 0 1 131072 35 1 0.049100 
 "H47" "hc" 0 1 131072 36 1 0.049100 
 "C30" "c3" 0 1 131072 37 6 -0.207000 
 "H48" "hc" 0 1 131072 38 1 0.049100 
 "H49" "hc" 0 1 131072 39 1 0.049100 
 "H50" "hc" 0 1 131072 40 1 0.049100 
 "C28" "c2" 0 1 131072 41 6 -0.458400 
 "H43" "ha" 0 1 131072 42 1 0.166200 
 "H44" "ha" 0 1 131072 43 1 0.166200 
 "C23" "c3" 0 1 131072 44 6 -0.072900 
 "H33" "hc" 0 1 131072 45 1 0.009900 
 "H34" "hc" 0 1 131072 46 1 0.009900 
 "H35" "hc" 0 1 131072 47 1 0.009900 
 "C7" "c3" 0 1 131072 48 6 -0.093300 
 "H4" "hc" 0 1 131072 49 1 0.014400 
 "H5" "hc" 0 1 131072 50 1 0.014400 
 "C11" "c3" 0 1 131072 51 6 -0.098300 
 "H9" "hc" 0 1 131072 52 1 0.061400 
 "H10" "hc" 0 1 131072 53 1 0.061400 
 "C15" "c3" 0 1 131072 54 6 -0.062100 
 "H16" "hc" 0 1 131072 55 1 0.002700 
 "H17" "hc" 0 1 131072 56 1 0.002700 
 "H18" "hc" 0 1 131072 57 1 0.002700 
 "C16" "c3" 0 1 131072 58 6 -0.201500 
 "H19" "hc" 0 1 131072 59 1 0.044500 
 "H20" "hc" 0 1 131072 60 1 0.044500 
 "H21" "hc" 0 1 131072 61 1 0.044500 
 "C12" "c3" 0 1 131072 62 6 -0.080700 
 "H11" "hc" 0 1 131072 63 1 0.047700 
 "H12" "hc" 0 1 131072 64 1 0.047700 
 "C14" "c3" 0 1 131072 65 6 -0.088700 
 "H14" "hc" 0 1 131072 66 1 0.028400 
 "H15" "hc" 0 1 131072 67 1 0.028400 
 "C18" "c3" 0 1 131072 68 6 -0.033900 
 "H23" "hc" 0 1 131072 69 1 0.006900 
 "H24" "hc" 0 1 131072 70 1 0.006900 
 "C21" "c3" 0 1 131072 71 6 -0.071200 
 "H29" "hc" 0 1 131072 72 1 0.029800 
 "H30" "hc" 0 1 131072 73 1 0.029800 
 "C19" "c3" 0 1 131072 74 6 -0.135700 
 "H25" "hc" 0 1 131072 75 1 0.037200 
 "H26" "hc" 0 1 131072 76 1 0.037200 
 "H27" "hc" 0 1 131072 77 1 0.037200 
 "C24" "c3" 0 1 131072 78 6 -0.141600 
 "H36" "hc" 0 1 131072 79 1 0.035900 
 "H37" "hc" 0 1 131072 80 1 0.035900 
 "H38" "hc" 0 1 131072 81 1 0.035900 
!entry.OBT.unit.atomspertinfo table  str pname  str ptype  int ptypex  int pelmnt  dbl pchg 
 "O1" "oh" 0 -1 0.0 
 "H41" "ho" 0 -1 0.0 
 "C20" "c3" 0 -1 0.0 
 "H28" "h1" 0 -1 0.0 
 "C17" "c3" 0 -1 0.0 
 "H22" "hc" 0 -1 0.0 
 "C10" "c3" 0 -1 0.0 
 "H8" "hc" 0 -1 0.0 
 "C5" "c3" 0 -1 0.0 
 "C8" "c2" 0 -1 0.0 
 "C4" "c2" 0 -1 0.0 
 "C2" "c3" 0 -1 0.0 
 "C1" "c3" 0 -1 0.0 
 "C3" "c3" 0 -1 0.0 
 "H1" "hc" 0 -1 0.0 
 "C9" "c3" 0 -1 0.0 
 "H6" "hc" 0 -1 0.0 
 "H7" "hc" 0 -1 0.0 
 "C6" "c3" 0 -1 0.0 
 "H2" "hc" 0 -1 0.0 
 "H3" "hc" 0 -1 0.0 
 "C13" "c3" 0 -1 0.0 
 "H13" "hc" 0 -1 0.0 
 "C22" "c3" 0 -1 0.0 
 "H31" "hc" 0 -1 0.0 
 "H32" "hc" 0 -1 0.0 
 "C25" "c3" 0 -1 0.0 
 "H39" "hc" 0 -1 0.0 
 "H40" "hc" 0 -1 0.0 
 "C26" "c2" 0 -1 0.0 
 "C27" "c3" 0 -1 0.0 
 "H42" "hc" 0 -1 0.0 
 "C29" "c3" 0 -1 0.0 
 "H45" "hc" 0 -1 0.0 
 "H46" "hc" 0 -1 0.0 
 "H47" "hc" 0 -1 0.0 
 "C30" "c3" 0 -1 0.0 
 "H48" "hc" 0 -1 0.0 
 "H49" "hc" 0 -1 0.0 
 "H50" "hc" 0 -1 0.0 
 "C28" "c2" 0 -1 0.0 
 "H43" "ha" 0 -1 0.0 
 "H44" "ha" 0 -1 0.0 
 "C23" "c3" 0 -1 0.0 
 "H33" "hc" 0 -1 0.0 
 "H34" "hc" 0 -1 0.0 
 "H35" "hc" 0 -1 0.0 
 "C7" "c3" 0 -1 0.0 
 "H4" "hc" 0 -1 0.0 
 "H5" "hc" 0 -1 0.0 
 "C11" "c3" 0 -1 0.0 
 "H9" "hc" 0 -1 0.0 
 "H10" "hc" 0 -1 0.0 
 "C15" "c3" 0 -1 0.0 
 "H16" "hc" 0 -1 0.0 
 "H17" "hc" 0 -1 0.0 
 "H18" "hc" 0 -1 0.0 
 "C16" "c3" 0 -1 0.0 
 "H19" "hc" 0 -1 0.0 
 "H20" "hc" 0 -1 0.0 
 "H21" "hc" 0 -1 0.0 
 "C12" "c3" 0 -1 0.0 
 "H11" "hc" 0 -1 0.0 
 "H12" "hc" 0 -1 0.0 
 "C14" "c3" 0 -1 0.0 
 "H14" "hc" 0 -1 0.0 
 "H15" "hc" 0 -1 0.0 
 "C18" "c3" 0 -1 0.0 
 "H23" "hc" 0 -1 0.0 
 "H24" "hc" 0 -1 0.0 
 "C21" "c3" 0 -1 0.0 
 "H29" "hc" 0 -1 0.0 
 "H30" "hc" 0 -1 0.0 
 "C19" "c3" 0 -1 0.0 
 "H25" "hc" 0 -1 0.0 
 "H26" "hc" 0 -1 0.0 
 "H27" "hc" 0 -1 0.0 
 "C24" "c3" 0 -1 0.0 
 "H36" "hc" 0 -1 0.0 
 "H37" "hc" 0 -1 0.0 
 "H38" "hc" 0 -1 0.0 
!entry.OBT.unit.boundbox array dbl 
 -1.000000 
 0.0 
 0.0 
 0.0 
 0.0 
!entry.OBT.unit.childsequence single int 
 2 
!entry.OBT.unit.connect array int 
 0 
 0 
!entry.OBT.unit.connectivity table  int atom1x  int atom2x  int flags 
 1 2 1 
 1 3 1 
 3 4 1 
 3 5 1 
 3 71 1 
 5 6 1 
 5 7 1 
 5 78 1 
 7 8 1 
 7 9 1 
 7 65 1 
 9 10 1 
 9 68 1 
 9 74 1 
 10 11 2 
 10 51 1 
 11 12 1 
 11 62 1 
 12 13 1 
 12 19 1 
 12 58 1 
 13 14 1 
 13 48 1 
 13 54 1 
 14 15 1 
 14 16 1 
 14 22 1 
 16 17 1 
 16 18 1 
 16 19 1 
 19 20 1 
 19 21 1 
 22 23 1 
 22 24 1 
 22 44 1 
 24 25 1 
 24 26 1 
 24 27 1 
 27 28 1 
 27 29 1 
 27 30 1 
 30 31 1 
 30 41 2 
 31 32 1 
 31 33 1 
 31 37 1 
 33 34 1 
 33 35 1 
 33 36 1 
 37 38 1 
 37 39 1 
 37 40 1 
 41 42 1 
 41 43 1 
 44 45 1 
 44 46 1 
 44 47 1 
 48 49 1 
 48 50 1 
 48 51 1 
 51 52 1 
 51 53 1 
 54 55 1 
 54 56 1 
 54 57 1 
 58 59 1 
 58 60 1 
 58 61 1 
 62 63 1 
 62 64 1 
 62 65 1 
 65 66 1 
 65 67 1 
 68 69 1 
 68 70 1 
 68 71 1 
 71 72 1 
 71 73 1 
 74 75 1 
 74 76 1 
 74 77 1 
 78 79 1 
 78 80 1 
 78 81 1 
!entry.OBT.unit.hierarchy table  str abovetype  int abovex  str belowtype  int belowx 
 "U" 0 "R" 1 
 "R" 1 "A" 1 
 "R" 1 "A" 2 
 "R" 1 "A" 3 
 "R" 1 "A" 4 
 "R" 1 "A" 5 
 "R" 1 "A" 6 
 "R" 1 "A" 7 
 "R" 1 "A" 8 
 "R" 1 "A" 9 
 "R" 1 "A" 10 
 "R" 1 "A" 11 
 "R" 1 "A" 12 
 "R" 1 "A" 13 
 "R" 1 "A" 14 
 "R" 1 "A" 15 
 "R" 1 "A" 16 
 "R" 1 "A" 17 
 "R" 1 "A" 18 
 "R" 1 "A" 19 
 "R" 1 "A" 20 
 "R" 1 "A" 21 
 "R" 1 "A" 22 
 "R" 1 "A" 23 
 "R" 1 "A" 24 
 "R" 1 "A" 25 
 "R" 1 "A" 26 
 "R" 1 "A" 27 
 "R" 1 "A" 28 
 "R" 1 "A" 29 
 "R" 1 "A" 30 
 "R" 1 "A" 31 
 "R" 1 "A" 32 
 "R" 1 "A" 33 
 "R" 1 "A" 34 
 "R" 1 "A" 35 
 "R" 1 "A" 36 
 "R" 1 "A" 37 
 "R" 1 "A" 38 
 "R" 1 "A" 39 
 "R" 1 "A" 40 
 "R" 1 "A" 41 
 "R" 1 "A" 42 
 "R" 1 "A" 43 
 "R" 1 "A" 44 
 "R" 1 "A" 45 
 "R" 1 "A" 46 
 "R" 1 "A" 47 
 "R" 1 "A" 48 
 "R" 1 "A" 49 
 "R" 1 "A" 50 
 "R" 1 "A" 51 
 "R" 1 "A" 52 
 "R" 1 "A" 53 
 "R" 1 "A" 54 
 "R" 1 "A" 55 
 "R" 1 "A" 56 
 "R" 1 "A" 57 
 "R" 1 "A" 58 
 "R" 1 "A" 59 
 "R" 1 "A" 60 
 "R" 1 "A" 61 
 "R" 1 "A" 62 
 "R" 1 "A" 63 
 "R" 1 "A" 64 
 "R" 1 "A" 65 
 "R" 1 "A" 66 
 "R" 1 "A" 67 
 "R" 1 "A" 68 
 "R" 1 "A" 69 
 "R" 1 "A" 70 
 "R" 1 "A" 71 
 "R" 1 "A" 72 
 "R" 1 "A" 73 
 "R" 1 "A" 74 
 "R" 1 "A" 75 
 "R" 1 "A" 76 
 "R" 1 "A" 77 
 "R" 1 "A" 78 
 "R" 1 "A" 79 
 "R" 1 "A" 80 
 "R" 1 "A" 81 
!entry.OBT.unit.name single str 
 "OBT" 
!entry.OBT.unit.positions table  dbl x  dbl y  dbl z 
 7.880000 -0.680000 -0.890000 
 8.196000 -1.339000 -1.492000 
 6.484000 -0.546000 -1.034000 
 6.253000 -0.260000 -2.062000 
 6.021000 0.588000 -0.116000 
 6.350000 0.339000 0.890000 
 4.478000 0.690000 -0.155000 
 4.213000 0.876000 -1.198000 
 3.750000 -0.630000 0.235000 
 2.225000 -0.436000 0.084000 
 1.650000 0.761000 0.166000 
 0.145000 0.898000 -0.050000 
 -0.627000 -0.315000 0.564000 
 -2.109000 0.115000 0.348000 
 -2.327000 -0.028000 -0.705000 
 -2.066000 1.646000 0.644000 
 -2.492000 1.860000 1.618000 
 -2.662000 2.197000 -0.075000 
 -0.582000 2.088000 0.604000 
 -0.447000 3.011000 0.050000 
 -0.219000 2.272000 1.607000 
 -3.236000 -0.604000 1.126000 
 -3.052000 -0.466000 2.189000 
 -4.621000 0.035000 0.867000 
 -4.613000 1.073000 1.179000 
 -5.334000 -0.463000 1.519000 
 -5.142000 -0.023000 -0.580000 
 -5.115000 -1.047000 -0.942000 
 -4.490000 0.551000 -1.229000 
 -6.557000 0.515000 -0.696000 
 -7.674000 -0.469000 -0.369000 
 -7.297000 -1.133000 0.407000 
 -7.996000 -1.339000 -1.595000 
 -7.113000 -1.837000 -1.982000 
 -8.723000 -2.106000 -1.341000 
 -8.411000 -0.732000 -2.393000 
 -8.949000 0.180000 0.174000 
 -9.443000 0.788000 -0.577000 
 -9.655000 -0.585000 0.484000 
 -8.738000 0.811000 1.031000 
 -6.773000 1.765000 -1.071000 
 -7.756000 2.193000 -1.137000 
 -5.957000 2.419000 -1.330000 
 -3.294000 -2.117000 0.867000 
 -2.465000 -2.637000 1.330000 
 -3.274000 -2.351000 -0.193000 
 -4.206000 -2.539000 1.280000 
 -0.135000 -1.576000 -0.146000 
 -0.454000 -1.559000 -1.181000 
 -0.571000 -2.470000 0.283000 
 1.404000 -1.714000 -0.074000 
 1.729000 -2.245000 -0.962000 
 1.654000 -2.371000 0.756000 
 -0.351000 -0.458000 2.079000 
 -0.816000 -1.362000 2.457000 
 0.707000 -0.523000 2.294000 
 -0.749000 0.368000 2.655000 
 -0.048000 1.050000 -1.584000 
 0.318000 0.194000 -2.135000 
 -1.080000 1.221000 -1.869000 
 0.518000 1.911000 -1.924000 
 2.426000 2.047000 0.352000 
 2.317000 2.649000 -0.549000 
 1.973000 2.632000 1.146000 
 3.912000 1.858000 0.649000 
 4.427000 2.780000 0.410000 
 4.068000 1.691000 1.711000 
 4.263000 -1.734000 -0.720000 
 3.925000 -1.509000 -1.730000 
 3.837000 -2.695000 -0.458000 
 5.786000 -1.862000 -0.720000 
 6.146000 -2.218000 0.240000 
 6.082000 -2.612000 -1.453000 
 4.030000 -1.053000 1.698000 
 3.575000 -2.016000 1.906000 
 5.087000 -1.150000 1.910000 
 3.617000 -0.343000 2.402000 
 6.711000 1.897000 -0.520000 
 7.774000 1.735000 -0.643000 
 6.316000 2.274000 -1.461000 
 6.581000 2.671000 0.228000 
!entry.OBT.unit.residueconnect table  int c1x  int c2x  int c3x  int c4x  int c5x  int c6x 
 0 0 0 0 0 0 
!entry.OBT.unit.residues table  str name  int seq  int childseq  int startatomx  str restype  int imagingx 
 "OBT" 1 82 1 "?" 0 
!entry.OBT.unit.residuesPdbSequenceNumber array int 
 0 
!entry.OBT.unit.solventcap array dbl 
 -1.000000 
 0.0 
 0.0 
 0.0 
 0.0 
!entry.OBT.unit.velocities table  dbl x  dbl y  dbl z 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 
The frcmod file for parameters of ligand OBT (substrate) is: 
 
Obtusifoliol (natural substrate of both TB and human CYP51) 
MASS 
 
BOND 
 
ANGLE 
 
DIHE 
 
IMPROPER 
c2-c3-c2-c3         1.1          180.0         2.0          Using default value 
c2-ha-c2-ha         1.1          180.0         2.0          Using default value 
 
NONBON 
 
The lib file for parameters of ligand OBT_DM (ODM, product of T. brucei CYP51) is: 
 
!!index array str 
 "ODM" 
!entry.ODM.unit.atoms table  str name  str type  int typex  int resx  int flags  int seq  int elmnt  dbl chg 
 "O1" "oh" 0 1 131072 1 8 -0.704400 
 "H35" "ho" 0 1 131072 2 1 0.439700 
 "C14" "c3" 0 1 131072 3 6 0.208500 
 "H14" "h1" 0 1 131072 4 1 0.020500 
 "C7" "c3" 0 1 131072 5 6 0.019300 
 "H3" "hc" 0 1 131072 6 1 0.063500 
 "C2" "c3" 0 1 131072 7 6 0.019100 
 "H1" "hc" 0 1 131072 8 1 0.017900 
 "C1" "c3" 0 1 131072 9 6 0.033600 
 "C4" "c2" 0 1 131072 10 6 -0.031700 
 "C6" "ce" 0 1 131072 11 6 -0.026000 
 "C8" "ce" 0 1 131072 12 6 -0.087300 
 "C3" "c3" 0 1 131072 13 6 0.071000 
 "C5" "c3" 0 1 131072 14 6 0.028600 
 "H2" "hc" 0 1 131072 15 1 0.019500 
 "C16" "c3" 0 1 131072 16 6 -0.023600 
 "H17" "hc" 0 1 131072 17 1 0.042100 
 "H18" "hc" 0 1 131072 18 1 0.042100 
 "C19" "c2" 0 1 131072 19 6 -0.220800 
 "H23" "ha" 0 1 131072 20 1 0.118700 
 "C18" "c3" 0 1 131072 21 6 0.052600 
 "H22" "hc" 0 1 131072 22 1 0.006900 
 "C22" "c3" 0 1 131072 23 6 -0.024500 
 "H30" "hc" 0 1 131072 24 1 -0.003100 
 "H31" "hc" 0 1 131072 25 1 -0.003100 
 "C24" "c3" 0 1 131072 26 6 -0.008100 
 "H36" "hc" 0 1 131072 27 1 0.025500 
 "H37" "hc" 0 1 131072 28 1 0.025500 
 "C25" "c2" 0 1 131072 29 6 -0.019700 
 "C26" "c3" 0 1 131072 30 6 0.202200 
 "H38" "hc" 0 1 131072 31 1 0.024500 
 "C28" "c3" 0 1 131072 32 6 -0.219000 
 "H41" "hc" 0 1 131072 33 1 0.051700 
 "H42" "hc" 0 1 131072 34 1 0.051700 
 "H43" "hc" 0 1 131072 35 1 0.051700 
 "C29" "c3" 0 1 131072 36 6 -0.219000 
 "H44" "hc" 0 1 131072 37 1 0.051700 
 "H45" "hc" 0 1 131072 38 1 0.051700 
 "H46" "hc" 0 1 131072 39 1 0.051700 
 "C27" "c2" 0 1 131072 40 6 -0.459200 
 "H39" "ha" 0 1 131072 41 1 0.166100 
 "H40" "ha" 0 1 131072 42 1 0.166100 
 "C23" "c3" 0 1 131072 43 6 -0.102100 
 "H32" "hc" 0 1 131072 44 1 0.020000 
 "H33" "hc" 0 1 131072 45 1 0.020000 
 "H34" "hc" 0 1 131072 46 1 0.020000 
 "C11" "c3" 0 1 131072 47 6 -0.068500 
 "H8" "hc" 0 1 131072 48 1 0.020200 
 "H9" "hc" 0 1 131072 49 1 0.020200 
 "C12" "c3" 0 1 131072 50 6 -0.043200 
 "H10" "hc" 0 1 131072 51 1 0.047900 
 "H11" "hc" 0 1 131072 52 1 0.047900 
 "C20" "c3" 0 1 131072 53 6 -0.056800 
 "H24" "hc" 0 1 131072 54 1 0.016200 
 "H25" "hc" 0 1 131072 55 1 0.016200 
 "H26" "hc" 0 1 131072 56 1 0.016200 
 "C13" "c3" 0 1 131072 57 6 -0.024100 
 "H12" "hc" 0 1 131072 58 1 0.032300 
 "H13" "hc" 0 1 131072 59 1 0.032300 
 "C10" "c3" 0 1 131072 60 6 -0.069900 
 "H6" "hc" 0 1 131072 61 1 0.031400 
 "H7" "hc" 0 1 131072 62 1 0.031400 
 "C9" "c3" 0 1 131072 63 6 -0.061800 
 "H4" "hc" 0 1 131072 64 1 0.018700 
 "H5" "hc" 0 1 131072 65 1 0.018700 
 "C15" "c3" 0 1 131072 66 6 -0.089200 
 "H15" "hc" 0 1 131072 67 1 0.060300 
 "H16" "hc" 0 1 131072 68 1 0.060300 
 "C17" "c3" 0 1 131072 69 6 -0.134000 
 "H19" "hc" 0 1 131072 70 1 0.038300 
 "H20" "hc" 0 1 131072 71 1 0.038300 
 "H21" "hc" 0 1 131072 72 1 0.038300 
 "C21" "c3" 0 1 131072 73 6 -0.207400 
 "H27" "hc" 0 1 131072 74 1 0.045900 
 "H28" "hc" 0 1 131072 75 1 0.045900 
 "H29" "hc" 0 1 131072 76 1 0.045900 
!entry.ODM.unit.atomspertinfo table  str pname  str ptype  int ptypex  int pelmnt  dbl pchg 
 "O1" "oh" 0 -1 0.0 
 "H35" "ho" 0 -1 0.0 
 "C14" "c3" 0 -1 0.0 
 "H14" "h1" 0 -1 0.0 
 "C7" "c3" 0 -1 0.0 
 "H3" "hc" 0 -1 0.0 
 "C2" "c3" 0 -1 0.0 
 "H1" "hc" 0 -1 0.0 
 "C1" "c3" 0 -1 0.0 
 "C4" "c2" 0 -1 0.0 
 "C6" "ce" 0 -1 0.0 
 "C8" "ce" 0 -1 0.0 
 "C3" "c3" 0 -1 0.0 
 "C5" "c3" 0 -1 0.0 
 "H2" "hc" 0 -1 0.0 
 "C16" "c3" 0 -1 0.0 
 "H17" "hc" 0 -1 0.0 
 "H18" "hc" 0 -1 0.0 
 "C19" "c2" 0 -1 0.0 
 "H23" "ha" 0 -1 0.0 
 "C18" "c3" 0 -1 0.0 
 "H22" "hc" 0 -1 0.0 
 "C22" "c3" 0 -1 0.0 
 "H30" "hc" 0 -1 0.0 
 "H31" "hc" 0 -1 0.0 
 "C24" "c3" 0 -1 0.0 
 "H36" "hc" 0 -1 0.0 
 "H37" "hc" 0 -1 0.0 
 "C25" "c2" 0 -1 0.0 
 "C26" "c3" 0 -1 0.0 
 "H38" "hc" 0 -1 0.0 
 "C28" "c3" 0 -1 0.0 
 "H41" "hc" 0 -1 0.0 
 "H42" "hc" 0 -1 0.0 
 "H43" "hc" 0 -1 0.0 
 "C29" "c3" 0 -1 0.0 
 "H44" "hc" 0 -1 0.0 
 "H45" "hc" 0 -1 0.0 
 "H46" "hc" 0 -1 0.0 
 "C27" "c2" 0 -1 0.0 
 "H39" "ha" 0 -1 0.0 
 "H40" "ha" 0 -1 0.0 
 "C23" "c3" 0 -1 0.0 
 "H32" "hc" 0 -1 0.0 
 "H33" "hc" 0 -1 0.0 
 "H34" "hc" 0 -1 0.0 
 "C11" "c3" 0 -1 0.0 
 "H8" "hc" 0 -1 0.0 
 "H9" "hc" 0 -1 0.0 
 "C12" "c3" 0 -1 0.0 
 "H10" "hc" 0 -1 0.0 
 "H11" "hc" 0 -1 0.0 
 "C20" "c3" 0 -1 0.0 
 "H24" "hc" 0 -1 0.0 
 "H25" "hc" 0 -1 0.0 
 "H26" "hc" 0 -1 0.0 
 "C13" "c3" 0 -1 0.0 
 "H12" "hc" 0 -1 0.0 
 "H13" "hc" 0 -1 0.0 
 "C10" "c3" 0 -1 0.0 
 "H6" "hc" 0 -1 0.0 
 "H7" "hc" 0 -1 0.0 
 "C9" "c3" 0 -1 0.0 
 "H4" "hc" 0 -1 0.0 
 "H5" "hc" 0 -1 0.0 
 "C15" "c3" 0 -1 0.0 
 "H15" "hc" 0 -1 0.0 
 "H16" "hc" 0 -1 0.0 
 "C17" "c3" 0 -1 0.0 
 "H19" "hc" 0 -1 0.0 
 "H20" "hc" 0 -1 0.0 
 "H21" "hc" 0 -1 0.0 
 "C21" "c3" 0 -1 0.0 
 "H27" "hc" 0 -1 0.0 
 "H28" "hc" 0 -1 0.0 
 "H29" "hc" 0 -1 0.0 
!entry.ODM.unit.boundbox array dbl 
 -1.000000 
 0.0 
 0.0 
 0.0 
 0.0 
!entry.ODM.unit.childsequence single int 
 2 
!entry.ODM.unit.connect array int 
 0 
 0 
!entry.ODM.unit.connectivity table  int atom1x  int atom2x  int flags 
 1 2 1 
 1 3 1 
 3 4 1 
 3 5 1 
 3 66 1 
 5 6 1 
 5 7 1 
 5 73 1 
 7 8 1 
 7 9 1 
 7 60 1 
 9 10 1 
 9 63 1 
 9 69 1 
 10 11 2 
 10 50 1 
 11 12 1 
 11 57 1 
 12 13 1 
 12 19 2 
 13 14 1 
 13 47 1 
 13 53 1 
 14 15 1 
 14 16 1 
 14 21 1 
 16 17 1 
 16 18 1 
 16 19 1 
 19 20 1 
 21 22 1 
 21 23 1 
 21 43 1 
 23 24 1 
 23 25 1 
 23 26 1 
 26 27 1 
 26 28 1 
 26 29 1 
 29 30 1 
 29 40 2 
 30 31 1 
 30 32 1 
 30 36 1 
 32 33 1 
 32 34 1 
 32 35 1 
 36 37 1 
 36 38 1 
 36 39 1 
 40 41 1 
 40 42 1 
 43 44 1 
 43 45 1 
 43 46 1 
 47 48 1 
 47 49 1 
 47 50 1 
 50 51 1 
 50 52 1 
 53 54 1 
 53 55 1 
 53 56 1 
 57 58 1 
 57 59 1 
 57 60 1 
 60 61 1 
 60 62 1 
 63 64 1 
 63 65 1 
 63 66 1 
 66 67 1 
 66 68 1 
 69 70 1 
 69 71 1 
 69 72 1 
 73 74 1 
 73 75 1 
 73 76 1 
!entry.ODM.unit.hierarchy table  str abovetype  int abovex  str belowtype  int belowx 
 "U" 0 "R" 1 
 "R" 1 "A" 1 
 "R" 1 "A" 2 
 "R" 1 "A" 3 
 "R" 1 "A" 4 
 "R" 1 "A" 5 
 "R" 1 "A" 6 
 "R" 1 "A" 7 
 "R" 1 "A" 8 
 "R" 1 "A" 9 
 "R" 1 "A" 10 
 "R" 1 "A" 11 
 "R" 1 "A" 12 
 "R" 1 "A" 13 
 "R" 1 "A" 14 
 "R" 1 "A" 15 
 "R" 1 "A" 16 
 "R" 1 "A" 17 
 "R" 1 "A" 18 
 "R" 1 "A" 19 
 "R" 1 "A" 20 
 "R" 1 "A" 21 
 "R" 1 "A" 22 
 "R" 1 "A" 23 
 "R" 1 "A" 24 
 "R" 1 "A" 25 
 "R" 1 "A" 26 
 "R" 1 "A" 27 
 "R" 1 "A" 28 
 "R" 1 "A" 29 
 "R" 1 "A" 30 
 "R" 1 "A" 31 
 "R" 1 "A" 32 
 "R" 1 "A" 33 
 "R" 1 "A" 34 
 "R" 1 "A" 35 
 "R" 1 "A" 36 
 "R" 1 "A" 37 
 "R" 1 "A" 38 
 "R" 1 "A" 39 
 "R" 1 "A" 40 
 "R" 1 "A" 41 
 "R" 1 "A" 42 
 "R" 1 "A" 43 
 "R" 1 "A" 44 
 "R" 1 "A" 45 
 "R" 1 "A" 46 
 "R" 1 "A" 47 
 "R" 1 "A" 48 
 "R" 1 "A" 49 
 "R" 1 "A" 50 
 "R" 1 "A" 51 
 "R" 1 "A" 52 
 "R" 1 "A" 53 
 "R" 1 "A" 54 
 "R" 1 "A" 55 
 "R" 1 "A" 56 
 "R" 1 "A" 57 
 "R" 1 "A" 58 
 "R" 1 "A" 59 
 "R" 1 "A" 60 
 "R" 1 "A" 61 
 "R" 1 "A" 62 
 "R" 1 "A" 63 
 "R" 1 "A" 64 
 "R" 1 "A" 65 
 "R" 1 "A" 66 
 "R" 1 "A" 67 
 "R" 1 "A" 68 
 "R" 1 "A" 69 
 "R" 1 "A" 70 
 "R" 1 "A" 71 
 "R" 1 "A" 72 
 "R" 1 "A" 73 
 "R" 1 "A" 74 
 "R" 1 "A" 75 
 "R" 1 "A" 76 
!entry.ODM.unit.name single str 
 "ODM" 
!entry.ODM.unit.positions table  dbl x  dbl y  dbl z 
 7.681000 -0.489000 -1.571000 
 8.068000 0.235000 -2.041000 
 6.290000 -0.302000 -1.453000 
 5.888000 0.038000 -2.409000 
 5.928000 0.743000 -0.386000 
 6.395000 0.427000 0.543000 
 4.391000 0.789000 -0.212000 
 3.981000 1.020000 -1.198000 
 3.773000 -0.584000 0.188000 
 2.238000 -0.456000 0.278000 
 1.637000 0.712000 0.525000 
 0.170000 0.791000 0.686000 
 -0.652000 -0.472000 0.901000 
 -2.089000 0.018000 0.520000 
 -2.146000 -0.057000 -0.563000 
 -2.051000 1.529000 0.849000 
 -2.394000 1.733000 1.864000 
 -2.688000 2.110000 0.189000 
 -0.594000 1.872000 0.690000 
 -0.250000 2.886000 0.597000 
 -3.307000 -0.724000 1.110000 
 -3.220000 -0.696000 2.194000 
 -4.643000 -0.016000 0.792000 
 -4.635000 0.986000 1.207000 
 -5.428000 -0.549000 1.323000 
 -5.026000 0.084000 -0.696000 
 -5.019000 -0.905000 -1.145000 
 -4.285000 0.670000 -1.227000 
 -6.393000 0.716000 -0.891000 
 -7.587000 -0.222000 -0.750000 
 -7.322000 -0.968000 -0.004000 
 -7.840000 -0.968000 -2.071000 
 -6.952000 -1.486000 -2.419000 
 -8.627000 -1.707000 -1.950000 
 -8.144000 -0.273000 -2.847000 
 -8.871000 0.459000 -0.269000 
 -9.258000 1.155000 -1.007000 
 -9.643000 -0.284000 -0.090000 
 -8.708000 1.005000 0.654000 
 -6.505000 2.002000 -1.176000 
 -7.454000 2.493000 -1.293000 
 -5.635000 2.623000 -1.304000 
 -3.370000 -2.201000 0.696000 
 -2.567000 -2.779000 1.136000 
 -3.305000 -2.323000 -0.381000 
 -4.304000 -2.650000 1.023000 
 -0.077000 -1.543000 -0.032000 
 -0.251000 -1.231000 -1.058000 
 -0.575000 -2.499000 0.094000 
 1.429000 -1.741000 0.167000 
 1.787000 -2.328000 -0.668000 
 1.610000 -2.353000 1.049000 
 -0.536000 -0.897000 2.378000 
 -1.033000 -1.842000 2.568000 
 0.503000 -1.007000 2.669000 
 -0.973000 -0.150000 3.032000 
 2.379000 2.025000 0.635000 
 2.127000 2.633000 -0.233000 
 2.008000 2.572000 1.497000 
 3.895000 1.888000 0.727000 
 4.338000 2.843000 0.477000 
 4.195000 1.671000 1.748000 
 4.190000 -1.609000 -0.893000 
 3.691000 -1.357000 -1.827000 
 3.857000 -2.604000 -0.623000 
 5.699000 -1.663000 -1.132000 
 6.215000 -2.060000 -0.264000 
 5.917000 -2.340000 -1.952000 
 4.265000 -1.082000 1.570000 
 3.859000 -2.066000 1.778000 
 5.343000 -1.165000 1.625000 
 3.942000 -0.426000 2.368000 
 6.522000 2.109000 -0.756000 
 7.584000 2.025000 -0.956000 
 6.042000 2.524000 -1.640000 
 6.420000 2.829000 0.046000 
!entry.ODM.unit.residueconnect table  int c1x  int c2x  int c3x  int c4x  int c5x  int c6x 
 0 0 0 0 0 0 
!entry.ODM.unit.residues table  str name  int seq  int childseq  int startatomx  str restype  int imagingx 
 "ODM" 1 77 1 "?" 0 
!entry.ODM.unit.residuesPdbSequenceNumber array int 
 0 
!entry.ODM.unit.solventcap array dbl 
 -1.000000 
 0.0 
 0.0 
 0.0 
 0.0 
!entry.ODM.unit.velocities table  dbl x  dbl y  dbl z 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 0.0 0.0 0.0 
 
The frcmod file of parameters of ligand ODM is: 
 
OBT product (OBT_DM) after demethylation by CYP51 
MASS 
 
BOND 
 
ANGLE 
 
DIHE 
c2-ce-c3-hc   1    0.380       180.000          -3.000      same as hc-c3-c2-c2 
c2-ce-c3-hc   1    1.150         0.000           1.000      same as hc-c3-c2-c2 
c2-ce-c3-c3   1    0.000         0.000           2.000      same as X -c2-c3-X  
ce-ce-c3-c3   1    0.000         0.000           2.000      same as c2-ce-c3-c3 
ce-ce-c3-hc   1    0.380       180.000          -3.000      same as c2-ce-c3-hc 
ce-ce-c3-hc   1    1.150         0.000           1.000      same as c2-ce-c3-hc 
 
IMPROPER 
c3-c3-c2-ce         1.1          180.0         2.0          Using default value 
c2-c3-ce-ce         1.1          180.0         2.0          Using default value 
c3-ce-c2-ha         1.1          180.0         2.0          Using default value 
c2-c3-c2-c3         1.1          180.0         2.0          Using default value 
c2-ha-c2-ha         1.1          180.0         2.0          Using default value 
 
NONBON 
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Conservation:              9         99   9   9                     99              9      9  
3ld6_chainA_p003   58  VKSPPYIFSPIPFLGHAIAFGKSPIEFLENAYEKY-GPVFSFTMVGKTFTYLLGSDAAALLFNSKNEDLN  126 
2vku_chainA_p001    6  ---LPRVSGGHDEHGHLEEFRTDPIGLMQRVRDEL-GDVGTFQLAGKQVVLLSGSHANEFFFRAGDDDLD   71 
3p99_chainA_p002   29  GKLPPVYPVTVPILGHIIQFGKSPLGFMQECKRQLKSGIFTINIVGKRVTIVGDPHEHSRFFLPRNEVLS   98 
Consensus_aa:          ....P.h.sshsbhGHhb.F.psPl.hhpph.cph.tsl.ohphhGKphhhl.ssc....hF.s.s-sLs 
Consensus_ss:                          hhh    hhhhhhhhhhhh   eeeeee  eeeeee  hhhhhhhhh   hhh  
 
 
Conservation:              9     9 99 99               9    9           9           9    99   
3ld6_chainA_p003  127  AEDVYSRLTTPVFGKGVAYDVPNPVFLEQKKMLKS-GLNIAHFKQHVSIIEKETKEYFES-WGE-SGEKN  193 
2vku_chainA_p001   72  QAKAY-PFMTPIFGEGVV-FDAS--PERRKEMLHNAALRGEQMKGHAATIEDQVRRMIAD-WGE-AGEID  135 
3p99_chainA_p002   99  PREVY-SFMVPVFGEGVAYAAPYPRMREQLNFLAE-ELTIAKFQNFVPAIQHEVRKFMAANWDKDEGEIN  166 
Consensus_aa:          ..chY..hhhPlFGcGVh..ss.....cpbphL.p..Lp..php.@hshIpcph+chh.s.Wsc..GEbs 
Consensus_ss:                hhhhhh     ee    hhhhhhhhhhhh h  hhhhhhhhhhhhhhhhhhhhh hh        
 
 
Conservation:                   9 9   99 9   9  9     9 9           9        99     9   9     
3ld6_chainA_p003  194  VFEALSELIILTASHCLHGKEIRSQL-NEKVAQLYADLDGGFSHAAWLL--PGWLPLPSFRRRDRAHREI  260 
2vku_chainA_p001  136  LLDFFAELTIYTSSACLIGKKFRDQL-DGRFAKLYHELERGTDPLAYVD--P-YLPIESFRRRDEARNGL  201 
3p99_chainA_p002  167  LLEDCSTMIINTACQCLFGEDLRKRLDARRFAQLLAKMESSLIPAAVFLPILLKLPLPQSARCHEARTEL  236 
Consensus_aa:          lh-.htphhI.Ttt.CLhGcchRppL.s.+hApLhhch-.th..hAhh.....bLPl.p..R.ccA+p.l 
Consensus_ss:          hhhhhhhhhhhhhhhhh          hhhhhhhhhhhhhhhhhhhhhh  h h     hhhhhhhhhhh 
 
 
Conservation:                    9              9 9  9       9       9  99      99 9999 9  9  
3ld6_chainA_p003  261  KDIFYKAIQKRR---QS---QEKIDDILQTLLDATYKDGR-PLTDDEVAGMLIGLLLAGQHTSSTTSAWM  323 
2vku_chainA_p001  202  VALVADIMNGRIANPPT---DKSDRDMLDVLIAVKAETGTPRFSADEITGMFISMMFAGHHTSSGTASWT  268 
3p99_chainA_p002  237  QKILSEIIIARK--EEEVNKDSSTSDLLSGLLSAVYRDGT-PMSLHEVCGMIVAAMFAGQHTSSITTTWS  303 
Consensus_aa:          ..lh.chh..R.....p...ppp.pDhLpsLlsh.hcsGp..ho.cElhGMhlthhhAGpHTSS.TssW. 
Consensus_ss:          hhhhhhhhhhhh  h           hhhhhhhhhh        hhhhhhhhhhhhh   hhhhhhhhhh 
 
 
Conservation:             9              9                             9  9  99    99       9 
3ld6_chainA_p003  324  GFFLAR--DKTLQKKCYLEQKTVCGENLPPLTYDQL-KDLNLLDRCIKETLRLRPPIMIMMRMARTPQTV  390 
2vku_chainA_p001  269  LIELMR--HRDAYAAVIDELDELYGDG-RSVSFHAL-RQIPQLENVLKETLRLHPPLIILMRVAKGEFEV  334 
3p99_chainA_p002  304  MLHLMHPANVKHLEALRKEIEE----FPAQLNYNNVMDEMPFAERCARESIRRDPPLLMLMRKVMADVKV  369 
Consensus_aa:          .h.Lh+..p.phb..h..Ebcp........ls@p.l.cphsbh-phh+EolR.cPPlhhhMR.h.s..pV 
Consensus_ss:          hhhhhh   hhhhhhhhhhhhhh         hhhh h  hhhhhhhhhhhhh  hhhh        eee 
 
 
Conservation:                 9     99                 9 9                 9999 9 9 9  9   9  
3ld6_chainA_p003  391  AGYTIPPGHQVCVSPTVNQRLKDSWVERLDFNPDRYLQ-DNPASGEKFAYVPFGAGRHRCIGENFAYVQI  459 
2vku_chainA_p001  335  QGHRIHEGDLVAASPAISNRIPEDFPDPHDFVPARYEQPRQEDLLNRWTWIPFGAGRHRCVGAAFAIMQI  404 
3p99_chainA_p002  370  GSYVVPKGDIIACSPLLSHHDEEAFPEPRRWDPERD-------EKVEGAFIGFGAGVHKCIGQKFGLLQV  432 
Consensus_aa:          .t@.l..GcblthSPhlsp+..-s@s-..c@sP.R...........c.h@lsFGAG.H+ClG..FthhQl 
Consensus_ss:            eee    eeee hhhh    hh                                      hhhhhhhh 
 
 
Conservation:          9 9     9 9 9               9            9 99  
3ld6_chainA_p003  460  KTIWSTMLRLYEFDLIDGYF-PTVNYTTMIHTPE--NPVIRYKRRS  502 
2vku_chainA_p001  405  KAIFSVLLREYEFEMAQPPESYRNDHSKMVVQLAQ-PAAVRYRRRT  449 
3p99_chainA_p002  433  KTILATAFRSYDFQLLRDEV-PDPDYHTMVVGPTASQCRVKYIRR-  476 
Consensus_aa:          KhIhthhhR.Y-Fphhps....pss@ppMlh......s.l+Y.RR. 
Consensus_ss:          hhhhhhhhhheeeee             eeee     eeeeeee   
 
Figure 9.1: Sequence alignment of M. tuberculosis, T. brucei and human CYP51. The I helix region
is marked by the box with dashed lines.
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Figure 9.2: Sequence alignment of human, rat and T. brucei CPR. Interface residues that were
identified by mutagenesis experiments as discussed in Chapter 5 are marked by the box with
dashed lines.
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